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ABSTRACT
Background: Southern Africa has a high incidence of bacterial meningitis in 
adults, often associated with HIV co-infection. Mortality exceeds 50%, even with 
appropriate antibiotic therapy, and is not improved with corticosteroids. Glycerol 
adjuvant therapy reduces long-term morbidity in bacterial meningitis in children, 
and its use is being promoted. We aimed to assess the effectiveness of glycerol as 
an adjuvant therapy for adults with bacterial meningitis in Africa, hi addition, we 
aimed to measure the effect of glycerol on reducing intracranial pressure and 
deafness.
Methods: The study was done in two phases. First, in an open-label dose-fmding 
study, 45 adult patients with symptoms, signs, and cerebrospinal fluid findings 
consistent with bacterial meningitis received 50, 75, or 100 ml of glycerol four 
times a day for 4 days. We then did a randomised, double-blind, placebo-controlled 
trial of oral glycerol in adults with bacterial meningitis. Patients with clinical and 
cerebrospinal fluid findings suggestive of bacterial meningitis were randomly 
assigned in blocks of 12 by use of a random number list produced by an 
independent statistician to receive either glycerol or an equivalent volume of sugar 
solution. Glycerol and placebo were indistinguishable by colour or taste. The 
primary outcome was mortality at 40 days, with secondary outcomes including 
disability and mortality restricted to pneumococcal disease; reduction in 
cerebrospinal fluid opening pressure and optic nerve sheath diameter measurement 
at Day 2 and hearing loss at Day 40. All patients were analysed for the primary 
outcome excluding those who were lost to follow-up. This trial is registered at 
controlled-tiials.com. number ISRCTN70121840.
Findings: 75 mL glycerol four times a day was the highest tolerated dose, and was 
used for die main study. 265 patients were assigned treatment: 137 glycerol and 128 
placebo. The trial was stopped early on the advice of the data and safety monitoring 
board after a planned interim analysis. By Day 40, 61 (49%) of 125 patients in the 
placebo group and 86 (63%) of 136 in the glycerol group had died (adjusted odds 
ratio 2-4, 95% Cl 1*3-4-2, p-0'003). There was no benefit from glycerol for death 
and disability by Day 40, and glycerol did not improve deadi and disability by Day 
40 or deadi at Day 40 in patients widi proven bacterial disease or pneumococcal 
disease. Two serious adverse events occurred diat were possibly due to the study 
drug. Optic nerve sheath diameter and CSF opening pressure were not reduced by 
glycerol. There was a trend towards less hearing loss at Day 40 in the glycerol aim 
five (5.6%) compared widi placebo 16 (21.3%) (p=0.026).
Interpretation: Oral glycerol therapy cannot be recommended as an adjuvant 
therapy in adults widi bacterial meningitis in resource-poor settings with a high HIV 
prevalence.
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CHAPTER 1: INTRODUCTION
1.1 Overview of Malawi, Blantyre and QECH
1.1.1 Malawi
Malawi is one of the most densely populated countries in sub-Saharan Africa with 
an estimated population of 12.3 million. A landlocked country, it is bordered by 
Zambia, Tanzania and Mozambique with most of its eastern border made up of 
Lake Malawi, the third largest lake in Africa. Malawi achieved independence from 
the United Kingdom in 1963. The major commercial centre is Blantyre and the 
capital city is Lilongwe with a population of around 400,000. Malawi relies 
heavily on agriculture for income and the main export crops are tobacco, tea and 
sugar. 85% of the population is estimated to work within the agricultural sector 
although the majority are subsistence fanners and the economy relies on support 
from the World Bank, International Monetary Fund and individual donor nations. 
It is ranked as one of the least developed nations and roughly 80% of total income 
is donor based. The overall GDP per capita was $201.80 in 2005 K Malawi’s 
climate is tropical and malaria is endemic. The dry season is between April and 
October.
According to World Health Statistics for 2006, life expectancy for women and men 
was 41 years. HIV prevalence is esthnated at around 14% 2 but these rates are higher 
in urban areas. Both infant and maternal mortality rates are some of the highest in the 
world: maternal mortality rates 1100/100,000 live births 3 and infant mortality of
1
76/1000 4. Overall, there are considerable health and economic concerns within 
Malawi.
1.1.2 Blantyre
Blantyre, named after the birthplace in Scotland of Dr David Livingstone, is the mam 
commercial, industrial and tourist centre of Malawi. Located in Southern region, it 
is the oldest and largest city in Malawi. The current population is estimated at 
900,000 with significant economic migration from rural areas and other areas for 
employment opportunities.
Surrounding Blantyre, unplanned townships provide accommodation for a large 
proportion of the local population. Poverty, high unemployment, alcohol misuse and 
overcrowding contribute to the high rates of communicable diseases including HIV 
around Blantyre. Compared with the rest of the country, Blantyre district has the 
highest numbers of HIV infected adults with a prevalence of 19% and an estimated 
150,000 HIV infected adults live in Blantyre 5.
1.1.3 Queen Elizabeth Central Hospital and tire College of Medicine
Queen Elizabeth Central Hospital (QECH), Blantyre, Malawi is a Government-run 
teaching hospital with a bed capacity of 1200. It offers free medical care to 
approximately 10,000 adult inpatients per year*, of whom approximately 70% have 
HIV infection 6. The department of Medicine admits approximately 4500 patients 
per month onto five wards which have two hundred beds. Clinicians have access to
2
limited laboratory and radiological investigations and, at the time of this study, 
frequently faced limitations with prescribing due to essential drug shortages. 
Medical staffing in QECH is provided by academic physicians from the College of 
Medicine (Ministry of Education) and from the Ministry of Health.
The College of Medicine, Blantyre was established in 1991 with the aim of 
providing training of medical students alongside the on-going research. Academic 
physicians provided teaching, clinical care for patients and earned out research. 
Within the QECH site, working alongside and often in collaboration with College of 
Medicine are the Malawi-Liverpool-Wellcome (MEW) Trust and Johns Hopkins 
Research Project.
1.2 Bacterial meningitis
1.2.1 Historical advances
Prior to the introduction of specific therapy, mortality from acute bacterial meningitis 
caused by pneumococcus and Haemophilus influenzae was ahnost universal and was 
up to 80% for meningococcus. In 1913, Flexner administered intrathecal equine 
meningococcal antiserum to 1300 patients and reduced mortality to 31%. 
Consequently, intrathecal antisera proved beneficial in H. influenzae, reducing 
mortality to 85%, but had little effect on improving mortality from pneumococcal 
disease7.
With the introduction of sulphonamides and subsequently chloramphenicol in the 
1930s and 1940s, mortality due to meningococcal and H influenzae meningitis fell
3
8 • *to <10% . Improvement in mortality from pneumococcal meningitis came 
following high dose penicillin therapy in the mid-1940s which resulted in mortality 
falling to 38% 9. Bacterial meningitis was then considered potentially curable but 
with variable mortality and morbidity for individual pathogens and patient groups. 
The mortality from adult bacterial meningitis has remained relatively unchanged 
since the 1980s despite advances in supportive treatment, improved understanding of 
pathophysiology and development of new antibiotics. Pneumococcal meningitis still 
carries a mortality over 25% 10. Tins highlights the need to search for alternative 
approaches to treatment to reduce mortality.
1.2.2 Incidence and mortality
Worldwide, bacterial meningitis is amongst the top ten causes of death related to 
infection u. In developed countries the incidence is estimated to be 2—5/100000 per 
year and may be ten times that in developing countries 12. Between 1974 and 1998, 
the incidence of bacterial meningitis increased by 800% in Southern Malawi and this 
is mostly attributable to the HIV epidemic. One in forty of acute medical admissions 
to the adult medical wards in QECH are due to meningitis, half of these are likely to 
be bacterial13. Overall mortality from bacterial meningitis in Malawi is around 53% 
and is 61% for pnerunococcal meningitis with 23% of survivors suffering 
neurological disability and 34% hearing loss 12,14. By comparison, overall mortality 
due to bacterial meningitis amongst adults in the West is 15% 15 with up to 50% of 
survivors suffering pennanent neurological disability on recovery 16. Such adverse 
outcomes may result directly from the infectious process or from other inflammatory
4
consequences such as cerebral oedema, increased intracranial pressure (ICP), altered 
cerebral blood flow, and neuronal injury 17.
1.2.3 Meningitis in Malawi
Cryptococcal meningitis is the most common type of meningitis in Malawi and is 
almost exclusively associated with HIV infection 13, 18. Tuberculous meningitis 
(TBM) also causes a considerable burden and in tins setting occurs predominantly in 
patients co-infected with HIV. These two causes of meningitis will not be discussed 
further. The most common bacterial pathogens seen in meningitis in sub-Saharan 
Africa are Streptococcus pneumoniae, Haemophilus influenzae. Neisseria 
meningitidis and Gram-negative rods, particularly mmrtyphi Salmonella spp. 
Numerous factors have contributed to the shifting epidemiology of bacterial 
meningitis in recent years and although vaccination has impacted on the incidence of 
invasive pneumococcal disease in adults in the developed world I0’19, in sub-Saharan 
Africa, where vaccines are least accessible, HIV is Hie single most important factor 
influencing the changing epidemiology of meningitis.
1.2.4 Corticosteroids in meningitis
Evidence for the benefit of corticosteroid adjuvant therapy has come from paediatric 
studies. No studies have demonstrated a clear improvement hi mortality. A meta­
analysis of eighteen studies involving 2750 cases of which 2074 were children, 
demonstrated a significant reduction in severe heating loss in those receiving steroid. 
In sub-group analyses, this effect was restricted to children with haemophilus
5
meningitis . The incidence of haemopliilns meningitis has fallen since the 
introduction of Hib vaccine and therefore these conclusions should be considered 
carefully in the context of current epidemiology.
Reduced incidence of hearing loss 21 or the incidence of neurological complications 
m children recovering from bacterial meningitis have been seen with steroids in 
two studies where H influenzae type b caused the majority of infection. These 
results were not reproduced in another European trial carried out prior to the 
introduction of Hib vaccination 23, or in the paediatric trial in Malawi where 
haemophilus meningitis was relatively infrequent (28% of cases)24.
Trials of steroid adjuvant therapy in adults have been less conclusive. Of eleven 
published trials identified, only four have been sufficiently powered to detect a 
mortality benefit. The main trial which has led to the introduction of steroid adjuvant 
therapy being recommended for suspected pneumococcal meningitis in Europe, is 
the prospective European trial by de Gans et al 15. Dexamethasone significantly 
reduced mortality from 15% to 7% and unfavourable outcome (death or neurological 
disability) from 25% to 15%. Patients with pneumococcal disease achieved greatest 
benefit from dexamethasone. A further study on a subset of tins cohort found no 
difference in long term neurological sequelae, including motor impairment, deafness 
and cognitive difficulties 25.
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A study in Vietnam in 435 patients over age 14 year's with suspected bacterial 
meningitis demonstrated that (by intention-to-treat analysis) dexamethasone had no 
statistically significant mortality advantage. However, patients receiving 
dexamethasone with definite bacterial meningitis had a statistically significant 
mortality advantage (relative risk of death at 1 month 0.43 (p=0.033)) whereas 
patients with probable meningitis had a (statistically non-significant) trend towards a 
higher mortality. Dexamethasone reduced the incidence of hearing loss amongst 
survivors 26. A randomised controlled trial of steroid therapy in adults in Malawi 14 
did not show any significant difference in mortality with corticosteroids either by 
intention-to-treat analysis or restricted to proven pneumococcal meningitis. There 
were no significant differences hi hearing impairment in survivors. The overall 
conclusion from this trial is that dexamethasone adjuvant therapy for bacterial 
meningitis in adults from an area with a high prevalence of HIV did not reduce 
mortality or morbidity. Corticosteroids are not routinely used in Malawi for bacterial 
meningitis.
1.2,5 Antibiotic therapy in Malawi
Prior to 2006, bacterial meningitis in Malawi was treated according to standard 
guidelines with parenteral penicillin and chloramphenicol for a minimum of 10 
days. During 2006, the national recommendation changed and ceftriaxone became 
first-line therapy. This was facilitated by the expiry of the patent for ceftriaxone 
and the general availability of good quality generic drug.
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In the Malawian steroids in adult bacterial meningitis trial 14, 8% of pneumococcal 
isolates were resistant to penicillin and 46% resistant to chloramphenicol. 
Antibiotic resistance was detected on culture by the disc diffusion method 
(resistance defined by zone of inhibition of >3 mm). Dual resistance to penicillin 
and chloramphenicol was not seen in any pneumococcal isolate but resistance to 
ceftriaxone was detected in one (0.5%). No meningococcus or Gram-negative 
isolate was resistant to ceftriaxone.
Ceftriaxone (and cefotaxime) have a proven record of clinical efficacy in the 
treatment of bacterial meningitis when compared to penicillin and chloramphenicol 
, Ceftriaxone can also be given once daily as effective treatment for adult 
bacterial meningitis 28,29 which has advantages for both patient comfort and nursing 
time.
1.2.6 Effect of HIV on invasive pneumococcal disease
HIV increases the incidence of invasive pneumococcal disease. In a population- 
based prospective review from the United States, the incidence of invasive 
pneumococcal disease in HIV-infected patients was 803 per 100,000 person year’s 
compared to 35 per 100,000 person years in the general population 33. A further 
retrospective review from USA demonstrated that recurrent pneumococcal 
bacteraemia was more likely in HIV infected patients: 23 out of 432 patients had 
recurrent episodes of pneumococcal bacteraemia and 87% of these episodes occurred
8
iii HIV-infected patients34. It is therefore unsurprising that the prevalence of HIV in 
sub-Saharan Africa impacts on both the incidence and recurrence rate of invasive 
pneumococcal disease, thereby influencing the epidemiology of pneumococcal 
meningitis.
Since the start of the HIV epidemic, there has been an eightfold increase in the rates 
of hospital admission for meningitis in Malawi 13 and over 80% of adults with 
bacterial meningitis in this region are HIV co-infected 14,35.
HIV infection is recognised as a major risk factor for pneumococcal meningitis in 
both adults 36 and in children 37 in Malawi. Pneumococcal meningitis is the most 
common and severe form of community acquired bacterial meningitis with the 
highest mortality rate and frequency of neurological sequelae 1!; the adverse impact 
of HIV infection only compounds this.
Despite this finding, it is unclear whether outcome from a single episode of invasive 
pneumococcal disease is affected by HIV status. A small European study of purulent 
meningitis (predominantly pneumococcal) in adults with HIV demonsfrated a 
favourable outcome compared with HIV negative adults. This was however a small 
study with twelve episodes of purulent meningitis in nine HIV-infected patients and 
one death (mortality 8.3%) 3S. In contrast, in a paediatric population from Africa, 
outcome from bacterial meningitis was significantly worse and recurrent episodes
9
more frequent in HIV infected children compared to HIV uninfected children 
(mortality 65% in HIV positive compared with 36% in HIV negative)37.
1.3 Impact of other interventions on invasive pneumococcal disease and 
bacterial meningitis
1.3.1 Antiretroviral therapy
In the USA, antiretroviral therapy (ART) has almost halved the incidence of 
invasive pneumococcal disease in patients with advanced HIV 39. ART is not yet 
available to the majority of HIV infected individuals in Africa, although access to 
ART continues to improve particularly as a result of the Gates partnership. 
National scale-up of ART in Malawi commenced in June 2004, and (following 
completion of the glycerol in adult bacterial meningitis trial) in December 2008, 
223,437 patients were registered for treatment 40. Progressive roll-out of ART 
remains a priority.
1.3.2 Prophylactic antibiotics
No analysis on the impact of prophylactic antibiotics on pneumococcal meningitis 
has been reported. Daily co-trimoxazole prophylaxis reduced HIV related morbidity 
and bacteraemia in Cote d’Ivoire 41 although this did not specifically assess the 
impact on invasive pneumococcal disease. No benefit was demonstrated in a similar 
trial of co-trimoxazole primary prophylaxis among adults in Senegal42.
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A randomised clinical trial in children in Zambia demonstrated strong evidence that 
daily co-trimoxazole prophylaxis is effective in reducing both mortality and 
morbidity 43. The main protective effect was seen in the reduction in severe 
pneumonia despite high levels (60-80%) of in vifro resistance of common bacterial 
infections to co-trimoxazole.
In adults, studies using historical controls and observational cohort studies across 
Africa have consistently demonstrated the effectiveness of co-trimoxazole 
prophylaxis in reducing mortality and morbidity 41* 43'50. This prompted the 
development of WHO recommendations in 2006 for prophylactic co-trimoxazole for 
those with symptomatic HIV (WHO clinical stages 2-4) or based on CD4 counts 
(where available) 51. There have been no studies to suggest any effect of 
prophylactic co-trimoxazole on the prevention of bacterial meningitis.
1.3.3 Vaccination
The goal of any vaccine programme is to prevent a potentially fatal disease. The 
majority of vaccines are developed within the West and may not be appropriate for 
resource poor settings due to vaccines being expensive, ineffective or not serotype 
appropriate 52 or have restricted availability due to manufacturing and distribution 
priorities. In addition, the development of successful vaccines in the West is liable to 
reduce the research interest into the diagnosis and management of bacterial 
meningitis in general. Vaccination can certainly change the epidemiology of
11
bacterial meningitis but is unlikely to be a health priority in Africa for some 
considerable time outside the setting of epidemic meningitis in the Sahel region.
There are around 90 known serotypes of pneumococcus, although a relatively limited 
number of these cause the most serious disease due to this organism. Antibody to the 
capsular polysaccharide provides only serotype-specific protection fiom disease. 
Pneumococcal vaccines, both conjugate and polysaccharide vaccines, show variable 
benefit in preventing invasive pneumococcal disease. In the developed world, the 
23-valent polysaccharide pneumococcal vaccine has been shown to protect against 
bacteraemia and meningitis 53’54; however, in Uganda, significantly more pneumonia 
and a trend towards more invasive pneumococcal disease was seen in vaccinated 
HIV infected adults (not on ART)55. Mortality was not affected by vaccination in the 
Ugandan study. A subsequent study in Taiwan demonstrated a reduction in 
pneumococcal disease in HIV infected patients receiving 23-valent pneumococcal 
polysaccharide vaccine and a non-significant decrease in mortality56.
Conjugate pneumococcal vaccines have been used in the USA since 2000 and have 
been included in UK childhood vaccine schedule since 2006, They have been 
highly effective in USA reducing invasive pneumococcal disease in children and 
demonstmting herd immunity effects in unvaccinated adults. The serotypes in this 
vaccine cover the principal circulating strains in North America which includes 
serotypes most often associated with reduced penicillin sensitivity 57. Although 
apparently highly effective in America, this vaccine may not be appropriate for use
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in Africa. At the time of this study, the 7-valent vaccine was available; this 
covered only 25% of invasive pneumococcal isolates in adults in sub-Saharan 
Africa at the time. 9-valent vaccine has been shown to cover 55% of invasive 
isolates from adults 52 and significant benefit was shown in children in South 
Africa vaccinated with a 9-valent conjugate vaccine designed for use in the USA
58 . A trial of the 7-valent conjugate vaccine in adults with a history of invasive 
pnemnococcal disease has recently been completed in Malawi and shows 
significant benefit in terms of preventing recurrence of invasive pneumococcal 
disease amongst HIV infected patients not on ART 59. Following on from this, the 
13-valent pneumococcal conjugate vaccine was introduced as part of the national 
vaccination programme in Malawi from November 2011.
With the widespread use of conjugate vaccine, epidemiological changes are 
occurring as serotypes causing invasive pneumococcal disease are increasingly 
serotypes not covered in the vaccine 60. This has prompted further vaccines to be 
developed as rapidly as possible even though there is no suggestion to date that this 
current vaccine will become redundant 61. In 2007, WHO recommended 
pneumococcal (conjugate) vaccination in all, based on the high levels of disease 
burden in developing countries and proven efficacy and safety of the pneumococcal 
conjugate vaccines.
Meningococcal meningitis periodically reaches epidemic proportions, mainly in the 
classical meningitis belt, an area that stretches from Senegal in the West to Ethiopia
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in the East 62,63, Effective vaccination is likely to reduce the occurrence or extent of 
epidemics but this is not straightforward. With the polysaccharide vaccine currently 
used during epidemics, repeated dosing is required in young children due to weak 
immunogenicity 64. The more recently developed conjugate meningococcal vaccines 
result in a more durable antibody response in addition to blocking colonisation and 
producing herd immunity 65’66, but the logistics for implementing mass vaccination 
is a challenge. Conjugate meningococcal A vaccine ("MenAfriVac"), was developed 
through a product development partnership between WHO and the Program for 
Appropriate Technology in Health (PATH). Multiple agencies including the Global 
Alliance for Vaccine and hnmimisation are working with die WHO, the PATH and 
the Serum Institute of India alongside local governments and health services to 
achieve die goal of vaccinating at risk populations 67.
As with meningococcus, the incidence of meningitis due to H influenzae does not 
appeal' to be affected by HIV co-infection and although H influenzae causes a 
significant burden of disease hi the paediatric population 37 incidence has fallen
significantly in areas with the implementation of an effective vaccination programme
10, 68
Meningitis caused by non-typhoid salmonella is strongly associated with HIV 
infection. Although uncommon in adults, it carries a case fatality rate of almost 80%
13
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1.4 Establishing the microbiological diagnosis
The ability to make a microbiological diagnosis in bacterial meningitis is variable in 
resource-poor settings. In the West, much effort is expended in identifying the 
causative organism so that appropriate therapy can be instituted early. Many 
institutions in sub-Saharan Africa have no culture facilities and clinicians must 
therefore rely heavily upon the history, the naked eye appearance of the 
cerebrospinal fluid (CSF) and, if available, microscopy. In some centres, including 
Blantyre, the use of urine dipsticks provided a semi-quantitative measure of CSF 
glucose and protein69,70, a valuable, rapid and relatively cheap contribution to aid in 
the diagnostic process. During the period of this study, the method of glucose and 
protein measurement in CSF changed to quantitative measurement. However, despite 
the availability of diagnostic tools such as these, significant difficulty in 
distinguishing different types of meningitis remains.
In Malawi, where cryptococcal meningitis is the most common CNS infection in 
adults l3, distinguishing TBM from cryptococcal meningitis remains a major 
challenge. Both are usually, but not always, associated with a lymphocytic 
pleocytosis and both tend to have a clinical history of more than 5 days 71,72.
The sensitivity of the India Ink stain limits its usefulness 73 and cryptococcal antigen 
testing or culture is not possible in the majority of centres. Reliance is commonly 
placed on high-protein and low glucose (detected by urine dipsticks) to predict TBM 
rather than bacterial or cryptococcal meningitis. The sensitivity of urine dipsticks in
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distinguishing cryptococcal meningitis from either TBM or from bacterial meningitis 
has not been formally addressed. However, a diagnostic scoring system has been 
developed in Vietnam which has shown reasonable sensitivity and specificity in 
distinguishing TBM from bacterial meningitis 74. The scoring system relies upon 
five key features which are available at or soon after presentation of a patient with 
suspected meningitis: age, time to presentation, peripheral and CSF white cell count 
and percentage neufrophilia in the CSF. This scoring system has been validated in a 
population with a similarly low incidence of HIV infection to that seen in Vietnam 
75; however, when evaluated in the context of high HIV prevalence setting 14, the 
Vietnam diagnostic index did not perform well with low specificities for diagnosing 
either bacterial meningitis (52%) or TBM (43%).
Diagnostic strategies for TBM include direct Ziehl-Neelsen staining, CSF culture 
and molecular methods such as polymerase chain reaction (PCR). The fonner has a 
low sensitivity, culture is too slow to be useful in making therapeutic decisions and 
as with PCR, is often not available in resource-poor settings.
1.5 Osmotherapy for raised ICP
1.5.1 Raised ICP in meningitis
Raised ICP impairs cerebral bloodflow and may be a significant contributory factor 
to mortality and morbidity from all forms of meningitis including bacterial 
meningitis 76, 11. The pathophysiology of raised ICP is complex and involves 
cytotoxins and interstitial oedema due to increased permeability of the blood—brain-
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barrier with subsequent elevations in ICP; in addition to increased intracranial blood 
volume and disturbances in CSF flow78.
Early reduction of the ICP should theoretically improve outcome. In their study, 
Lindvall et al 79, demonstrated a worse outcome with higher ICP. Fifteen patients 
with bacterial meningitis and reduced conscious level (Glasgow Coma Scale [GCS] 
<8/15) were selected for Intensive Care management, invasive monitoring of ICP 
and interventions (including thiopental) to reduce ICP to <20 mmHg. Overall 
mortality was 33% (five patients died). ICP was significantly higher in the five 
patients who died compared with survivors both initially and after 19 horn's 
treatment; initial ICP was 46±8.6 mmHg in non-survivors versus 20.3±4.6 mmHg in 
survivors (p<0.05), and after treatment was 61.2±12.8 mmHg in non-survivors 
versus 19.4±1.35 mmHg in survivors (pO.OOl). ICP reduced linearly with ICP- 
reducing therapy in survivors whereas no reduction hi ICP was seen in those who 
died. The authors state an improvement in outcome with ICP-reducing therapy in 
bacterial meningitis however this was not a randomised study, there was no control 
arm and no explanation of expected ICP or mortality rate without intervention 79.
Osmotic therapy has been used extensively for raised intracranial pressure in acute 
brain injury due to trauma 80“82, investigated comprehensively for use in stroke 83-86 
and tried (unsuccessfully) to improve outcome in cerebral malaria87. Osmotic 
agents used to control raised intracranial pressure includes mannitol81, glycerol88,
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sorbitol89, sodium lactate90 and hypertonic saline 9l. All are administered 
parenterally but glycerol has the advantage of being able to be taken orally.
Glycerol, a hyperosmolar liquid widely used as a food additive, has an excellent 
safety profile, is low cost, easily administered and widely available. If effective, it 
would be an ideal adjuvant therapy, particularly in resource poor settings. Glycerol 
has been suggested as a potentially promising adjuvant treatment in bacterial 
meningitis in children. In three paediatric studies, glycerol reduced neurological 
sequelae but not death when given both alone and in combination with 
dexamethasone92”94,
No trials of glycerol adjuvant therapy in bacterial meningitis have previously been 
reported in adults.
1.5.2 Glycerol
Glycerol (glycerine) is a clear, colourless, odourless, viscous liquid when pme, and 
has a warm, sweet taste. A naturally occurring liquid, it is primarily synthesized from 
propylene (obtained from petroleum) but can also be obtained as a by-product in the 
manufacture of soap from animal or vegetable oils and fats and is produced during 
the fermentation of sugar's. Glycerol is cheap and widely available in sub-Saharan 
Africa.
18
Used in an extensive range of industries (including the food and beverage industry, 
medicine, cosmetics, cellophane and paper, explosives, lubricants, electrical 
equipment and metals), glycerol has been used as a food additive and for cosmetic 
purposes for many year's and is widely used amongst sportsmen and sportswomen to 
improve performance and thermoregulation by hyper-hydration prior to endurance 
events 95. Medicinally, it has been used as a laxative, in the treatment of acute 
glaucoma and in the diagnosis of Meniere’s disease. It is well absorbed orally and 
poorly absorbed across rectal mucosa.
Adverse effects of glycerol
Toxicity data for oral glycerol is limited but indicates that it is safe in the dosages 
used in this trial 96. Side effects are infrequent, most commonly gastrointestinal in 
nature and generally mild. They include nausea, vomiting, diarrhoea, bloating and 
headache; with additional rare reports of confusion, dizziness, hyperglycaemia, 
polydipsia, hyperosmolar non-ketotic coma and dry mouth 88,97. There is one case 
report of reversible hemiparesis and seizures in a male following inadvertent 
ingestion of 500 ml pure glycerol 98 and a case of acute encephalopathy attributed 
to accidental glycerol overdose 10°. A 72 year old male presented with confusion 
following a glycerol test for Meniere’s disease and glycerol overdose (of 
approximately 3.75 g/kg glycerol rather than 0.5-1.5 g/kg which is usually used in 
this context) was inferred from elevated triglyceride levels. The patient 
spontaneously recovered although he was amnesic of the event10°.
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With intravenous administration of glycerol, intravascular haemolysis, 
haemoglobinuria and renal failure can occur*. This is not seen with oral 
administration of glycerol 101. The effect of glycerol on blood glucose is 
controversial. Glycerol affects glucose metabolism which can theoretically lead to 
an increase in serum glucose levels 102'104. However, a study in both healthy and 
well-controlled Type 2 diabetic patients did not show any clinically significant 
increases in blood glucose following oral glycerol in either group 105.
There have been a few reports of hyperosmolar non-ketotic coma reported in the 
context of glycerol therapy. One occurred in a diabetic with chronic renal failure 
when glycerol was given repeatedly for glaucoma 106 and another in two elderly 
patients treated with glycerol for cerebral oedema I07. Following administration of 
parenteral glycerol, the sudden expansion of extracellular fluid may precipitate 
cardiac failure due to hypervolaemia in those with pre-existing cardiac disease; in 
renal insufficiency accumulation may lead to overexpansion of extracellular fluid 
and circulatory overload 108.
Pharmacology of glycerol
Few studies have been published on glycerol’s pharmacokinetics and most 
pharmacodynamic information is from animal studies on lowering intracranial or 
ophthalmic pressure. The pharmacokinetics of glycerol in humans is still 
incompletely described; its mechanism of action is drought to be through an osmotic 
reduction of intracranial pressure.
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Glycerol has a half-life of 0.2-1 hour; it is predominantly metabolised by the liver 
and undergoes renal filtration although die risk of accumulation in renal 
insufficiency is low. There is little evidence that glycerol causes an osmotic diuresis. 
There are no known significant interactions and limited data in pregnancy in either 
humans or animals 101, l09> 110.
After oral administration, glycerol absorption in die intestine is rapid; maximum 
serum concentrations of glycerol are reached after 15-20 min 10°. Following entry 
into cells, glycerol may enter cellular glycolysis or gluconeogenesis. Glycerol 
metabolism is mainly by three enzymes:
• glycerol kinase which converts glycerol to glycerol-3-phosphate
• glycerol-3-phosphate dehydrogenase which converts glycerol-3-phosphate 
into dihydroxyacetone phosphate
• triose phosphate isomerase which converts dihydroxyacetone phosphate into 
glyceraldehyde-3 -phosphate.
Eidier glyceraldehyde-3-phosphate or dihydroxyacetone phosphate may be used as 
substrates for glycolysis or gluconeogenesis. The majority of glycerol is released 
from its storage within triglycerides during lipolysis. Glycerol metabolites are 
utilized for the synthesis of glucose, glycogen, and body fats ni.
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The exact mechanism of action is unclear but glycerol is an osmotic dehydrating 
agent which increases osmotic pressure. Its laxative effect occurs by drawing fluid 
into the colon and thereby stimulating evacuation. Within the blood, glycerol is 
thought to exert much of its effect by increasing serum osmolality. Glycerol has 
previously been used in stroke, head injury and glaucoma to reduce elevated tissue 
pressure 81,82, S4, S6,112-116.
In a small prospective study of oral glycerol therapy in both healthy individuals and 
those with Type 2 diabetes, plasma osmolarity (pOsm) increased significantly with 
maximal change seen 105 min following ingestion 105. Peak change in pOSM was 
8.6% for healthy individuals (receiving 3 ml/kg glycerol), and 8.5% and 4.2% for 
diabetic patients (receiving 3 ml/kg and 1.5 ml/kg respectively) supporting a dose- 
response relationship.
In a randomised double blind placebo controlled paediatric study of 36 children with 
bacterial meningitis, Singhi et al 117 investigated whether increase in serum 
osmolality is glyceroPs mode of action in bacterial meningitis. While receiving 
study drug (glycerol, dexamethasone, both agents or neither agent), urme output, 
blood pressure and pOsm were monitored. Plasma osmolality increased in the 
glycerol group - the maximum level was seen at 6 hours and this was maintained up 
until at least 18 hours but not beyond 24 hours. Osmolality increased by a maximum 
of 3% (from 294±22 mOsm/kg to 302±31 mOsm/kg) in the glycerol only group, and 
by 1% (from 295±19 mOsm/kg to 298±21 mOsm/kg) in the glycerol-dexamethasone
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group. The osmolality change was significant at 18 hours (p=0.01) but did not reach 
statistical significance at other time points. There was no evidence of osmotic 
diuresis and no change in blood pressure. The authors conclude that increased pOsm 
causing reduced CSF excretion and improved cerebral blood-flow with reduction in 
cerebral oedema is the possible mechanism for the beneficial effects of glycerol in 
tins setting. Clinical success of therapy was a secondary endpoint not reported.
In addition to its osmotic action, there are several additional potential mechanisms of 
action of glycerol in the brain which have been suggested in the literature. Glycerol 
readily crosses the blood brain barrier (more readily than other osmotherapy agents) 
where it could provide an alternative source of energy for brain tissue if glucose 
is lacking - glycerol can be converted to glucose and pyruvate and as a component 
of fat, glycerol is normally produced and metabolised in tissues. Parenteral glycerol 
has been shown to reduce the cerebral symptoms of hypoglycaemia in rabbits 119j 120.
Glycerol may increase regional cerebral blood flow and regional cerebral blood 
volume hi ischaemic brain by reducing focal cerebral oedema facilitating 
redistribution of cerebral blood flow (however, no reduction of healthy brain volume 
was observed in magnetic resonance imaging studies) 121. Such improvement in 
cerebral blood flow could occur by modulation of the leukocyte-endothelium 
interaction. This interaction plays a critical role in the pathogenesis of brain injury 
by ischaemia and reperfusion leading to secondary brain damage. Compared with 
saline, intravenous glycerol has been shown to significantly reduce adherent
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leukocytes within microvasculature in rats. This modulation of adherence prevents 
leukocytes horn interfering with the blood cell and plasma flow and is thought to be 
a factor in the neuroprotective effect of glycerol122.
ICP rising above original pressure, or ’rebound phenomenon4 is often cited as a 
potential adverse effect of glycerol (and other osmotic agents) but there is conflicting 
published data, mostly following head injury or in animals. Some have not found 
any evidence of rebound phenomenon 113, 123-125 and others dispute the existence of 
rebound phenomenon.
Kaufmann and Cardoso 126 demonstrated that repeated doses of mannitol lead to 
accumulation of mannitol within the extravascular compartment and the 
development of cerebral oedema as a consequence. This has subsequently been 
refuted 81,127. It would appear that glycerol and mannitol pass through a damaged 
blood-brain barrier (BBB) 125; elimination from CSF is slower than from serum but 
because glycerol can be metabolised by neuronal cells (leading to a reduction in 
extravascular concentration) this may make it less likely to produce rebound 
phenomenon than mannitol. Despite this, it has been suggested that during the 
elimination phase of glycerol, CSF:serum osmotic gradient can be temporarily 
reversed causing a paradoxical rise of ICP. In stroke patients given 50 g glycerol by 
intravenous (IV) infusion, intracranial pressure fell by almost 50% and lasted just 
over an hour” but a small rebound in ICP occurred after 40 min. This was explained
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by a temporary reversal of the serum to CSF fluid concentration gradient during 
glycerol elimination 12S.
Berger et al 129 concluded that IV glycerol in stroke patients has a brief effect on 
serum osmolarity but a more sustained effect on raised ICP. However, they did not 
recommend its use in stroke because of lack of evidence of long-term benefit and 
concerns around accumulation of glycerol in brain tissue causing potential rebound 
effects following initial reduction in ICP.
In a retrospective study of 16 patients with brain injury, Troupp et al 124 concluded 
that glycerol could be used short-term (for a few days) but not long term to reduce 
intracranial pressure. Mannitol, glycerol and urea were given either alone or in 
combination; three received glycerol. One patient with frontal haematoma (which 
was surgically removed) had elevation of ICP to >50 mmHg following the fust dose 
of glycerol but not the second dose. This was explained as possible rebound 
phenomenon but also possibly secondary to neurosurgery; however outcome was not 
reported in the other two patients.
Garcia-Sola et al125 performed a comparative study of mannitol and glycerol in 18 
goats and found no evidence of any rebound in ICP. ICP was measured with an 
epidural latex balloon immediately post-infusion and long-term (following repeated 
infusions). Glycerol reduced ICP less than mannitol but with no rebound 
phenomenon and less elevation of blood pressure.
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In a clinical investigation reported by Wald et al82,15 patients with head injury were 
administered glycerol at a dose of 0.5-1.0 g every 3-4 hours depending on 
intracranial pressure and duration of drug effect (dose range 4-70 g, mean 54 g). 
ICP was reduced by over 50% in more than 70% of patients; no rebound elevation in 
ICP was reported. The study concluded that glycerol is both safe and effective as an 
adjunct to reduce ICP following trauma.
One case report describes rebound phenomenon following IV and oral glycerol and 
IV mannitol in a patient with glioblastoma multiforme 130. Osmotic therapy was 
administered to reduce ICP. During IV glycerol infusion the ICP initially fell to 
almost normal levels but subsequently increased above the initial level despite 
elevated pOsm. Four hours following oral glycerol, CSF pressure increased to levels 
higher than originally. Administration of mannitol and recent neurosurgery may 
have influenced this result.
There remains conflicting data on the cause of any possible ’rebound phenomenon4. 
In animal and human studies where it has been observed, the postulated 
pathophysiology is an inversion of the osmotic gradient between plasma and brain at 
some point during osmotherapy * * .
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1.5.3 Glycerol in stroke
There have been multiple clinical trials using glycerol for both haemorrhagic and 
ischaemic acute stroke (see Table 1). None have demonstrated significant benefit 
either by reducing mortality long-term or improving outcome in terms of 
neurological sequelae. A Cochrane review identified 10 randomised studies in acute 
ischaemic stroke in which a total of 482 glycerol-treated patients were compared 
with 463 control patients 8S. There was no evidence of an effect of glycerol on 
mortality at the end of planned follow-up. Functional outcome was only directly 
comparable in two trials; there was a non-significant reduction in odds of death or 
dependence (odds ratio (OR), 0.73; Cl, 0.37-1.42). As many of these trials were 
performed prior to routine use of computed tomography (CT), most patients did not 
have radiological confirmation of the diagnosis of stroke. Overall, there was no 
reliable evidence of efficacy of glycerol in patients with cerebral oedema in acute 
stroke88.
Table 1. Glycerol in acute cerebrovascular disease
Group Type No. of 
patients
Dose/pathway 
of glycerol
Results
Meyer et al 
(1971)116
Descriptive 36 IV/PO given 
within 72 h, for
4 days
Better mental status 
and motor strength.
No clear long-term 
benefit.
Mathew et al 
(1972)133
Double­
blind
randomised
54 IV glycerol vs 
placebo for 4-6 
days
Significant 
improvement in 
neurological 
examination.
No long-term data.
No improvement in 
mortality.
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Larsson et al 
(1976)134
Randomised 27 IV glycerol vs
IV dextrose, 
given within 6 
h, for 6 days
No immediate (1-10 
days) or late (3 
months) benefit.
No difference in 
mortality.
Bayer et al 
(1987) 86
Double­
blind
randomised
173 IV glycerol vs 
placebo started 
within 48 h
Significant 
improvement in 
cognition, motor 
strength, and speech 
during early 
treatment.
Significant 
improvement in early 
mortality.
No differences in 
morbidity or 
mortality at 12 
months.
Yu et al 
(1993)84
Double­
blind
randomised
113 IV glycerol vs. 
placebo
No significant 
differences (Barthel 
Index and
Scandinavian Stroke 
Scale).
1.5.4 Glycerol in meningitis
Evidence for the benefit of glycerol adjuvant therapy in human bacterial meningitis 
is limited. There are three published studies to date on outcome in children where 
adjuvant glycerol therapy has been used 92’94. In each, bacterial meningitis was 
treated with ceftriaxone and patients were randomised to receive oral glycerol, 
dexamethasone IV, both agents or placebo. Apart from the earliest study by Kilpi 
et al a daily dose of glycerol 6 mg/kg daily divided into four doses was used. 
None of the studies demonstrated a clear mortality advantage. All three studies 
found a benefit in terms of reduction in hearing loss or neurological sequelae.
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The first published trial using glycerol adjuvant therapy in bacterial meningitis was 
carried out by The Finnish Study Group in 122 children 92. Glycerol therapy - at a 
lower dose than used in subsequent trials (4.5 g/kg in three divided doses) — 
prevented neurological abnormalities (0/61 vs 5/57; p=0.024). Oral glycerol reduced 
hearing loss when analysis was restricted to severe and profound bilateral hearing 
impairment (0% vs 7%; p=0.049). Overall, there was little difference between the 
treatment arms for hearing loss and neurological sequelae at follow-up; 7% (4/61) 
who received glycerol, and 19% (11/57) who did not receive glycerol, had 
neurological or hearing impairment (p=0.052). The relative risk of sequelae without 
glycerol was calculated as 2.94 (95% CIs, 0.99-8.72).
Subsequently a multi-centred, randomised, double blinded study in Latin America by 
Peltola et al93 recruited 654 children with bacterial meningitis to four treatment arms 
- oral glycerol, IV dexamethasone, oral glycerol plus IV dexamethasone or oral 
placebo (carboxymethylcellulose). There were no significant mortality benefits. 
Fewer neurological sequelae were seen in those children receiving glycerol or 
glycerol plus dexamethasone (OR, 0.31 [95% Cl, 0.13-0.76]; p<0.01 and 0.39 [95% 
Cl, 0.17-0.93] p<0.03) respectively, compared with those patients who received 
placebo. Profound healing loss occurred with similar regularity in all four* groups. 
The authors concluded that glycerol prevents severe neurologic sequelae hi 
childhood meningitis and advocated its use particularly in resource-poor settings. Of 
note, the majority of cases were caused by H. influenzae type b (221/654, 34%) with 
20% (132) pnemnococcal and 17% meningococcal. Not only is this is in contrast to
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many areas where Hib vaccination programmes have significantly reduced the 
prevalence of H. influenzae type b but also led to study limitations which could have 
affected interpretation of results.
There is good evidence that dexamethasone adjuvant therapy reduces audiologic 
and/or neurologic sequelae in Hib meningitis 20’ 135j 136. The omission of 
corticosteroid adjuvant therapy raises ethical concerns in this setting with high Hib 
prevalence; it is therefore reasonable that one of the 10 participating centres opted 
out of the placebo-placebo arm. However, the published trial results amalgamated 
all data and did not provide individual centre data. Thus any difference that may 
have been present in the centre that followed a different treatment protocol was not 
able to be reviewed, hi addition, use of pre-admission parenteral antibiotics was an 
exclusion criterion (although oral antibiotics were permitted); this may have 
affected culture results and may have added bias in that potentially more severe 
cases were excluded.
A small prospective randomised double blind study in India by Sankar et al 94 did 
not find any significant difference between the dexamethasone and glycerol groups. 
No significant difference was seen in neurological (p=0.29) or hearing (p=0.68) 
outcome with glycerol in children with acute bacterial meningitis treated with 
ceftriaxone 94. Fifty-eight children were randomised to receive oral glycerol 1.5 g/kg 
6 hourly, dexamethasone, both or placebo. An organism was isolated in half of all 
patients; 42% (10/24) pneumococcal, 29% (7/24) H. influenzae type b, 29% (7/24)
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other organisms. Seven (12%) patients had neurological sequelae and 10 patients 
(17%) had hearing impairment.
A further study from India was designed to demonstrate glycerol’s mechanism of 
action in bacterial meningitis in children 117. Mortality was an unreported secondary 
outcome.
A meta-analysis of currently available data is in preparation 137. Overall, glycerol 
may reduce deafness in meningitis but due to the small size of most trials, the 
evidence is low quality. No mortality benefit has been seen.
1.6 Measurement of intracranial pressure
1.6.1 Background
Raised ICP may be one of the factors contributing to mortality in bacterial 
meningitis. There are invasive and non-invasive methods to measure ICP both 
directly and indirectly and these include intracranial methods, lumbar* puncture, 
transcranial Doppler sonography (mainly in children) and optic nerve sheath 
diameter measurement. Not all of these methods are readily available, particularly in 
resource poor settings.
ICP is most accurately measured directly with an infracranial device. 
Intraventricular pressure monitoring using direct ventricular* manometry was 
developed in the 1960s and although ventricular catheterisation is still used, this
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invasive technique carries risk of both haemorrhage and infection. Extra­
ventricular devices were developed in the 1990s and include minimally invasive 
electronic or fiberoptic microsensor devices which are placed in brain parenchyma. 
Although widely used throughout the world in neurosurgical units, such methods 
are not readily available out-wxth specialised and well resourced centres I38.
Although not strictly a direct measure of ICP, lumbar puncture with CSF opening 
pressure correlates well with lumbar epidural pressure and ICP. However, lumbar 
puncture cannot be repeated frequently and can be contraindicated, for example 
with an intracranial mass lesion. Readings can vary with position and orthostatic 
changes have complex interactions with intracranial pressure. When seated, the 
difference in intracranial pressure and lumbar CSF pressure is equivalent to the 
height of the hydrostatic column. When a person is tilted vertically head down, 
ICP rises three times higher compared with the magnitude of reduction that occurs 
when they are tilted head-up 95. Hydrostatic pressure, elasticity of the lumbar thecal 
sac and venous compression along the neuraxis all contribute to these changes in 
ICP. In addition to postural effects, regional cerebral blood-flow, fall in Pa02, rise 
in PaC02 and body temperature are all stimuli which can increase ICP 139. Some 
of these parameters have been manipulated therapeutically with variable success to 
try to reduce elevated ICP 14°. Depending on the underlying aetiology, correcting 
the patient's position, lowering core temperature, hyperventilation to induce 
hypocapnoea, use of hyper-osmolar agents (mannitol) and drainage of CSF have all 
been used in intensive therapy settings to treat intracranial hypertension.
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Normal CSF opening pressure is generally accepted as 5~20 cm CSF with an upper 
limit of normal 18-20 cm 141. Body mass index (BMI) does not appeal* to affect this 
significantly. A study by Whitely et al142 in 242 adults undergoing their first lumbar 
puncture found increased BMI was only weakly associated with an increase in ICP 
but that this was not sufficiently different to be relevant to clinical practice. Then 
population was overweight with a median BMI 26 kg/m2 (normal BMI = 20- 
25 kg/m2) with CSF opening pressures of 12-25cm CSF were normal.
Computed tomography can allow raised ICP to be inferred from radiological signs 
but this has limitations and such imaging is not routinely available in resource-poor 
settings.
1.6.2 Optic nerve sheath diameter measurement
More recently, optic neive sheath diameter (ONSD) measurement by ultrasound has 
been used to evaluate ICP. This simple, non-invasive technique can be repeated as 
often as required to evaluate ICP. Several studies suggest that ultrasound 
measurement of ONSD provides accurate, reproducible information in the presence 
of elevated ICP (Table 2). Only basic ultrasonography skills are required and it can 
be done with standard paediatric ultrasound equipment. Other advantages to this 
non-invasive technique include no radiation exposure; being accessible at the 
bedside and therefore able to be taken to critically ill patients (rather than moving 
them); and ability to be easily repeated to re-evaluate a patient.
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The optic nerve sheath is continuous with the brain’s dura mater. CSF pressure 
variations are transmitted to the sub-arachnoid space surrounding the optic nerve and 
influence the ONSD. Increased ICP causes expansion of the optic nerve sheath 
3 mm posterior to the papilla which can be measured using a standard paediatric 
ultrasound probe in the transverse plane (Figure 1).
Sonographic optic nerve sheath diameter measurement has been used successfully in 
emergency rooms 148,15°, children with hydrocephalus l44, with other causes of raised 
intracranial pressure and in one paediatric study in a resource-poor setting 143. 
There is well documented intra-observer and inter-observer reproducibility of optic 
nerve sonography in the literature I54' 156‘158.
Figure 1. The technique of ocular ultrasound and the image 
The cursors are set at 3 mm behind the globe to measure the ONSD
Reproduced with permission: 
Newman WDetal. Br J Opthalmol 2002;86:1109-1113144
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Newman el al 144 found that the mean ONS enlarged with age, but most of this 
increase occurred in the first year of life with less increase thereafter to age 16 years. 
Table 2 summarises the findings of the main published studies using ultrasound to 
measure ONSD. Overall, the literature supports an optic nerve sheath diameter 
>5 mm in adults as indicating elevated ICP.
Other conditions which can also cause ONS enlargement include tumours (ONS 
meningioma, optic nerve glioma, neurofibroma, metastases, leukaemia and 
lymphoma); neuritis; sarcoid; trauma including haemorrhage in and around the optic 
nerve; thyroid compressive neuropathy (in Grave’s disease) and idiopathic 
inflammation 159.
1.6.3 Summary
hi bacterial meningitis, raised intracranial pressure is usually detected by CT brain, 
an expensive, time-consuming investigation not readily available in resource-poor 
settings; opthalmoscopy for papilloedema, which is difficult to detect in early stages 
even by experienced examiners and has a low sensitivity; and lumbar puncture with 
opening pressure which cannot be repeatedly performed. Ultrasound measurement 
of the ONSD is a simple, non-invasive technique which provides reproducible 
measurements to indicate if there is elevation of ICP. Expansion of the ONS occurs 
before the appearance of papilloedema and therefore ONSD measurement is able to 
diagnose raised ICP earlier than ophthahnoscopy 145,160. Within our trial, we aimed 
to determine whether ONSD was affected by glycerol therapy and if it correlated
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with CSF opening pressure at lumbar puncture. In addition, we aimed to 
demonstrate whether it can be used as a prognostic tool in this context.
1.7 Hearing and disability in bacterial meningitis
Hearing loss is the most common sequela of bacterial meningitis in children. It 
occurs in up to 35% of survivors and is more common with pneumococcal than 
meningococcal infection 16M63.
hi the trial of adjuvant steroid therapy in adults with bacterial meningitis in Malawi, 
36% (36/99) of surviving adults were found to have deafness and this increased to 
43% (28/65) of those with proven pneumococcal meningitis 14. The exact 
pathophysiology is likely due to a combination of direct labyrinth involvement, 
cochlear neuroepithelial damage, and vascular insult I64. Hearing loss typically 
occurs early within the course of the illness, usually within the first 2 days 165, l66. 
This is supported by animal studies where rabbits show signs of hearing loss within 
12 hoius of intrathecal injection with Streptococcus 167. Hearing is regained if 
appropriate antibiotics are administered within 12 hour's whereas untreated rabbits 
remain deaf.
Predictors of hearing loss in children include length of hospitalisation, 
development of seizures, cranial nerve neuropathies, elevated CSF protein, and 
decreased CSF glucose 16S. In the Latin American study, reduction in GCS at
40
presentation and young age were also found to be predictive 169. There is no 
similar' literature for adults.
The presence of fits may not be a direct marker of disease severity because the cause 
for seizures in bacterial meningitis may be multifactorial and includes cerebral 
irritation, raised intracranial pressure, metabolic disturbances and high fever 
(particularly in children). Cranial nerve neuropathy is however a sign of a severe 
infection and is highly correlated with the development of hearing loss 168.
Since the 1970s, glycerol has been suggested as a potential adjuvant therapy for the 
prevention of sequelae in meningitis. Herson and Todd 170 suggested it might be of 
benefit in Hib meningitis and the other paediatric studies were subsequently 
completed 92,169.
1.8 Summary
Meningitis is one of the most common causes of adult inpatient deaths in high HIV- 
prevalent areas . Even with effective antibiotics, in-hospital mortality from 
bacterial meningitis is over 50% in regions where HIV is common. Steroids, which 
have been found to be effective adjuvant treatment in low-HIV settings, have been 
found to be ineffective where most meningitis is HIV-related 14, 36. Bacterial 
meningitis in adults in Malawi is most commonly due to S. pneumoniae and the 
majority of patients are co-infected with HIV. Since the start of the HIV epidemic, 
the incidence of bacterial meningitis in Malawi has risen markedly and mortality
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from pneumococcal meningitis in this region exceeds 50%, with up to half of 
survivors being left with neurological sequelae such as deafness, intellectual 
impairment or physical disability 15?36.
In summary, bacterial meningitis continues to be a significant health problem in 
developing countries. There are many reasons why mortality is high in this setting 
and several strategies have been considered in order to address this issue. Increasing 
awareness of the symptoms and epidemiology of bacterial meningitis amongst both 
health workers and the public, and the promotion of early hospital referral, early 
diagnosis and appropriate antibiotic therapy are likely to improve prognosis. 
Improved access to ART, vaccine development and deployment, and the use of 
primary antibiotic prophylaxis may reduce the incidence of bacterial meningitis.
In order for a new intervention to be employed in the developing world, it must be 
cheap, sustainable, easily administered and safe. Glycerol is all of these and is widely 
available making it a potentially highly appropriate therapy for resource poor 
settings. Data from paediatric studies suggest an advantage from adjuvant glycerol 
therapy, particularly with outcome in terms of neurological sequelae and hearing 
loss. Theoretically, the osmotic effect of glycerol on reducing raised ICP might 
confer some benefit in terms of mortality. There are no studies of adjuvant glycerol 
therapy in adults with bacterial meningitis. This led to us designing a study to 
initially assess tolerability of oral glycerol and then whether oral glycerol would 
improve outcome in adults with bacterial meningitis in Malawi.
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CHAPTER 2: METHODS
2.1 Background
Resource poor settings such as those in sub-Saharan Africa have the highest 
incidence of bacterial meningitis and mortality rate — currently, mortality exceeds 
50% in Malawi. More effective locally appropriate treatments are an urgent priority. 
The most common organism isolated in bacterial meningitis is S. pneumoniae 171. 
Despite advances in supportive care, the availability of novel antibiotics, and our 
understanding of the pathophysiology of the disease, mortality from pneumococcal 
meningitis in adults has not improved significantly over the last half of the previous 
century . Glycerol has been shown to reduce neurological sequelae in children 
with bacterial meningitis in Latin America. If similarly effective in adults, glycerol 
would represent a cheap, locally available adjuvant therapy appropriate for use in 
this setting. It has been used as a food additive and for medicinal and cosmetic 
purposes for many years. We set out to investigate the use of glycerol to improve 
outcome.
Tliis study provides the first information on the efficacy of glycerol in meningitis in 
adults. The data informs investigators of the potential benefits, constraints and side 
effects of glycerol adjuvant therapy. It was anticipated that the results from this 
study may precede a larger multicentre trial in four tropical research centres aimed at
43
investigating the use of glycerol in bacterial, tuberculous and cryptococcal 
meningitis.
This chapter provides a comprehensive overview of methods used to carry out the 
study. It describes the aims of the study and the methodology required to obtain these 
aims. The original study proposal, data profonna, consent forms and patient 
information sheets are in Appendix 1-7.
2.2 Study design and objectives
This was a prospective double-blind placebo controlled randomised trial recruiting 
patients admitted to the QECH, Blantyre, Malawi (See Chapter 1 for the 
description of QECH). It was conducted in two phases.
Phase 1: open label dose-finding and tolerability study from March to July 2006. 
Phase 2: Double-blind placebo controlled clinical trial commenced September 
2006 and recruitment finished August 2008.
The main trial objectives were to identify if glycerol is effective at reducing 
mortality and improving outcome in adult Malawian patients with bacterial 
meningitis.
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There were three specific objectives:
1. To investigate the feasibility and tolerability of glycerol as an adjuvant 
therapy in adult bacterial meningitis.
2. To assess the efficacy of glycerol adjuvant therapy in reducing mortality 
from adult bacterial meningitis in Malawi at Day 10 and Day 40.
3. To assess the degree of neurological deficit in survivors at Day 10 and Day 
40.
The study had ethical approval prior to starting recruitment from the College of 
Medicine Research and Ethics Committee, Malawi in December 2005 and from 
Liverpool School of Tropical Medicine, Research Ethics Committee, UK in 
February 2006. The trial design was approved by the data and safety monitoring 
board (DSMB) and the Trial Steering Group (TSG) prior to the start of recruitment.
2.3 Participants
All medical patients with suspected bacterial meningitis routinely had a lumbar 
puncture with opening pressure measurement as part of their admission 
investigations. The decision to perform a lumbar puncture was not part of the trial 
algorithm. All such patients were referred to the glycerol trial staff and assessed for 
eligibility to enter the trial. Those eligible for enrolment were identified from the 
macroscopic appearance of their CSF or from CSF microscopy results. Due to delays 
in receiving initial laboratory results, all patients suspected of having meningitis with
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hazy/cloudy CSF were recruited before CSF microscopy results were known. 
Individuals under follow-up within other research projects were eligible for inclusion. 
Most patients were recruited from the medical admissions ward; others were located 
elsewhere in the hospital once their cerebrospinal fluid results had been obtained by 
the study team from the laboratory.
Records were kept of all patients who were potential recruits to GLAM. This 
included those who refused consent and those who were not recruited for other 
reasons - died before recruitment, missed by the trial team, discharged home before 
CSF results known, pregnant women.
2.4 Inclusion criteria and consent for Phase 1 and 2
Inclusion criteria were clinical suspicion of meningitis plus CSF evidence of 
bacterial meningitis or cloudy CSF if microscopy was not immediately available i.e. 
within 30 min (See Table 3). Exclusion criteria were age, cryptococcal meningitis; 
pregnancy, heart failure, known Type 2 diabetes or capillary whole blood glucose 
(BM) >12 mmol/L. Patients were excluded if their CSF contained <100 white 
cells/jul or lymphocytic meningitis; they were <16 year's old, pregnant, had a 
diagnosis of Type 2 diabetes (due to the possibility of precipitating hyperosmolar 
non-ketotic coma) or heart failure (due to the possibility of exacerbating congestive 
car'diac failure); or had CSF results indicating infection by cryptococcus (India ink or 
cryptococcal antigen positive on CSF) or mycobacteria (lymphocytic CSF). 
Treatment with antibiotics prior to recruitment was not a criterion for exclusion.
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Table 3. Inclusion and exclusion criteria
Inclusion criteria
Adults Age >16 year's old
Clinical suspicion of meningitis 
(any 1 of)
Headache
Neck pain or stiffness
Reduced conscious level
Photophobia
Confusion
Fits
Rash
Fever
CSF evidence of bacterial 
meningitis
Cloudy CSF*
>100 white cells/pl with predominant neutrophils 
Gram-stain showing bacteria
Informed consent given By patients or their guardians
Patient/guardian willing to 
follow study protocol
Exclusion criteria
Pregnancy
Type 2 diabetics
BM >12 mmol/L
Heart failure
CSF results indicating infection with cryptococcus or mycobacteria*
*if microscopy was delayed >30 min 
lymphocytic meningitis
Individuals were given or read an infonnation sheet (Appendix 6 and 7) in Chichewa 
(the local language) or English and given the opportunity to ask questions. If the 
individual wished to enrol in the study, the study clinician interviewed them in order 
to ensure they understood the nature of the study and the information provided. In 
particular, potential recruits needed to understand die nature of a placebo-controlled 
dial. Verbal and written informed consent was obtained from the patient or their 
legal guardian a member of the trial staff or, overnight, from a specialised blood 
culture muse (working on an invasive pneumococcal disease study) who were 
trained in obtaining informed consent. Wherever possible, consent from the patient
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was obtained in the presence of their guardian. Where patients were deemed to be 
incapable of giving valid informed consent next-of-kin or guardians were asked to 
give consent on their behalf. Those unable to read or write gave witnessed verbal 
consent and a thumbprint as proof of consent. Once satisfied, the study clinician 
witnessed the completion of the consent to participate form and countersigned it 
(Appendix 4 and 5).
All trial staff were trained to obtain informed consent and were fully aware that 
properly acquired informed consent is central to the perfonnance of ethically sound 
and scientifically credible clinical trials.
Refusal did not adversely affect patients’ care, and these patients received antibiotic 
therapy according to Malawi guidelines. The purpose of the study was fully 
explained to patients; it was made clear that participation was entirely voluntary and 
that if the patient did not wish to participate, this would not influence management of 
their condition and they would be offered the best possible diagnostic and treatment 
options. Patients could withdraw from the study at any point in time. Patients were 
informed that they were free to ask for the results of the study when available.
2.5 Phase 1: Dose finding and tolerability study
Forty five adult patients with symptoms, signs and CSF findings compatible with 
bacterial meningitis were recruited for assessment of glycerol tolerability. Following
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consent, fifteen patients each received glycerol at a dose of 50, 75 or 100 ml four 
times a day for four days. Previous paediatric studies had used 6 ml/kg/day 94 and in 
the average Malawian this would be achieved with a total daily dose of 300-360 ml 
glycerol. Glycerol was diluted with water at a ratio of 5:4 so that the consistency 
was indistinguishable from that of 50% sugar solution (the proposed placebo for 
Phase 2). Patients therefore received diluted glycerol 90, 135 or 180 ml QDS.
Clinical details of all cases, mcluding possible or probable adverse events due to 
glycerol administration, were recorded. Patients were followed up to Day 10 or until 
discharged home.
2.6 Glycerol and placebo: presentation
Glycerol BP 99% (manufactured by Organic Chemical Corporation (Pty) Ltd, 
Durban, South Africa) and Malawian sugar- was purchased locally. Glycerol 
(Img/ml) was diluted with water in a ratio 5:4 to a consistency indistinguishable 
from the placebo. Placebo was sugar solution made of sugar and water (1 kg in 1000 
ml water).
It was anticipated that both fluids would appear- as a slightly viscous, colourless liquid 
but the sugar- solution was a pale yellow colour. Addition of 125 ml of Orange 
SOBO® (a locally produced orange squash) into each bottle of glycerol and 100 ml 
into each bottle of 50% sugar- solution ensured both liquids were the same in 
appearance. Both liquids were a pale orange colour and were more palatable and
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indistinguishable as assessed by blinded medical and clerical staff within the 
Department of Medicine, QECH.
The glycerol solution and placebo were made in batches in order to keep up with 
demand. 2430 ml diluted glycerol and equal volumes of placebo were placed in 
bottles which were kept separate until labelled with the GLAM study number. This 
provided two extra doses per bottle which could be used if the patient vomited shortly 
after mgestion when the dose was repeated. 125 ml SOBO® was added to each bottle 
of glycerol and 100 ml to each bottle of placebo. This final solution given to patients 
contained 528.3 mg/ml glycerol (125 ml SOBO® + 1350 mg glycerol + 1080 ml 
water); each 135 ml solution therefore contained 71.3 mg glycerol.
2.7 Randomisation and blinding
Randomisation was perfonned by an independent statistician using Stata version 9.0 
to randomise in blocks of size 12. Three independent scientists with no involvement 
with GLAM were nominated to label bottles as they were made. Treatment 
allocation was in opaque sealed envelopes which were opened sequentially by an 
independent person not directly involved in tire trial who then labelled pre-prepared 
containers of glycerol and placebo with the unique Study number. Bottles were 
either labelled or disposed of. No other person had access to the randomisation code 
and all envelopes were accounted for. Study drug was then placed in consecutive 
order within a secure room. Clinicians and patients were blind to study allocation.
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Study drug was stored in a cool dark office prior to being transferred to a small 
locked fridge on the ward for dispensing to patients. Once a patient fulfilled the 
study criteria and informed consent was obtained, the patient’s name was entered 
into the GLAM Trial Register and the next available Trial number was allocated to 
them. Allocation of the next available study number constituted entering the trial 
and the intention-to-freat analysis was based on study allocation hrespective of 
subsequent treatment. The GLAM trial number was written onto each page of the 
proforma. A master register of all patients recruited to the trial and their allocated 
GLAM study number was maintamed within the GLAM Trial office.
The appropriate bottle with that GLAM number on (with a dispensing cup marked at 
the correct level) was taken to the patient. Study drug was then given to the patient 
to drink - in Phase 1 patients were randomised to 90, 135 or 180 ml; in Phase 2 all 
patients received 135 ml four times a day. Patients who were unable to swallow had 
a naso-gastric (NG) tube inserted to give the study drug. Treatment with glycerol or 
placebo was administered by trial staff.
2.8 Identification of participants
Trial staff were informed of any patient suspected of having bacterial meningitis 
who was admitted to the medical admission ward. Each patient underwent a 
lumbar puncture with opening pressure prior to recruitment to GLAM. Opening 
pressure was measured using disposable gamma sterilised flexible calibrated spinal
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manometers (0-34cm calibrations) purchased from Baldwin Medical 
(www.baldwinmedical.com.au) (Figure 2).
2 g IV ceftriaxone was administered to any patient suspected of having bacterial 
meningitis following lumbar puncture. Any adult patient with cloudy CSF was 
considered eligible for enrolment to the study. All CSF was taken the laboratory for 
analysis and once results of microscopy were known, additional patients were then 
recruited to the study if they fulfilled the inclusion criteria.
Figure 2. Spinal manometer
a
Male Luer Slip
Connector. 
Suitable for all 
Spinal Tap < 
Canulla.
0 - 34cm
Graduated
Manometer
Female Luer 
Lock Connector
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The laboratory was open during the day and therefore patients admitted overnight 
had their samples processed the following day. Patients recruited to the study with 
cloudy CSF who were subsequently found to have CSF microscopy suggesting non- 
bacterial meningitis had then' study drug withdrawn and their treatment modified as 
necessary. All such patients continued to be followed up as if they were part of the 
trial (intention-to-treat).
2.9 Enrolment
Following consent, each patient or, hi the event of tire patient being unconscious, 
then legal guardian underwent an interview by a clinical officer or trial nurse to 
document baseline demographic characteristics, current medical problems, duration 
of symptoms, past medical history including AIDS-defining conditions and 
neurological sequelae, social history and a full drug history. Each patient was 
examined by a trial clinical officer or the principal investigator (PI). All data was 
documented in a study proforma (Appendix 3).
Malawi has no residential address system and therefore keeping track of study 
participants has always been challenging. Individuals may return to then* home 
villages for long intervals during planting or harvesting seasons. At recruitment, a 
map was drawn within the proforma to record where participants lived in order to 
locate them for follow-up if the need arose.
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2.10 Intervention trial management
Following consent, glycerol/placebo was given to the patient to swallow. If the 
patient was unable to swallow or had a GCS of <8/15, a NG tube was inserted for 
administration. If they had not already received a 2 g dose of ceftriaxone, this was 
administered at the same time or immediately after.
Patients received IV ceftriaxone 2 g twice a day for at least 10 days plus 
glycerol/placebo orally four times a day for 4 days (16 doses). Treatment was 
modified if an enrolled patient was subsequently found to have an alternative 
diagnosis to bacterial meningitis (Figure 3). Cryptococcal meningitis was treated 
with fluconazole according to national protocol. All patients continued to be 
monitored and followed up and managed by the study team.
After 48 hours of glycerol therapy (and at least four doses of ceftriaxone), a repeat 
LP was carried out for CSF examination (microscopy, culture and storage for 
glycerol levels) and to measure CSF opening pressure. This was done in the 
morning in order that CSF samples reached MLW laboratory in a timely manner for 
processing; some patients therefore had their second LP after more than 48 hours of 
therapy because of the time they were admitted. Blood for serum biochemistry and 
glycerol levels were taken simultaneously. In view of the short half-life of glycerol 
(elimination half-life 30-45 min) 173, CSF and blood samples were to reach the 
laboratory for processing within 10 min of being taken and freezing (at -80°C) was 
requested within 1 hour of the sample being taken.
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Figure 3. Intervention trial: Patient journey
Allocate GLAM Trial number
Start fluconazole. Continue 
ceftriaxone until reviewed by PI.
May be dual infection.
After 48 hours of treatment (4 doses of ceftriaxone)
CRAG positive
Cloudy CSFCSF to Wellcome Lab
Blood culture, FBC, 
MPs
Gram-stain 
bacteria in CSF
showing
Lumbar puncture with 
opening pressure
Recruit to study: Informed consent
India ink positive 
CSF with other 
findings
Day 40 review and neurological assessment
>100 white cells/pl of CSF, 
>50% neutrophils
Give glycerol/placebo orally or via NG tube
2nd LP with opening pressure + 
EDTA blood to Wellcome lab
EDTA blood 
(Wellcome lab)
U&Es, LFTs, blood
Glycerol 
discontinued. 
Patient remains 
under GLAM 
care as if he/she 
were still part of 
the trial
Complete 10 days IV ceftriaxone
Neurological assessment Day 10
Daily glycerol/placebo QDS for 4 days (16 doses) 
Daily ceftriaxone 2 g BD for 10 days
Adult ^16 years
Headache, fever, neck stiffness
No heart failure/pregnancy/Type 2 diabetes
NOTE: Those 
patients with 
meningitis who are 
not recruited to the 
study will receive 
appropriate 
antibiotic, anti­
tuberculous, or 
antifungal therapy 
according to Malawi 
guidelines.
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2.11 Clinical procedures
The patient interview was performed by a clinical officer or Trial nurse. Patient 
examination and lumbar punctures were carried out by clinical officers. There were 
no absolute contraindications for lumbar puncture. CT scan was not available as an 
emergency investigation. A history of fits, altered conscious level or focal 
neurological deficit were not considered a contraindication for LP in this setting 
because it was felt that the need for a CSF examination to diagnose meningitis 
outweighed the risks of potential complications associated with lumbar puncture. 
The PI performed fundoscopy and sonographic ONSD measurements and also 
regularly earned out neurological examinations to ensure standards were maintained. 
Trial clinical officers were regularly appraised particularly in clinical examination 
skills as pail of contmuing medical education.
Blood sampling and NG tube msertion was predominantly carried out by the Trial 
nurses but also by Trial clinical officers. All nursing staff had already received 
training in venepuncture prior to working for this study. Clinical officers were 
already experienced at taking patient histories and carrying out a physical 
examination, they were also experienced at performing lumbar punctures.
NG tubes were inserted and secured by a GLAM nurse or clinical officer. Once 
inserted, the tube was marked (with a pen) at the nose to demarcate die level to 
which it had been mserted. NG tube position was checked by:
i) Aspiration of the tube and seeing that the aspirate turned blue litmus 
paper pink.
5o
ii) Injecting 30 ml of air into the NG tube and by hearing die air bubbling 
while auscultating with a stethoscope over the epigastric area.
Litmus paper and stethoscopes were kept within the locked GLAM filing cabmets on 
the admissions, male and female wards.
The procedure and level to which die tube had been inserted was documented on the 
treatment chart. In this way, the next nurse to look after the patient would know if 
the tube had fallen out at all. Position of the tube was checked daily before 
administration of study drug.
Chest radiographs are not done routinely on admission and were only requested if 
indicated. The most common reasons for requesting a chest radiograph were 
suspected pulmonary tuberculosis or aspiration pneumonia. If tuberculosis entered 
the differential diagnosis dien three sputa were requested to be examined for acid fast 
bacilli; mycobacterial culture was not available.
2.11.1 Optic nerve sheath diameter measurement
ONSD measurements were made by the PI using a handheld Sonosite-180 
ultrasound machine (Sonosite Inc., WA, USA) with a 7 MHz curved array transducer 
(4—7 MHz 11 mm array transducer set to highest resolution frequency of 7 MHz). 
This design is for general paediatric use and was used by Beare et al143 to validate 
ONSD measurements in African children with raised ICP. The scan type was set to
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‘Neonatal’ throughout, with maximum scan depth set to 4 cm with the gain control 
on the default setting. Conductive ultrasound gel was placed over a closed eye lid 
and ONSD measurements were obtained from the temporal side with the ultrasound 
probe held against the closed eye lid. This achieved an axial view through the eye 
with a longitudinal section of optic nerve. The left eye was usually imaged.
The optic disc and optic nerve (the longest section achievable) was included in the 
freeze-frame. The best image was obtained by scrolling through the preceding 10 
seconds of images. ONSD measurements were made using electronic callipers 
3 mm posterior to the globe. Measurements were taken perpendicularly across the 
optic nerve and the mean of three measurements from different scans was calculated. 
On-screen measurements were concealed from the operator until each was 
completed.
ONSD measurements were made within 24 hours of recruitment to GLAM (Day 0), 
after 48 hours of therapy, at Day 10 and at follow-up on Day 40. Simultaneous 
direct ophthalmoscopy was also carried out on dilated pupils. Lumbar puncture with 
opening pressure was performed prior to recruitment to GLAM and after 48 hours of 
therapy.
2.11.2 Hearing assessment
Hearing was assessed by live voice speech presentation audiometry 174, 175 and, 
where possible, by single frequency (1000 Hz) pure tone audiometry. Audiometry
58
was performed by the PI or appropriately trained GLAM trial nurse at Day 10 and at 
follow-up on or after Day 40. Only those followed up at Day 40 in the clinic and able 
to cooperate with the test were included. We were not able to conduct pure tone 
audiometry in patients followed up in the community as the instrument was 
dependent upon an electrical supply which was not available in most patients’ 
homes; nor did we perform pure tone audiometry in patients who remained on tire 
ward at the time of follow-up because of the requirement to perform this test in a 
quiet setting.
Patients were placed in a quiet environment. With the patient wearing headphones 
and facing away from the person testing, the audiometer was set to ‘Pine Tone’, with 
100 Hz frequency and initially 50 dB intensity. Each ear was tested in turn and the 
patient asked to indicate verbally or with a hand movement when a tone was heard. 
The tone switch was held for 2 seconds; if heard, tire ‘Intensity5 was reduced by 
10 dB and the process repeated in a stepwise manner until the tone was not heard. 
The ‘Intensity5 was then increased by 5 dB and retested — if heard, tire intensity was 
reduced by 10 dB and retested; this was repeated in order that the level of intensity 
(dB) at which die patient hears was confirmed on a total of three occasions. This 
was recorded as the threshold level for die given frequency on die audiograph for the 
corresponding ear.
Each step was repeated at 2000 Hz, 3000 Hz, 4000 Hz, 6000 Hz, 8000 Hz and 
finally repeated at 500 Hz.
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Mild hearing loss was defined as ‘unable to localise finger mb at approximately 5 cm 
from the ear*, unable to hear whispered voice at 30cm or a hearing threshold above 
40 dB\ Severe hearing loss was defined as ‘unable to hear spoken voice at 30 cm 
from the ear or a hearing threshold of >60 dB\ For speech presentation, patients 
were asked to repeat three words presented to each ear from behind the patient, with 
occlusion of the contra lateral ear. Words were in the appropriate vernacular, 
consisted of two equally emphasised syllables and avoided high frequency sounds 
(e.g. T, ‘s’, ‘v’, ‘ch’, ‘th’). Failure to correctly repeat two or more words was taken 
to represent hearing impairment for that test. Where possible, tests were conducted 
in a setting where there was minimum ambient noise.
2.12 Laboratory investigations
Trial samples were analysed in the QECH laboratory or the MLW laboratory or were 
bedside (point-of-care) tests (Table 4).
CSF and blood for culture was sent to the MLW laboratory. Blood was cultured at 
37°C for a minimum of 48 hours (BacT/alert) and sub-cultured onto 5% sheep blood 
agar and lysed sheep blood agar for further incubation at 37°C. Antibiotic sensitivity 
was determined by disc diffusion (modified Stokes method) in line with British 
Society of Antimicrobial and Chemotherapy guidelines. Isolates with a zone of 
inhibition of >3 mm less than the control organism were classified as resistant.
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CSF microscopy was routinely performed using standard laboratory techniques for 
cell count, differential white cell count (when >20 cells/mm3 present), India ink 
staining and Gram stain. Gram staining was only done if there were more than 
10 white cells per pi or organisms were seen on direct microscopy. Cryptococcal 
Antigen Agglutination Tests (CRAG) were not routinely carried out however CSF 
CRAG (Pastorex Crypto Plus Biorad) were performed on a subset of patients as 
part of another study running concurrently 176. CSF was cultured on sheep blood 
and chocolate agar for 48 hours and Sabouraud-Dextrose-Agar (for Cryptococcus 
neoformans) and subcultured onto liquid media as appropriate.
Quantitative measures of CSF glucose and protein were not available. Estimates of 
protein and glucose levels were measured with a urine dipstick (Multistix 8SG 
Bayer) which provided colour-coded results for protein and glucose respectively as: 
negative (0 mg/dl: 0 mmol/L); trace (30 mg/dl: 5.5 mmol/L); 1+ (31-100 mg/dl: 5.5- 
14 mmol/L); 2+ (101-300 mg/dl: 28 mmol/L); 3+ (301-2000 mg/dl: 55 mmol/L); 
and 4+ (> 2000 mg/dl: 111 mmol/L).
Blood for malaria film, full blood count and biochemistry was analysed by the 
QECH laboratory. HIV testing was carried out on all patients using Uni-Gold 
Recombigen® HIV Rapid test [Trinity Biotech pic, Ireland] and Determine® HIV-1/2 
[Abbott]. Capillary blood glucose was measured at least twice a day while taking 
study drag.
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Table 4. Trial samples
Specimen At recruitment (if not already 
taken)
After 48 hours therapy
Urine Pregnancy test*
Blood
20 ml
8-10 ml culture, MLW lab
3 ml Full blood count (EDTA), 
QECH lab
Malaria blood film, QECH lab
4 ml (clotted) U&Es, LFTs,
QECH lab
4 ml (clotted) U&Es, LFTs,
QECH lab
Capillary blood glucose:
Glucostix® test
1 ml whole blood HIV test (Phase
2 only)
4 ml EDTA blood MLW lab 
(stored at -80°C, GLAM “A” 
Whole blood planned for qPCR)
1 ml EDTA blood, MLW lab 
(stored at -80°C; GLAM “B” 
plasma planned for glycerol 
levels)
CSF 2 ml whole CSF, MLW lab 
(retrieved from initial LP, stored 
at -80°C, planned for qPCR)
6 ml CSF, MLW lab:
4 ml microscopy, culture and
India ink stain and 2 ml stored at - 
80°C (planned for glycerol levels)
*Bedside urinary pHCG in females of child-bearing age
2.13 HIV testing
HIV status was not required at the time of enrolment to Phase 1; all participants were 
encouraged to access voluntary counselling and testing for HIV. No patient who 
declined HIV testing was denied entry to the trial. Experience from the previous trial 
14, suggested that take-up of HIV testing would be high and that over 80% would be 
HIV infected. During Phase 1 we found that there were a number of patients in 
whom knowing their HIV status would have been helpful with their management. 
This was particularly when CSF results suggested possible cryptococcal meningitis. 
Many patients in Phase 1 were not capable of informed consent due to their clinical
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condition and therefore diagnostic HIV tests were carried out in some cases. HIV 
testing of participants’ anonymised stored samples was planned at the end of the trial 
to give an overall unlinked percentage of HIV seropositivity in Phase 1 participants.
HIV tests were planned for all patients in Phase 2. Blood was sent to Tiyanjane 
clinic (voluntary comaselling and testing clinic) within QECH for testing with two 
kits: Uni-Gold Recombigen® HIV Rapid test [Trinity Biotech pic, Ireland] and 
Determine® HIV-1/2 [Abbott]. Results were obtained by the GLAM trial clerk.
HIV test results were given to patients once they were well enough to attend for 
post-test counselling. Relatives and patients’ guardians were all encouraged to 
attend for voluntary counselling and testing for HIV regardless of the patient’s HIV 
status. All patients found to be HIV positive were informed of their results before 
discharge horn hospital. Tills was done by a member of the GLAM team or via 
Tiyanjane clinic. On discharge, patients were commenced on co-trimoxazole 
prophylaxis and referred to the antiretroviral (ART) clinic.
At the start of the study eligibility for ARTs in Malawi was determined by WHO 
clinical staging system 177; during the study, from 2006 onwards, CD4 counts 
became more readily available and these were increasingly used prior to 
commencing ARTs. Bacterial meningitis is a WHO stage III disease and patients
63
were therefore eligible for free and indefinite access to ARTs under the current 
programme. Recruitment to the trial did not result in any delay in access to ART.
2.14 In-patient care
Documentation
All documentation including the proforma, any forms and laboratory specimens were 
labelled by hand with the GLAM Study number.
The signed informed consent, die proforma (with enrohnent data fonn, inclusion and 
exclusion check list, and results) and any additional sheets of continuation paper were 
placed in a plastic file on the GLAM desk close to the patient’s bedside. These 
formed tire patient’s notes. Files were not stored at the end of patients’ beds because 
of staff and patients’ concerns regarding confidentiality with visitors reading the 
notes.
On discharge, the notes were removed from the file, given to the PI for checking and 
stored until the follow-up visit. On discharge, the GLAM study number and the date 
of the 40-day follow-up appointment was recorded in the study register and into the 
patient’s health passport (handheld notes).
Once the follow-up visit had taken place, the notes were returned to the PI to ensure 
the proforma was complete before it was fransferred to MLW statistics department for 
data to be entered into the study database.
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Confidentiality
Details of individuals participating in the study remained confidential. The study was 
conducted in accordance with standard clinical practice in relation to patient 
information, hi addition study participants’ files which constituted patient notes were 
kept accessible to staff members but away fiom participants5 bedsides and HIV test 
results were kept in the filing cabinet on the ward and at discharge, results were 
written into the proforma and the patient asked to attend Tiyaniane clinic for 
counselling.
Following discharge, all study participants’ files were kept securely in the Pi’s office 
until transfer to MLW statistics department for data entry. Files were only accessible 
to the study team. Database entries did not include names or addresses, only study 
numbers and initials. Databases were password protected.
Patient care on the wards
Patients were treated in hospital for a minimum of 10 days and looked after on the 
general medical wards by the GLAM trial team during their inpatient stay.
Each day, the trial nurses carried out assessment and measurement of a participant’s 
pulse, temperature, blood pressure, respiratory rate, urine output and blood glucose. 
Observations were performed twice daily while the patient was taking study drug 
and once a day thereafter. Results were recorded in the proforma.
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Participants were examined daily by a Trial Clinical officer or the PI. This included 
assessment of clinical progress, GCS and potential side effects of glycerol - 
confusion, fits since admission, diarrhoea, nausea, vomiting, dizziness, anuria, 
jaundice or other event. Patients were examined for signs of aspiration pneumonia - 
crackles in the chest or respiratory distress - and a chest radiograph was requested if 
new signs in the chest developed. All details were entered into the proforma.
The Clinical Officer also dealt with any other medical problems as appropriate and in 
consultation with the PI if necessary. Patients could be transferred to a high 
dependency unit for oxygen therapy if required; antibiotic therapy could be modified 
if indicated by sensitivity patterns or clinical response.
Those unable to swallow safely or those with a GCS <8 had a NG tube inserted for 
administration of study drug; tire NG tube was also be used for administration of 
fluids, other medication and nutrition (if the guardians consented).
Patients were closely monitored for hyperglycaemia. While taking study drug, 
capillary whole blood glucose (BM) was measured twice daily using disposable 
Glucostix® (Bayer Diagnostics). These are visually inteipreted reagent strips — a 
large drop of blood is placed on the Glucostix® test pads, then blotted after 30 
seconds, after a further 90 seconds the result is read visually from the colour blocks 
found on the bottle, A larger green pad measures blood glucose levels from 1-6
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mmol/L the other smaller orange pad measures blood glucose levels from 8^44 
mmol/L.
Dischar ging patients home
On the day of discharge, the health passport (handheld patient notes) were completed 
to record the admission, management and GLAM Trial number. Patients were given 
an appointment to return for a Day 40 review. Money for transport was given on 
Day 40 once reviewed.
The completed proforma was given to the PL
2.15 Management of side effects
Hvnerglvcaemia
If the blood glucose rose above 20 mmol/L and ketonuria was present, study drug 
was discontinued, adequate hydration ensured and management for diabetic 
ketoacidosis commenced (according to protocol, Department of Medicine, College 
of Medicine). If ketonuria was absent, study drug was discontinued. Blood glucose 
was continued to be observed and adequate hydration maintained.
Ideally, an IV infusion of insulin would have been used to maintam 
nonnoglycaemia. This was not possible on the general medical wards at QECH. 
Following discussion with the TSG and DSMB, it was felt that attempting to give 
insulin for hyperglycaemia was more likely to be hazardous - the risks of
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hypoglycaemia and hypokalaemia combined with the loss of practical application of 
results (insulin given in this context would be even more unsafe out-with a trial 
setting) led us to exclude insulin as part of standard care for hyperglycaemia in 
GLAM.
Persistent hyperglycaemia was treated as new onset diabetes and managed with oral 
hypoglycaemic agents (or as diabetic ketoacidosis if the patient was unable to 
swallow).
Aspiration pneumonia
A chest radiograph was requested on any patient who developed signs or symptoms 
suggestive of aspiration - cough, shortness of breath, fast respiratory rate, or crackles 
in the chest. The radiograph was looked at by the PI to identify radiological signs of 
aspiration; it was also used to check the position of the NG tube.
If a diagnosis of aspiration pneumonia was made, Gag reflex and ability to swallow 
was assessed and the patient was commenced on metronidazole (orally if swallow 
safe, via NG or intravenously otherwise).
Swallow assessment:
Ensure GCS >7/15 (If GCS <8/15, swallow unsafe, insert aNG tube).
Sit the patient up, give a few small sips of water.
If the patient coughs or has difficulty, the swallow is unsafe.
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Insert a NG tube if swallow unsafe.
Other possible side effects
Patients were reviewed daily for side effects of glycerol mcluding headache, 
diarrhoea, nausea, vomiting and bloating. These were treated symptomatically:
i. Promethazine and/or other anti-emetics for nausea and vomiting
ii. Loperamide for diarrhoea
iii. Paracetamol and/or ibuprofen for headache.
Adverse events were recorded and reported to the DSMB (see Appendix 8).
2.16 Measurement of endpoints and follow-up
Trial endpoints were:
For Phase 1: Tolerability of glycerol adjuvant therapy and serious adverse events 
Mam trial primary endpoint: death by Day 40 
Main trial secondary endpoints:
1) Death by Day 10.
2) Death or disability (Glasgow Outcome Score (GOS) 1&2) at Day 40.
3) Hearing loss at Day 40.
4) Occurrence of all serious adverse events other than death (reported as part of the 
endpoint).
5) Incidence of adverse events in the 10 days of follow-up (during the antibiotic 
treatment period), including gastrointestinal side effects (defined as vomiting,
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diarrhoea or nausea), and fits.
6) CSF opening pressure after 2 days of therapy.
7) Time to death.
8) Incidence of raised blood glucose (capillary blood glucose >11.1 mmol/L).
9) Per-protocol analysis day 40 deaths restricted to those not withdrawn from 
glycerol/placebo.
10) Days to GCS >13.
Patients were formally reviewed at 10 days and after 40 days. At review, patients 
had a standardised neurological examination including fimdoscopy, hearing 
assessment, ONSD measurement and GOS.
If a patient failed to attend their Day 40 follow-up appointment, a probation period of 
1 week after non-attendance at a 40-day follow-up appointment was given. After this, 
attempts were made to locate them by travelling to their home or village. If the 
patient was still not found, verbal report of a patient’s death was accepted as was a 
verbal report that they were alive (but lost to follow-up).
For survivor’s, the principal outcome measure were the GOS (Table 5), which 
provides a measure of functional ability and/or dependency irrespective of the 
nature of neurological deficit 14 and hearing loss. Disability was represented by 
scores of 1, 2 or 3.
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Table 5. Definitions of the Glasgow Outcome Score measures
OS Definition
4 No disability. Minor neurological deficits which had no impact on any 
activity of daily living were allowed e.g. isolated cranial nerve palsies, 
unilateral hearing loss
3 Disabled but functionally independent and able to return to work or school
2 Disabled and dependent upon others on a daily basis (including severe 
bilateral hearing loss). Unable to return to previous level of work or school
1 Disabled and completely dependent
0 Death
2.17 Management of the trial
This followed the principles laid down in the MRC guidelines for good clinical 
practice in clinical trials, which are concordant with the International Conference 
on Hannonisation's Good Clinical Practice Guidelines.
Trial Steering Group
The TSG provided overall supervision of the study, and in particular', provided 
independent advice through the chairman of die group to die Investigator, the MRF 
and the Host institutions. The group incorporated individuals with relevant 
complementary experience and skills to advise on die running of a randomised 
controlled trial of glycerol adjuvant tiierapy in adult bacterial meningitis in Africa.
Plans for TSG meetings were made prior to commencing recruitment and took place 
before die trial started, shortly after the trial started and towards the end of 
recruitment.
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The TSG met at least twice per year. More frequent email correspondence ensured 
die TSG chair was kept infonned regularly of trial progress. An annual progress 
report was produced detailing recruitment numbers, numbers of deaths, summary of 
adverse events and trial progress (see Appendix 10, TSG members and terms of 
reference).
Data and Safety Monitoring Board
Two of the DSMB members were situated locally enabling them to visit the trial site 
to ensure Trial protocol and GCP was maintained; the other member was based in 
the UK and was kept informed by email (Appendix 11 DSMB). The DSMB were 
actively involved in the trial from the outset and reviewed a summary of Phase 1 data 
prior to commencement of Phase 2. They also received annual progress reports and 
interim reports of mortality which included a summary of all deaths (age, diagnosis, 
treatment given, time to death, cause of death) to guide when the interim analysis 
was likely to be required. The interim analysis was planned after 100 deaths.
Due to geographical constraints, neither the TSG nor the DSMB were able to meet 
physically regularly but virtual meetings via email occurred regularly.
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2.1$ Data management and analysis plan
All clinical data, laboratory results and outcome measures were recorded on a 
GLAM trial proforma (Appendix 3). Once completed, the information was double 
entered into the Access (Microsoft) database by MLW statistics department. 
Following data entry, the forms were filed in MLW statistics department. 
Participants' names were not recorded on the computerised database.
The trial databases were used to perform the interim and final analysis. Data were 
analysed with STATA 8.0 (Statacorp) and SPSS version 18.
The following data is verifiable from source documents: signed consent forms; dates 
of visits including dates glycerol given; CSF opening pressure on admission and 
after 48 hours; laboratory results; eligibility and baseline values for all patients; all 
clinical endpoints; all serious/severe adverse events; clinic compliance.
An initial blinded analysis was performed to check the completeness of data, the 
analytical method and the linkage of the database files and this was followed by a 
planned unblinded analysis following 100 deaths. The DSMB then advised early 
discontinuation of the trial and this was agreed by the TSG. The final analysis then 
went ahead as an intention-to-treat analysis.
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Statistical assumptions
The assumptions used to calculate the required sample size included placebo: 
glycerol equals 1; the death rate was around 50% and the prevalence of adult proven 
bacterial meningitis (in QECH) was 140 per annum (with >80% probable cases). In 
addition, for Phase 2, (power calculations based on a 0.05, p 0.9 indicate that) 216 
patients per arm were required to detect a 30% reduction in mortality from 56% to 
40%. Incidence at the time of calculation meant this would likely be achieved within 
30 months of recruitment to Phase 2.
Estimates of patient recruitment rates and follow-up rates of over 95% were 
considered entirely realistic based upon data from the steroid trial performed in the 
same setting I2, I4. Sample size calculations were revised to take into account the 
study design and provide 90% power to detect a fall in mortality from 56% to 40%. 
A change in mortality of this magnitude or greater is likely to be considered of 
clinical relevance to most clinicians in Malawi.
Effect of glycerol on change in CSF pressure: assuming that at least 56% of patients 
will remain alive and consent to the second lumbar puncture at 48 hours, the study 
will be powered at 90% to detect a fall in CSF pressure of 4 cm CSF with a = 0.01.
Sample size calculations for residual neurological deficit were not stated since data 
from the steroid trial suggested that this is a rare event (10.2%). It was anticipated
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that an increase in the number of patients surviving with neurological sequelae 
could occur- if there was a significant reduction in mortality in the treatment arm. 
Sub-analyses by HIV status was not planned as over 90% of patients were likely to 
be HIV positive.
It was calculated that two hundred and sixteen patients per treatment arm (432 
patients in total) would be required to provide data on efficacy of glycerol adjuvant 
therapy. Therefore, it was planned that recruitment for Phase 2 (Mam trial) should 
continue until 450 patients had been recruited (or the trial stopped if the TSG 
decided to halt recruitment on the basis of a recommendation from the DSMB).
Original GLAM analysis plan:
Phase 1: Tolerability of glycerol adjuvant therapy and serious adverse events.
Phase 2 (main trial) primary endpoint: death by 1 month.
Secondary endpoints:
1) Physician decision to alter treatment based on die occurrence of complications.
2) Death or residual neurological deficit (GOS and hearing loss) at discharge, and 1 
month after completing antibiotic therapy.
3) Time to death, time to discharge.
4) Effect of glycerol on change in CSF pressure. We will also aim to perform a sub­
study on a limited set of patients to gain data on CSF penetration of glycerol. There 
is no published data available for this. Sample size calculations for residual
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neurological deficit have not been stated since data from the steroid trial suggest that 
this is a rare event (10.2%).
Modified analysis plan 2009:
The primary endpoint was death by Day 40; with modified intention-to-treat analysis 
(counting patients not followed to Day 40 as missing) and with die primary analysis 
using logistic regression without stratification.
Secondary endpoints included time to death, number of deaths by Day 10, and death 
and disability or hearing loss at Day 40. Disability was defined as GOS 1 or 2. 
Hearing loss (in those alive and with a GOS of 3 or 4 at Day 40) was defined as 
either subjective hearing loss, or only able to hear speaking (not finger rub or 
whispering) hi either ear or inability to hear* 40 dB on audiometry. Additional 
secondary endpoints were occurrence of all serious adverse events felt possibly to be 
due to the study drug; adverse events in the 10 days of follow-up (during the 
antibiotic treatment period), including gastrointestinal side effects (vomiting, 
diarrhoea or nausea), fits and hyperglycaemia (capillary blood glucose 
>11.1 mmol/L). CSF opening pressure after two days of therapy and days to GCS 
>13 were also analysed as a measure of effect of glycerol on ICP.
Various subgroup analyses were projected including deaths by Day 10 and 40 
according to HIV status and death by Day 40 according to diagnosis - whether
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proven (bacteria seen or cultured from CSF or blood) or probable (>100 white cells 
with 50% polymorphs in CSF but no organism isolated) bacterial meningitis and 
whether pneumococcal disease.
Primary analyses were conducted imadjusted, and in a logistic model adjusted for the 
pre-specified potential confounding factors. Potential confounding factors were 
proposed as patients’ age; gender; HIV serostatus and degree of immunosuppression 
measured by history of previous AIDS defining events (Stages 3 & 4, WHO 
classification) and whether patients were on ART; organism isolated from samples 
(proven, probable and pneumococcal meningitis); duration of symptoms (specified 
as the longest of headache, neck stiffness, confusion, fever, fits, photophobia, 
reduced conscious level) and pre-admission antibiotic use; severity of disease as 
measured by history of fits prior to admission and GCS on admission; and opening 
pressure in the second LP, as an exploratory variable to explain the outcome.
It was planned that CSF glycerol and blood glycerol levels would be measured to 
assist subsequent studies to improve dosing if glycerol was shown to significantly 
reduce mortality by Day 40.
Statistical issues.
Baseline data were reported without tests of association. Simple descriptive data 
were analysed using a Chi squared test or Fisher’s exact test as appropriate. For both 
primary and secondary outcomes, OR and 95% Cl were calculated both unadjusted
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and adjusted for predefined prognostic factors in a logistic regression model. Factors 
in the model were gender, age, GCS, length of history, fits prior to randomisation, 
organisms in blood or CSF, pre-randomisation antibiotic therapy, HIV status, prior 
AIDS defining event and history of ART. For adjusted OR, provided no more than 
10% of data on potential confounding factors for any given factor were missing, 
dummy outcome variables were used (which are around the median of reported 
variables), to avoid cases being dropped from the model.
Differences in time to death up to 40 days between the glycerol and placebo arms 
was tested using Cox’s proportional hazard ratios. These were calculated with data in 
non-failures censored at the time of last known encounter. Kaplan-Meier curves for 
the primary outcome were shown with 95% CIs.
Subgroup analyses were performed on patients with ‘proven or probable’ bacterial 
meningitis, proven bacterial meningitis alone and proven pneumococcal meningitis. 
A logistic regression model was used to explore the association between 
predetermined baseline variables selected prior to the start of recruitment and 
outcome.
The significance level for die primary outcome was determined as p<0.05. For 
secondary outcomes p<0.01 was used to determine statistical significance if the 
primary outcome was not significant. All other secondary outcomes had statistical 
tests which are informative but were not used to claim a difference between study
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arms. Data were handled and analysed by K. Ajdukiewicz, PI; C. Wliitty and B. 
Faragher, statisticians. A locked database was sent to N. French, TSG Chairman 
prior to unblinding and analysis.
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CHAPTER 3: RESULTS 
TOLERABILITY STUDY
DOSE FINDING AND
3.1 Baseline characteristics
The dose-finding study commenced in March 2006 and recruitment continued until 
July 2006. Forty five patients with symptoms, signs and CSF findings compatible 
with bacterial meningitis were randomised to the three doses of glycerol for 
assessment of glycerol tolerability. Baseline characteristics were similar* in all groups 
(Table 6).
Phase 1 was expected to take 3 months but recruitment was slower than anticipated, 
wards were quieter than usual during this period and this was thought to be due to a 
number of factors: crops grew well this year and many people went back to their 
villages to assist with the harvest; following the harvest, guardians may not have been 
able to spare time to bring individuals to hospital thus reducing admissions and 
delaying presentation; this was followed by cold weather which often results in a fall 
in admissions to tire hospital.
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Table 6. Baseline characteristics in Phase 1
Group 1:
50 ml glycerol 
four times a 
day (n=15)
Group 2:
75 ml glycerol 
four times a 
day (n=15)
Group 3:
100 ml glycerol 
four times a 
day(n=15)
Prior AIDS defining illness 
Stage modified WHO 3 or 4 
(%)
8 (53.3) 6(40) 8 (53.3)
Age [years] : median (IQR) 32 (26-37) 35 (26-40) 32 (20-47)
Female (%) 10(66.6) 8 (53.3) 10(66.6)
Initial GCS <12 5 (33.3) 3 (33.3) 6(40)
CSF white cell count: 560 1000 160
median (IQR) (125-2080) (160-2080) (124-1040)
Proven bacterial (%) 6(40) 7 (46.7) 7 (46.7)
Pneumococcal disease (%) 6(40) 6(40) 6(40)
CSF opening pressure: 
median (IQR)
20 (3.5-32.5) 21.5(16.5-32) 16(10-20.5)
Fits or history of fits in last
2 weeks
6(40) 3(20) 3(20)
Prior antibiotic use (%) 7 (46.7) 6(40) 3(20)
Duration of symptoms: 
median (IQR)
3 (3-5) 3 (2-8) 4(3-7)
IQR=interquartile range
A causative pathogen was isolated in 22 patients (47 %): 18 S. pneumoniae, one H. 
influenzae, two Cryptococcus neoformans and one Escherichia coli.
3.2 Adverse events and tolerability
There was no clear relationship between the dose of glycerol and frequency of side 
effects (Table 7). Approximately 50 % experienced nausea, vomiting or diarrhoea. 
Vomiting did not occur in patients receiving glycerol via NG tube. Transiently 
elevated BM glucose >12.2 mmol/L was observed in 14 (31%). Hyperglycaemia 
ranged from 12.2 to 20.4 mmol/L in all but one patient with a single reading of
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40 mmol/L at recruitment who died prior to receiving study drug. No-one received 
treatment with insulin and five individuals had hyperglycaemia (<20.4 mmol/L) after 
glycerol had been discontinued; suggesting Type 2 diabetes or a stress response was 
the cause of the hyperglycaemia.
The 75 ml dose was best tolerated; patients randomised to the largest volume found 
it difficult to swallow. Eight patients in the 50 ml arm, seven in the 75 ml arm and 
10 in the 100 ml arm died in hospital. Based on volume tolerability the 75 ml (75 
mg) dose was used for the subsequent trial.
Table 7. Results of the dose-finding study
Group 1:
50 ml (50 mg) 
glycerol four 
times a day 
(90 ml diluted 
volume) 
(n=15)
Group 2:
75 ml (75 mg) 
glycerol four 
times a day 
(135 ml diluted 
volume) 
(n=15)
Group 3:
100 ml (100 mg) 
glycerol four 
times a day 
(180 ml diluted 
volume) 
(n=15)
Died 10(67%) 8 (53%) 12(80%)
Gastrointestinal side
effects*
7 (47%) 8 (53%) 8 (53%)
Number with capillary 
blood glucose 
>12.2 mmol/L+
5 (33%) 3 (20%) 6 (40%)
Number with proven
bacterial meningitis
4 (27%) 6 (40%) 7 (47%)
> ■- ■ u m-------- —-------------------------------—
Nausea, vomiting, diarrhoea
+WHO definition for diabetes 178
Nineteen patients (42.2%) had NG tubes inserted at some point during their 
admission. One patient developed new chest signs while an NG tube was in-situ.
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This patient was treated for aspiration pneumonia but died before a chest radiograph 
was able to be performed.
3.3 Influence of Phase 1 on Phase 2 main trial
Glycerol was well tolerated. During Phase 1, patients were not recruited overnight. 
Anyone admitted overnight with signs and symptoms of meningitis was recruited to 
the study the following morning if they fulfilled the inclusion criteria. Some patients 
did not survive to recruitment. Following Phase 1, arrangements were made to 
facilitate recruitment to the study overnight - anyone fulfilling inclusion criteria with 
cloudy CSF was able to be entered into the study if they gave informed consent.
There is evidence that patients with hyperglycaemia following stroke, acute 
myocardial infarct, pneumonia and those acutely ill on intensive care do less well 
than those with normoglycaemia l79. Aiming for a blood glucose level of <8 mmol/L 
is reasonable in the acutely ill, even in those who are not known diabetics. The 
mechanisms of benefit of euglycemia appear to be multifactorial180484
There is limited evidence available on patients with severe sepsis or septic shock. A 
meta-analysis 185 found no mortality benefit to glucose - insulin - potassium (GIK) 
infusion in critically ill patients although they acknowledge that studies were 
restricted to acute myocardial infarction and cardiovascular' surgery patients.
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During Phase 1 we modified the exclusion criteria by introducing a capillary blood 
glucose measurement at recruitment and excluding those with capillary blood glucose 
>12 mmol/L. Although transient hyperglycaemia can occur as a stress response in 
sepsis and other acute illnesses, glycerol induced transient hyperglycaemia (and 
increased serum osmolality) is thought to be clinically significant in those with Type 
2 diabetes and we therefore wanted to avoid giving glycerol to anyone with 
undiagnosed Type 2 diabetes. In addition, it was proposed that those who developed 
hyperglycaemia (blood glucose>20 mmol/L) subsequently should have then study 
drug discontinued and be managed with rehydration in die first instance and for 
diabetic ketoacidosis if ketonuria was present (according to hospital management 
guidelines). It was agreed, in discussion with the TSG and DSMB, that 
administration of IV insulm for transient hyperglycaemia would not be safe in view 
of limited monitoring options for serum potassium levels and blood glucose, 
particularly overnight.
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CHAPTER 4: RESULTS - INTERVENTION TRIAL
4.1 Patient recruitment and flow through the trial
The intervention trial started on 10 September 2006, and recruitment was stopped on 
23 August 2008 following a planned interim analysis after 100 deaths. The data 
safety monitoring board advised halting recruitment on the grounds of futility; with 7 
months of the trial still to run and 61% of the predetermined recruitment achieved. 
Patients already recruited to the trial were followed up until completion of follow-up 
or the primary endpoint was reached.
Three thousand seven hundred and sixteen patients were screened; 265 (70%) of 380 
patients who fulfilled entry criteria, were randomised, 137 (51.7%) received glycerol 
and 128 (48.3%) placebo (Figure 4).
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Figure 4. Flow through the trial
128 received placebo137 received glycerol
380 met entry criteria
0 lost to follow-up 
1 withdrew consent
2 lost to follow-up 
1 withdrew consent
265 were randomised to the trial
Day 40 outcome 
125
Day 40 outcome 
136
3716 patients underwent lumbar puncture
371 had cryptococcal meningitis
799 had lymphocytic or non-diagnostic
CSF
2166 had normal CSF
63 died before recruitment 
18 refused consent 
13 were pregnant 
3 were below 16 years old
2 cryptococcal meningitis
3 outpatients
13 other reasons (3 lab data missing; 6 
patients not found; 1 unnamed sample; 1 
GLAM patient readmitted; 2 our error)
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4.2 Baseline characteristics
Admission characteristics and laboratory results were similar in the glycerol and 
placebo arms (Table 8). One hundred and eighteen (44.5%) patients were diagnosed 
as having microbiologically proven bacterial meningitis, of whom 64 (54.2%) were 
randomised to die intervention arm and 54 (45.8%) to the placebo aim; 122 patients 
were found to have probable bacterial meningitis, of whom 63 (51.6%) were 
randomised to receive glycerol and 59 (48.4%) to receive placebo.
Twenty five patients (9.4% of recruited patients) were randomised but subsequently 
found to have diagnoses other than bacterial meningitis; 13 cryptococcal meningitis, 
three likely tuberculous meningitis (with lymphocytic CSF) and nine had cloudy 
CSF with less tiian 100 white cells — some of these may have had a traumatic lumbar 
puncture resulting in CSF turbidity. All were included in the intention-to-treat 
analysis.
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Table 8. Baseline characteristics in intervention trial
Placebo
(n=128)
Glycerol
(n=137)
HIV seropositive* 104 (83.9%) 111 (82.8%)
Prior AIDS defining illness Stage modified 
WHO 3 or 4 33 (25.8%) 36 (26.3%)
Age [years] : median (IQR) 32 (27-38) 32 (27-40)
Female 67 (52.3%) 72 (52.6%)
Initial GCS <12 48 (37.5%) 39 (28.5%)
CSF white cell count: median (IQR) 400 (200- 1040) 395 (200-1120)
Proven bacterial 54 (42.2%) 64 (46.7%)
Pneumococcal disease 52 (40.6%) 46 (33.6%)
CSF opening pressure : median (IQR) 28(18-34) 21.5(12.5-34)
Fits or history of fits in last 2 weeks 51 (39.8%) 49 (35.8%)
Prior antibiotic use (%) 59 (46.1%) 53 (38.7%)
On antiretrovirals (%) 16(12.5%) 23(16.8%)
Duration of symptoms: median (IQR) 6 (3-8) _____* (3-7)
HIV status not known for four patients receiving placebo and three patients receiving glycerol
4.3 Clinical presentation
4.3.1 Symptoms
The prevalence of symptoms amongst patients with proven and with probable 
bacterial meningitis are shown in Table 9. The most common symptoms reported 
were headache (257: 97.0%) and fever (244: 92.1%). Photophobia was reported in 
47 (17.7%) cases and fits prior to admission in 100 (37.7%) cases.
Amongst patients with proven acute bacterial meningitis (ABM), a history of fitting 
was not more common in patients with pneumococcal disease (21/98: 21.4%) 
compared to those with non-pneumococcal bacterial meningitis (7/20: 35.0%) 
[Fisher exact test p=0.248].
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A history of headache or fits was more common in those with probable meningitis 
than proven bacterial meningitis (p=0.018 and p=0.048 respectively); a history of 
reduced conscious level or confusion were both more likely in those with proven 
bacterial meningitis (pO.OOl and p=0.001 respectively).
Table 9. Demographic and historical characteristics of patients with proven and 
probable bacterial meningitis
Proven ABM 
(n=118)
Probable
ABM
(n=122)
Fisher exact 
test p-value
History <48 horns 23 (19.5) 16(13.1) 0.221
History headache 108 (91.5) 120 (98.4) 0.018
History fever 110(93.2) 114(93.4) 1.000
History neck stiffness 97 (82.2) 97 (79.5) 0.626
History photophobia 14(11.9) 24 (19.7) 0.113
History of fits 28 (23.7) 44(36.1) 0.048
History of reduced conscious level 87 (73.7) 56 (45.9) <0.001
Reduced conscious level on 
admission (GCS <12) 53 (44.9) 30 (24.6) 0.001
History of confusion 85 (72.0) 63 (51.6) 0.001
4.3.2 Length of history and pre-hospital care
Median time to presentation was 6 days (IQR 3-9; range 0-140 days). The majority 
of patients (184/265; 69.4%) had sought or received some form of medical advice or 
therapy prior to presenting to hospital (Figure 5). Receipt of antibiotic therapy prior 
to recruitment was recorded in 112 (42.3%). The proportion of patients with a 
delayed time to presentation was significantly greater in those who had received pre-
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admission antibiotics (101/112: 90.2%) than in those who had not (116/148: 78.4%) 
[Fisher exact test p=0.012].
Figure 5. Treatment obtained prior to admission
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Table 10. Exposure to antimicrobials prior to recruitment
Antimicrobial Number of patients 
n=112 (%)*
Penicillin V / Amoxicillin (+- clavulanic acid) 26 (23.2)
Chloramphenicol 13(11.6)
Erythromycin 6(5.4)
Ceftriaxone / Cefotaxime 5 (4.5)
Anti- tuberculous therapy 6(5.4)
Doxycyline 9 (8.0)
Cotrimoxazole 49 (43.8)
Metronidazole 2(1.8)
Ciprofloxacin 6(5.4)
Fansidar™ 70 (62.5)
Fluconazole 3 (2.7)
Benzylpenicillin 13(11.6)
Gentamicin 5 (4.5)
*Eighty one patients had combination antibiotic therapy prior to admission; nine were taking 
cotrimoxazole prophylaxis
Those with probable meningitis were significantly more likely to have received 
antibiotics prior to admission than those with proven bacterial meningitis (65/122: 
53.3% vs 36/118: 30.5%) [Fisher exact test pO.OOl]. A wide range of antibiotics 
were taken; 81 patients received combination antimicrobials while nine patients were 
taking cotrimoxazole prophylaxis (Table 10).
Oral sulphadoxine-pyrimethamine (Fansidar™), the first line therapy for treatment 
of malaria in Malawi during the study, was received by 70 (26.4%) patients prior to 
presentation at some time during the course of the presenting illness. Thirty three 
(12.5%) patients had received quinine and 3 (1.1%) an artesunate-based preparation.
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Attendance at a traditional healer was reported by 40 out of 254 (15.7%) patients - 
the majority of these (25: 62.5%) received herbal preparations to drink or eat; others 
had scarification or body adornments.
4.3.3 Examination and laboratory characteristics
Ninety/265 (34.0%) of patients had a recorded admission temperature of >38°C. A 
fever was more likely to be present in patients with proven bacterial meningitis than 
in patients with probable bacterial meningitis (p<0.001). Reduced conscious level 
(GCS <12) and neck stiffness were also more likely to be present in those with 
proven bacterial meningitis (p=0.001).
The triad of fever, neck stiffness and change in mental status which describes the 
severe meningitis phenotype I71, was present in only 39/265 (14.9%) of patients 
(Table 11). It was more likely to be present amongst patients with proven bacterial 
meningitis as compared to patients with probable bacterial meningitis (23.7% vs 
7.6%; p=0.001).
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Table 11. Prevalence of fever, reduced conscious level and neck stiffness at
presentation
Proven ABM Probable ABM Fisher exact test p-value
Temp >38°C 55/118(46.6%) 27/120 (22.5%) <0.001
GCS <12 53/115(46.1%) 30/121 (24.8%) 0.001
Neck stiffness on 
examination
111/117
(94.9%) 98/121 (81.0%) 0.001
Triad of all 3 28/118(23.7%) 9/119(7.6%) 0.001
Neurological examination
Excluding examination of the eighth cranial nerve, 43 patients (27.9%) of 154 who 
were adequately assessed had a cranial nerve palsy identified on admission and 
208/261 (79.7%) had focal limb paresis. Overall, in 260 patients who had a 
systematic examination, focal neurological deficit was identified in 210 (80.8%) 
patients at the time of admission. (Eighth cranial nerve palsies and abnormal deep 
tendon reflexes were not included in this analysis).
There were limited data available on baseline hearing assessment or visual acuity 
due to the inability to assess these in such a sick population. Deafness at baseline 
was reported by patients or their guardians in 5/134 (3.7%) in the glycerol arm and 
3/127 (2.4%) in the control arm (p=0.723).
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There was no significant ditTerence between the two groups in terms of baseline 
neurological deficits including cranial nerve palsy, limb paresis or visual 
impairment. Those with proven meningitis were more likely to have a cranial nerve 
palsy at presentation compared with those with probable bacterial meningitis (Tables 
12 and 13). There was no correlation between cranial nerve palsy and CSF OP or 
ONSD. In those who had CSF OP measured. 19/34 (55.9%) had CSF OP >20 cm 
and 15/34 (44.1%) CSF OP <20 cm (p=0.838). Nine/34 (26.5%) had ONSD >5 mm 
and 25/34 (73.5%) ONSD <5 mm (p=0.326).
Table 12. Baseline neurological assessment
Placebo (%) Glycerol (%)
Fisher exact 
test
p-value
Cranial nerve palsy 16/69 (23.1%) 27/85 (31.8%) 0.280
Limb paresis 102/125 (81.6%) 106/136 (77.9%) 0.538
Focal deficit 102/125 (81.6%) 108/135 (80.0%) 0.756
Debility (GOS 1 or 2) 1/127 (0.8%) 2/135(1.5%) 1.000
Blindness 3/49 (6.1%) 1/65(1.5%) 0.313
Deafness 3/127 (2.4%) 5/134 (3.7%) 0.723
Table 13. Baseline neurological assessment according to diagnosis
Proven ABM 
(%)
Probable ABM
(%>
Fisher exact 
test p-value
Cranial nerve palsy 27/60 (45.0%) 16/78 (20.5%) 0.003
Limb paresis 96/115 (83.5%) 95/121 (78.5%) 0.408
Focal deficit 98/114(86.0%) 95/121 (78.5%) 0.173
Debility (GOS 1 or 2) 2/117(1.7%) 1/121 (0.8%) 0.617
Blindness 2/33 (6.1%) 1/65 ( 1.5%) 0.262
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4.3.4 Predisposing factors
a) Local factors
Features from the history which might represent predisposition to secondary 
bacterial meningitis including otitis media or ear* discharge were seen in 8/41 
(19.5%) patients complaining of earache on admission. No patient gave a history of 
neurosurgery, head injury or prosthetic implants at any site.
b) Immunocompromise
No patients known to have diabetes mellitus were recruited to the study; all patients 
had a random capillary blood glucose measurement at admission, one patient had 
levels of >11.1 mmol/L. None remained persistently hyperglycaemic. No patient 
had a blood glucose of < 3 mmol/L at admission.
One hundred and one patients (38%) were aware they were HIV positive at 
recruitment but only nine were on cotrimoxazole prophylaxis and seven on 
antiretroviral therapy. Eight patients stated they were HIV negative; two of these 
tested HIV positive during the study. HIV serostatus was not known in 156 (59%) at 
the time of recruitment. Out of 258 patients tested, 215 (83.3%) were subsequently 
foimd to be HIV seropositive; 43 (16.7%) were HIV negative.
4.3.5 HIV serostatus
HIV test results were positive in 78/98 (79.6%) with pneumococcal meningitis and 
in 105/122 (86.1%) patients with probable bacterial meningitis (p-0.210). In those
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with proven bacterial meningitis, those with pneumococcal meningitis were 
significantly more likely to be HIV infected than those with non-pneumococcal 
meningitis (78/98 [79.6%] vs 11/20 [55.0%]; p=0.042).
4.3.6 Blood cultures
In patients with proven bacterial meningitis, blood cultures were positive in 47/118 
(39.8%) cases. The proportion with positive blood cultures was significantly lower 
in pneumococcal meningitis as compared to non-pneumococcal meningitis (30/98 
[30.6%] vs 10/17 [58.8%] respectively; p=0.030). Positive blood culture formed part 
of the definition for proven bacterial meningitis.
4.3.7 CSF examination
Organisms were seen on Gram’s stain in 81 out of 118 (68.6%) CSF specimens from 
patients with proven bacterial meningitis. A total of 25/103 (24.3%) patients had a 
positive CSF culture without a positive Gram stain, and seven patients had a positive 
blood culture with a CSF neutrophil pleocytosis but negative CSF Gram stain and 
culture.
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Table 14. Effect of pre-admission antibiotics on blood/CSF culture and CSF
gram stain positivity
Pre-admission
antibiotics
No antibiotics 
(%)
Fisher exact test 
p-value
CSF Gram stain positive 19/106(17.9%) 60/143 (42.0%) <0.001
CSF culture positive 33/111 (29.7%) 70/149 (47.0%) 0.007
Blood culture positive 18/103(17.5%) 28/130(21.5%) 0.509
CSF or blood culture 
positive 35/106 (33.0%) 79/142 (55.6%) <0.001
Preadmission antibiotic therapy significantly reduced the rate of CSF gram stain and 
culture positivity (Table 14). Of the 112 patients who were reported to have received 
either antimicrobial therapy (including Fansidar but excluding quinine) within the 48 
hours prior to randomisation, organisms were seen on Gram stain in 17.9% of cases 
as compared to 42.0% of antibiotic naive patients (pO.OOl). Pre-admission 
antibiotic therapy reduced the rates of CSF or blood culture positivity from 79/142 
(55.6%) to 35/106 (33.0%) (pO.OOl).
The CSF white cell count ranged from 0 to 13600. Median CSF white well count 
was 400/pl (IQR 200-1070). Median CSF white cell count was 400/pl in both 
proven bacterial meningitis (IQR 200-1070) and pneumococcal disease (IQR 240- 
1320); median CSF white cell count was 440/pl in non-pneumococcal disease (IQR 
220-1050).
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Quantitative assessment of CSF glucose and protein was not available for the 
majority of the study. Multistix reagent strips 69 were used and low CSF glucose of 
<5.5 mmol/L was indicated if “negative” or “trace” and CSF protein >1 g/L by >3+ 
(“++-I-” or “Ml I ”) on Multistix.
Table 15. Low CSF glucose and high protein
Low CSF glucose High CSF protein Low CSF glucose + high protein
Pneumococcal
meningitis
70/78
(89.7%)
p=0.053
80/86
(93.0%)
p=0.021
68/77
(88.3%)
p=0.123Non-
pneumococcal
meningitis
12/17
(70.6%)
13/18
(72.2%)
12/17
(70.6%)
Bacterial
meningitis
82/95
(86.3%) pO.OOl
93/104
(89.4%) p=0.002
80/94
(85.1%) pO.OOlProbable
meningitis
63/106
(59.4%)
79/110
(71.8%)
62/105
(59.0%)
170/225 (75.6%) of patients had low CSF glucose and 185/238 (77.7%) had high 
CSF protein of >1 g/L (Table 15). Low CSF glucose and high protein were more 
likely with proven bacterial meningitis then probable meningitis (p<0.001).
4.4 Diagnoses
Two hundred and forty (90.5%) cases fulfilled the criteria for bacterial meningitis 
and the diagnosis of bacterial meningitis was excluded in 42 (15.8%) subsequent to 
randomisation. A causative bacterial pathogen was identified in the blood or CSF of 
118/265 patients (44.5%) thus defining the group of patients with proven bacterial 
meningitis. 122/265 (46.0%) had no bacteria isolated; these were classified as
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probable bacterial meningitis (this included 17 patients with cryptococcal 
meningitis). Twenty five patients did not fulfil the criteria for bacterial meningitis 
according to CSF results - 13 of these had cryptococcus, three likely TBM, two viral 
meningitis, one was unknown (85% polymorphonuclear leukocytes (PMNL) without 
white cell count) and six did not have meningitis (Figure 6). No patient reported a 
previous history of meningitis.
Three patients had microbiologically proven dual infection; all had cryptococcal 
meningitis, two with concurrent Group A streptococcal and one with pneumococcal 
meningitis (see Table 16).
Figure 6. Diagnoses
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Thirty three (12.5%) had a sole diagnosis of cryptococcal meningitis - all fulfilled 
entry criteria based on cloudy CSF but 13 were subsequently found to have CSF 
white cell count <100. Seventeen patients who fulfilled entry criteria based on CSF 
white cell count and differential were found to have cryptococcal meningitis either 
on CSF culture, blood culture, CSF microscopy or CRAG. For the purposes of 
analysis, these cases were classified as probable bacterial meningitis as per protocol.
Table 16. Organisms isolated
Organism Number of cases 
(%)
S. pneumoniae 97 pneumococcus only1 pneumo +crypto 98 (37)
Neisseria meningitidis 6 (2.3)
H influenzae 0
Other Gram-negative
E. coli 4
Non-typhi Salmonella 1
Klebsiella spp. 1
6(2.3)
Other Gram-positive
Group A Streptococcus 2
Group A Strep + crypto 2 
Staphylococcus aureus 1
Other Strep 3
8 (3.0)
Cryptococcal meningitis Cryptococcus only 30 (dual infection 3)
30 (11.3)
No organism identified
Probable meningitis 105
Likely TBM 3
Other 3 [2 likely viral; 1 had 85% 
PMNL no white cell count]
No meningitis 6
117(44.2)
Thirty eight CRAG tests were performed on CSF; 29 (76.3%) of these were 
negative. All nine positive CSF CRAG tests were ha HIV infected patients and CSF
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was negative for cryptococcus on microscopy (India ink stain). Only three were 
culture positive (blood or CSF) for cryptococcus (one on second CSF).
4.5 Principal outcomes
All randomised patients received at least one dose of their assigned treatment. 
Follow-up of survivors to Day 40 was 125/128 (97.7%) in the placebo group and 
136/137 (99.3%) in the glycerol group. Outcome at 40 days from recruitment was 
thus available in 261 patients (98.5%).
Overall mortality was 147/261 (56.3%). Mortality was 64/116 (55.2%) in patients 
with proven bacterial meningitis, and 51/96 (53.1%) in patients with pneumococcal 
meningitis (Table 17). Two patients were lost to follow up (both randomised to 
receive placebo) and two patients withdrew consent (one randomised to receive 
glycerol and one to receive placebo). Withdrawal of consent was inferred from both 
patients — one absconded from the ward; the other patient’s guardians refused to 
allow insertion of a NG tube for administration of study drug.
Mortality at 40 days horn enrolment was 86/136 (63.2%) in the glycerol group and 
61/125 (48.8%) in the placebo group (adjusted OR 2.4 [95%CI 1.3-4.2; p=0.003]).
Results of the intention-to-treat analysis and the predefined analyses for those with 
‘proven and probable’ bacterial meningitis, and pneumococcal meningitis are shown 
in Table 17. Outcome in terms of mortality at 10 days or at 40 days were worse in
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the glycerol aim. Further exploratory analyses describing the association between 
predetermined baseline factors and mortality at 40 days in the two groups of patients 
are shown in Table 18; mortality was significantly higher in those randomised to 
glycerol who were female, were HIV positive, had proven pneumococcal disease, 
presented late (>48 horns into their illness) or who had CSF OP >20 cm. Outcome at 
Day 40 for those who presented to hospital early in their illness (within 48 horns of 
symptom onset) was similar in the treatment and placebo arms (mortality 14/27 
(51.9%) vs 9/16 (56.3%); p=0.976). There was no evidence that glycerol was 
effective in any subgroup.
Table 17. Outcome
Group OR (95%CI) [p-valuel
Placebo Glycerol Unadjusted Adjusted*
Died before Day 40 61/125(48.8%)
86/136
(63.2%)
1.8 (lT-3*0)
p=0-02
2-4(1-3-4-2) 
p=0-003
Died before or 
disability Day 40^
75/124
(60.5%)
93/135
(68.9%)
1-4 (0-87-2-4)
p=0-2
1-7 (0-97-3-1) 
p-0-07
Death by Day 10 53/126(42.1%)
80/136
(58.8%)
2-0 (1-2-3-2) 
p=0-007
2-7 (1-5-4-8)
p=0-001
Per-protocol analysis 
death to Day 40
57/106
(53.8%)
77/118
(65.3%)
T6 (0-9-2-8)
p=0-08
2-2 (1-2-4-1)
p=0-01
Death by Day 40 
restricted to proven 
bacterial disease
21/53
(39.6%)
43/63
(68.3%)
3-3 (1-5-7.0)
p=0-002
5-5(1-9-15-4)
p=0-001
Death by Day 40 
restricted to 20/51 31/45
3-4 (T5-8-0) 
p=0-004
8-2 (2-4-28*5)
p=0-001
pneumococcal
disease
(39.2%) (68.9%)
*Pre-specified factors HIV, age, organism in blood or CSF, antiretrovirals, pre-treatment antibiotics, 
fits prior to admission, GCS, duration symptoms, sex, prior AIDS defining events. 
fNo Day 40 data for two patients
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There was a trend towards clinically detectable hearing loss being more common in 
those receiving placebo (14/53 26.4% vs 4/43 9.3%; p=0.035). Hearing loss was 
sensori-neural in all apart from one with a dead left ear. This patient was apparently 
not aware of his deficit as did not self report deafness prior to testing.
At Day 40, disability was less common in those who had received glycerol (12/47 
[25.5%] vs 27/53 [50.9%]; p=0.013) however, there was no evidence of benefit of 
glycerol in terms of death and disability at Day 40.
Table 18. Sub-group analysis for mortality at 40 days by baseline 
characteristics
Placebo (%) Glycerol (%) p-value
(Kaplan-Meier)
Overall mortality ITT 61/125 (48.8) 86/136(63.2) 0.007
Pneumococcal disease 20/51 (39.2) 31/45 (68.9) 0.001
Other bacterial meningitis 0/2 (0) 11/18(61.1) 0.173
Probable meningitis 32/57(56.1) 36/63 (57.1) 0.651
Cryptococcal meningitis 9/16(56.3) 10/17(58.3) 0.895
Not meningitis 2/4 (50.0) 2/2(100) 0.583
Prior antibiotics 26/58 (44.8) 30/53 (56.6) 0.141
HIV positive 52/101 (51.5) 74/110(67.3) 0.005
HIV negative 5/20 (25) 9/23 (39.1) 0.299
Time to presentation <48 hour 9/16(56.3) 14/27 (51.9) 0.976
Time to presentation >48 hour 52/107 (48.6) 70/107 (65.4) 0.006
Haemoglobin <10 g/dl 18/29 (62.1) 27/35 (77.1) 0.088
GCS <12 31/48 (64.6) 32/39 (82.1) 0.023
GCS >12 30/77 (39.0) 51/93 (54.8) 0.021
Male 29/60 (48.3) 37/64 (57.8) 0.248
Female 32/65 (49.2) 49/72 (68.1) 0.008
Fits prior to presentation 23/36 (63.9) 23/36 (63.9) 0.885
Temperature >38 28/46 (60.9) 31/43 (72.1) 0.196
ONSD >5 cm Day 0 7/15 (46.7) 17/30 (56.7) 0.476
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ONSD >5 cm Day 2 3/11 (27.3) 5/12(41.7) 0.394
CSF OP >20 cm Day 0 30/62 (48.4) 35/53 (66.0) 0.025
CSF OP >20 cm Day 2 10/22 (45.5) 6/10 (60) 0.270
Most deaths occurred within the glycerol arm during the first 4 days of therapy when 
study drug was being administered (Table 19, Figure 7). By Day 2, survival was 
67,6% in the glycerol arm falling to 54.4% by Day 3 and 51.5% by Day 4. There 
was clearly a greater mortality rate within the first few days - almost half of those 
receiving glycerol had died by Day 5.
Table 19. Survival rates (%
Day Placebo Glycerol
1 91.2 83.8
2 82.4 67.6
3 79.2 54.4
4 76.8 51.5
5 71.9 50.7
6 66.3 49.3
7 63,0 45.6
8 59.8 43.4
9 58.2 42.6
10 54.9 40.4
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Figure 7. Survival to Day 40 by study drug
Kaplan-Meier survival estimates
20
analysis time
placebo glycerol
4.6 Adverse events
Rates of adverse events potentially related to glycerol were not different between the 
two arms. Two adverse events thought possibly due to study drug in view of the 
rapid and unexpected deterioration in clinical condition resulted in withdrawal of the 
patients from the trial. A 70 year old HIV positive female was admitted with 1 week 
of headache, fever and confusion and on admission had GCS 13/15. She was 
randomised to receive glycerol. Her conscious level improved but on Day 2 she 
developed seizures refractory to anticonvulsant therapy and she became hypertensive 
(170/90 mmHg from a baseline of 120/80 mmHg). Salmonella typhimurium was
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cultured fi'om CSF; a second lumbar puncture was not carried out and study ding 
was discontinued on Day 3. She died on Day 12. The second case was a 35 year old 
HIV positive female with a 1 day history of ilhiess and GCS 12/15 on admission 
who was randomised to placebo. She improved rapidly to GCS 15/15 by Day 2; S. 
pneumoniae was cultured from blood and CSF. Discharge was planned on Day 10 
when she developed generalised weakness and vomiting without fever; she 
maintained a normal blood pressure and good urine output. On Day 11 her 
conscious level fell to GCS 6/15, no focal neurological deficit was identified. She 
died on Day 13. The likely diagnosis was felt to be a major cerebrovascular event 
secondary to meningitis. CT brain scan was not able to be performed in either 
patient due to their rapid clinical deterioration.
Gastrointestinal effects
Gastrointestinal adverse events thought possibly due to the study drug were no 
different between the arms (see Table 20), There were no differences in nausea, 
vomiting or diarrhoea between the two aims.
Glycaemic control
Random blood glucose was assessed at admission, twice daily while on study drug 
and once daily thereafter. Blood glucose was not found to be above 12.2 mmol/L in 
any patient during their admission. Therefore no patient required the addition of 
insulin therapy; no patient developed diabetic ketoacidosis or evidence of
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hyperosmolar non-ketotic coma. No patients had an admission random blood 
glucose of <3 mmol/L.
Table 20. Adverse events possibly related to glycerol therapy during the first 3 
days of therapy
Event Glycerol (%) Placebo (%) Fisher exact test p-value
Hyperglycaemia* 0 0 1.000
Diarrhoea 18/136(13.2%) 20/127(15.7%) 0.602
Vomiting 58/135 (43.0%) 45/128 (35.2%) 0.208
Nausea 48/87 (55.2%) 32/76 (42.1%) 0.117
Fits 48/135 (35.6%) 25/127(19.7%) 0.006
♦Random capillary blood glucose > 12.2 mmol/L
Fits during therapy
Fits were more common in the glycerol arm particularly within the first 4 days of 
therapy (Figure 8, Table 21). The difference in rates was statistically significant on 
Days 2 and 4 (p=0.006 and p<0.001 respectively).
Fitting on Days 1-3 was a significant risk factor for death (pO.OOl) and was 
associated with worst survival outcomes. This effect was of greater importance in 
the placebo arm where the presence of fits on Days 1-3 increased the risk of death 
by 4.118 (95% Cl, 2.408-7.041; pO.OOl) whereas in the glycerol arm it was only 
1.631 (95% Cl, 1.054-2.524; p=0.028).
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Figure 8. Prevalence of fits Days 1-10
Day
Table 21. Prevalence of fits according to randomisation
Placebo (%) Glycerol (%) p-value
Day 1 22/117(18.8) 33/120 (27.5) 0.123
Day 2 9/114(7.9) 25/121 (20.7) 0.006
Day 3 9/105 (8.6) 18/104(17.3) 0.066
Day 4 4/99 (4.0) 21/85 (24.7) <0.0001
Day 5 5/93 (5.4) 9/71 (12.7) 0.157
Day 6 4/93 (4.3) 7/70(10) 0.209
Day 7 5/86 (5.8) 3/67 (4.5) 1.00
Day 8 6/81 (7.4) 3/63 ( 4.8) 0.732
Day 9 4/77 (5.2) 2/55 (3.6) 1.00
Day 10 2/74 (2.7) 2/55 (3.6) 1.00
There were highly significant differences overall between the four groups: glycerol 
or placebo, fits Days 1-3 or no fits (p<0.001). Glycerol was a significant risk factor
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for death (p=0.009) compared with placebo. In the presence of fits (Days 1-3), 
survival outcome was so poor that there was little difference between the treatment 
arms. However, in the absence of fits (Days 1—3) survival was better but glycerol 
appeared harmful in this setting and decreased survival (Figure 9).
Figure 9. Survival to Day 40 by study drug and whether fits occurred on Days 
1-3
Placebo, no fits 
Placebo fits Days 1-3 
Glycerol, no fits 
Glycerol, fits Days 1-3
Days of follow-up
4.7 Outcome predictors
In order to ascertain features associated with poor outcome, further analyses were 
pertormed (fable 18). Mortality at 40 days from randomisation for all patients and
109
for patients with proven or probable bacterial meningitis was 55%. Mortality for 
patients with proven bacterial meningitis and with proven pneumococcal meningitis 
was 55% and 53% respectively.
In patients with proven bacterial meningitis, mortality was not significantly greater 
for pneumococcal disease than for non-pnemnococcal disease (51/96 (53%) versus 
11/20 (55%) p=1.0) although the number of patients with non-pneumococcal disease 
was small.
None of the six patients with meningococcal meningitis died. The highest mortality 
(100%) was in those with Gram negative rod meningitis - all six patients died; five 
by Day 10 and one by Day 40.
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CHAPTER 5: OPTIC NERVE SHEATH DIAMETER
5.1 Introduction
Raised ICP may be a significant contributory factor to mortality and morbidity from 
bacterial meningitis 76,77 therefore early reduction of the ICP should hypothetically 
improve outcome. At the time of this trial there was little published data on 
reduction of ICP in adult bacterial meningitis; a small study in intensive care unit 
demonstrated a worse outcome with higher ICP 19. If glycerol were to be effective at 
reducing ICP it would be ideal adjuvant therapy particularly in resource poor settings 
given that it is cheap, widely available and can be administered orally.
Within the trial, we assessed ICP using CSF opening pressure, ONSD measurements 
and direct fundoscopy. We aimed to identify the presence of raised ICP and to 
determine whether ONSD was affected by glycerol therapy and if it correlated with 
CSF opening pressure at lumbar puncture. In addition, we aimed to demonstrate 
whether it can be used as a prognostic tool in this context. ONSD >5 mm was 
considered enlarged and 5 mm or less normal.
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5.2 Results
5.2.1 Phase 1: Dose finding and tolerability study
Within the dose-finding preliminary study, 39/45 (87%) patients had ONSD 
measurements at recruitment, 24/29 (83%) after 48 hour's therapy and 14/20 (70%) at 
Day 10.
Table 22. Phase 1 ONSD results
Median
ONSD [mm]
(IQR)
Daily glycerol dose 
n=45
200 mg 
(50 mg QDS)
300 mg 
(75 mg QDS)
400 mg 
(100 mg QDS)
p value (Chi2)
ONSD DayO 4.8 (4.0-5.3) 4.3 (3.&-4.T) 4.6 (4,0-5.1) 0.384
ONSD Day 2 4.9 (4.5-5.3) 4.2 (3.9-5.1) 4.2 (3.3-4.S) 0.316
ONSD Day 10 4.0 (3.8-4.3) 4.1 (3.8-4.9) 3.9 (3.9-3.9) 0.368
There was no difference in ONSD readings between the different doses at baseline, 
after 2 days therapy or at Day 10 (Table 22). The mean ONSD at recruitment was 
4.6 mm (IQR 4.0-5.0). Ten well adults who were either students or members of 
security or clerical staff and who were assumed to have normal ONSD and ICP were 
used as the controls. Mean ONSD was 3.5 mm (Table 23).
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Table 23. ONSD in controls
Sex Age (years) ONS diameter (mm)
1. M 37 2.8
2. F 37 3.4
3. F 23 2.7
4. F 36 2.8
5. F 26 3.2
6. M 57 4.0
7. M 27 3.6
8. M 39 3.6
9. M 40 3.5
10 M 21 3.7
11. M 24 4.0
12. M 27 4.3
Mean 32.8 3.5
There was no statistical difference between ONSD and CSF OP between the groups 
either at recruitment or after 2 days therapy (Table 24).
Table 24. Phase 1: ONSD and CSF opening pressure
Daily glycerol dose
200 mg 
(50 mg QDS)
300 mg 
(75 mg QDS)
400 mg 
(100 mg QDS)
P“
value
ONSD
<5
ONSD
>5
ONSD
<5
ONSD
>5
ONSD 1 ONSD 
<5 >5
CSF OP Day 0 >20 cm 4/7 1/4 5/10 1/2 2/9 0/3 0.940
CSF OP Day 2 >20 cm 2/7 0/1 2/9 0/0 1/3 1 0/0 0.968
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5.2.2 ONSD in intervention study
In the intervention trial, ultrasound measurement of ONSD was made on 196/265 
(74%) at recruitment, 123/199 (62%) after 48 hours of therapy, 88/132 (67%) at Day 
10 and 75/118 (64%) at Day 40 (Table 25). There was no statistical difference in 
ONSD between the intervention arm and the placebo arm at baseline or Days 2, 10, 
and 40.
Table 25. ONSD results: Intervention study
Glycerol 
n=128 (95% Cl)
Placebo
n=137 (95% Cl)
p-value
ONSD Day 0 4.7 (4.5-4.S) 4.4 (4.2^1.6) 0.036
ONSD Day 2 4.5 (4.3-4.7) 4.3 (4.1-4.5) 0.158
ONSD Day 10 4.4 (4.0-4.7) 4.1 (3.9-4.3) 0.158
ONSD Day 40 3.9 (3.8-4.1) 4.0 (3.9^1.2) 0.457
Raised ICP was suspected in 134 because of clinical signs (papilloedema, CSF OP 
>20 cm, abnormal eye movements or abnormal pupil reactions or GCS <8/15). No 
patient had a CT brain scan. No correlation was seen in this group between ONSD 
and CSF opening pressure (Day 0 and Day 2), GCS <8, gaze palsy or abnormal pupil 
reactions (Table 26 and Figure 10). ONSD was likely to be >5 mm in those with 
papilloedema at presentation (p=0.002).
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Table 26. Correlation between ONSD and signs of raised ICP
Day 0 After 4 8 hours therapy
ONSD
<5
ONSD
>5
P-
value
ONSD
<5
ONSD
>5
P-
value
GCS<8 18/151
(H-9)
11/45
(24.4)
0.054 16/100
(16)
5/23
(21.7)
0.542
Papilloedema on 
admission
2/105
(1.9)
6/35
(18.2)
0.002
Gaze palsy 8/90 (8.9) 5/31
(16.1)
0.314
Abnormal pupil 
reactions
5/71 (7.0) 1/21 (4.8) 1.0
CSF OP >20 62/111 
(55.9)
24/34
(70.6)
0.163 16/75
(21.3)
4/20 (20) 1.0
GCS <12 47/149
(31-5)
22/45
(48.9)
0.05 41/135
(30.3)
14/43
(32.6)
0.85
Figure 10. ONSD and CSF opening pressure
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ONSD >5 mm was not associated with increased mortality. ONSD was not a 
predictor of outcome (Table 27).
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CHAPTER 6: HEARING LOSS AND DISABILITY
6.1 Introduction
Hearing loss is the most common sequelae of bacterial meningitis in children. It 
occurs in up to 35% of survivors and is more common with pneumococcal than 
meningococcal infection 161. One paediatric study suggests that glycerol is of benefit 
in terms of reducing deafness in survivors (0% vs 7%, p=0.049)92.
6.2 Methods
Hearing was assessed by live voice speech presentation audiometry 174, 175 and, 
where possible, by single frequency (1000 Hz) pure tone audiometry at Day 10 and 
Day 40.
Patients were placed in a quiet enviromnent. The patient was faced away horn the 
person testing and the audiometer was set to ‘Pure Tone’, with 100 Hz frequency and 
initially 50 dB intensity. Each ear was tested in turn and the patient asked to indicate 
verbally or with a hand movement when a tone was heard. The process was repeated 
in a stepwise manner gradually reducing dB in order to determine the level of 
intensity (dB) at which the patient was able to hear. This was the threshold level for 
the given frequency on the audiograph for the corresponding ear.
Each step was repeated at 2000 Hz, 3000 Hz, 4000 Hz, 6000 Hz, 8000 Hz and 
finally repeated at 500 Hz.
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Mild hearing loss was defined as ‘unable to localise finger rub at approximately 5 cm 
from the ear, unable to hear whispered voice at 30cm or a hearing threshold above 40 
dB\ Severe hearing loss was defined as ‘unable to hear spoken voice at 30 cm from 
the ear or a hearing threshold of >60 dB\ For speech presentation, patients were 
asked to repeat three words presented to each ear from behind the patient, with 
occlusion of the contra lateral ear. Words were in the appropriate vernacular', 
consisted of two equally emphasised syllables and avoided high frequency sounds 
(e.g. ‘fi, ‘s’, V, ‘ch’, ‘th’). Failure to correctly repeat two or more words was taken 
to represent hearing impairment for that test. Where possible, tests were conducted 
in a setting where there was minimum ambient noise.
6.3 Results
Twenty one (21%) of 100 patients who had formal hearing assessment at Day 40 
after enrolment had detectable hearing loss. Fourteen patients had moderate-to- 
severe hearing loss, of whom three had bilateral hearing loss (Table 28). Hearing 
loss was mild in seven (7%) of these patients and was unilateral in three and bilateral 
in four. Hearing loss was more common in the control group (5/90 [5.6%] versus 
16/75 [21.3%]; p=0.026). It was not possible to formally assess hearing at the time of 
admission as most patients had impairment of consciousness at presentation and in 
addition were unable to be transferred to a quiet room for assessment.
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Eight/261 patients (3.1%) were reported by their guardians to have some degree of 
hearing impairment at the time of recruitment, only one of whom was profoundly 
deaf and unable to communicate by speech.
A total of 22/100 (22%) patients who were assessed at 40 days had a disability 
defined by the GOS. The proportion of survivors with any disability (determined by 
GOS, presence of cranial nerve palsy or limb paresis, blindness or deafness) was 
significantly higher in the control arm compared with the glycerol aim (27/53 
[50.9%] vs 12/47 [25.5%]; p=0.013).
Disability was not more common amongst patients with pneumococcal disease 
(15/38, 39.5%) compared to patients with probable meningitis (20/49, 40.8%) 
(p-1.0). There was no disability in any of the seven survivors with non- 
pneumococcal meningitis.
Patterns of hearing loss and of disability amongst survivors are presented in Table 28 
and 29.
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Table 28. Pattern of hearing loss amongst survivors who were assessed at 40 
days
Hearing Loss Glycerol
n=90
Placebo
n-75
p-value
Mild unilateral 1 2
Mild bilateral 1 3
Moderate unilateral 0 1
Moderate bilateral 0 1
Severe unilateral* 1 3
Severe bilateral 1 2
Total hearing loss 1 4
Any hearing loss 5 (5.6%) 16(21.3%) 0.026
Table 29. Pattern of disability amongst survivors who were assessed at 40 days
Day 0 Day 40
Placebo
(%)
Glycerol
(%)
p-value Placebo
(%)
Glycerol
(%)
p-value
Cranial
nerve palsy
16/69
(23.1)
27/85
(31.8)
0.280 7/53
(13.2)
3/47 (6.4) 0.328
Limb
paresis
102/125
(81.6)
106/136
(77.9)
0.538 22/53
(41.5)
10/47
(21.3)
0.034
Focal
deficit
102/125
(81.6)
108/135
(80.0)
0.756 22/53
(41.5)
10/47
(21.3)
0.034
Debility 
(GOS 1 or 
2)
1/127
(0.8)
2/135
(1.5)
1.0 14/53
(26.4)
8/47 (17.0) 0.335
Blindness 3/49
(6.1)
1/65(1.5) 0.313 3/49
(6.1)
0/44(0) 0.244
Profound
deafness
9/53
(14.3)
3/47 (6.4) 0.13
Any
disability
27/53
(50.9)
12/47
(25.5)
0.013
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CHAPTER 7: DISCUSSION
7.1 Admission characteristics and background
Over 1500 cases of meningitis were admitted to QECH over the 23 months of the 
trial. Cryptococcal meningitis was the most common cause of meningitis (373 
episodes) followed by bacterial meningitis (230 episodes). There were 799 abnormal 
CSFs, some of which were lymphocytic (and may have been TBM) or had <100 
white cells/pl and the diagnosis was not clear. These will have included cases of 
viral meningitis and meningoencephalitis.
There are several notable features at presentation that characterise patients within the 
study. The high prevalence of HIV infection (81%) within our patients is 
comparable with the (90%) prevalence in the steroid trial in Malawi 14 but higher 
than the overall reported prevalence in Malawi (14% in 2006). Independent 
surveillance data suggests however that the prevalence is likely to be over 30% in 
urban settings within Malawi 186. HIV testing was not performed in any of the 
previous paediatric studies of glycerol in meningitis but it was thought unlikely that 
many of them were HIV infected.
Patients in this trial also presented to hospital much later than other studies - median 
time to presentation from onset of symptoms was 6 days. Measurement of tune may 
be imprecise in those who live more rurally without the need to record tune
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Survivors who received glycerol were less likely to have a disability than those who 
received placebo (p^O.OlS) and there was a trend towards less hearing loss than in 
the placebo ann (5/90, 5.6% vs 16/75 21,3% (p=0.026)).
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accurately. Delays to presentation in this setting have be seen previously 14. The 
reasons for this are unclear and likely to be multifactorial, including difficulties with 
accessing and cost of secondary care, cultural beliefs including traditional medicines, 
and poor diagnostic ability within secondary care. Late presentation does not 
improve outcome and overall mortality in our trial was 56% (53% in pneumococcal 
disease and 57% in probable meningitis). This is comparable with mortality of 51% 
(65% in probable meningitis and 50% in pneumococcal) seen in the steroid trial in 
Malawi l4. Mortality in Malawi out-with a trial setting is over 60% 13 compared to 
the much lower mortality in Europe of around 30% 187.
The majority of patients in this trial (69.4%) had received medical care (oral or 
parenteral antibiotics, anti-malarial treatment or attendance at a traditional healer) 
prior to randomisation, particularly those who had probable bacterial meningitis. 
This was similar to findings in the steroid trial where 64% had received pre­
admission treatment. Median age of patients in this trial was 32 years (IQR 27-40) 
which was comparable with the steroid trial where the mean age was 32 years. Mean 
age of presentation in Europe is 45 years and the difference may be explained by 
HIV prevalence in the two populations. Most (42.2%) had received antibiotics and 
just over a quarter (26.4%) anti-malarials. During this study, standard treatment for 
malaria changed from Fansidar™ (sulfadoxine pyrimethamine) to aitesunate 
combination treatment. This change from a simple to a more complex and lengthier 
treatment regime may have impacted on the number of patients taking empiric
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malaria treatment for non-specific symptoms, including fever, prior to seeking 
medical attention.
Diagnosis of bacterial meningitis using symptoms and signs alone is difficult. In our 
trial, the classical triad of fever, neck stiffness and altered level of consciousness was 
present in only 16% of patients with proven or probable bacterial meningitis and in 
24% of those with proven bacterial meningitis. This is much lower than was seen in 
the steroid trial (51% and 59% respectively) and in the European study in which 44% 
of patients demonstrated this triad . Given that patients in Malawi present later in 
the course of their disease, it might have been expected that more patients would 
have developed these symptoms and signs at presentation. Relying on clinical signs 
alone is inadequate to diagnose meningitis hi this setting and a lumbar* puncture is 
required.
Cryptococcal meningitis tends to present insidiously with a longer history than 
bacterial meningitis and with headache as the most prominent symptom 35. It can, 
however, have a more fulminant presentation with altered mental state and neck 
stiffness 188. It was not always possible to diagnose cryptococcal meningitis on CSF 
microscopy and biochemistry alone. India ink examination of CSF is the only test 
routinely available for the diagnosis of cryptococcal meningitis in Malawi, as is the 
case in most health-care settings in sub-Saharan Africa. Cryptococcal antigen testing 
provides both a high sensitivity and specificity in the diagnosis of cryptococcal 
meningitis, but at present the kits are too expensive for many developing countries.
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Tliiity“three patients (12%) in our trial had proven cryptococcal meningitis. 
Seventeen of these fulfilled CSF criteria for ‘probable bacterial meningitis’ and were 
included in this category for the analyses (because they fulfilled the criteria for this 
definition); three had proven dual CNS infections with other bacteria.
Duration of symptoms also tends to be longer in TBM prior to presentation but has 
similar’ clinical features to bacterial meningitis. In resource poor settings, TBM is 
strongly associated with HIV infection 35> 189. Distinguishing TBM fiom bacterial 
meningitis on clinical grounds is challenging unless retinal tubercles are seen on 
fimdoscopic examination (these are present in the minority). A diagnosis of TBM 
was made in three patients who were randomised in our study on the basis of turbid 
CSF at admission. Subsequent CSF analysis revealed lymphocytic CSF with 
elevated protein levels consistent with a diagnosis of TBM and at the time of this 
study there were no facilities at QECH for TB culture.
Viral meningitis is usually a more mild disease than bacterial meningitis and is 
generally self-limiting. Viral meningitis in Malawi is an infrequent diagnosis in 
those admitted to hospital. In 2000, an estimated 3.6% of adult in-patients with 
meningitis had a viral aetiology I3. Confirmation of such a diagnosis is unfeasible 
outside the context of the research setting.
Several factors may predispose to bacterial meningitis including CNS prosthetic 
devices, head injury and localised infections. Meningitis associated with prosthetic
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devices is comparatively common in the West; no patients in our trial had prosthetic 
material in the CSF space or history of neurosurgery and none had a history of head 
injury. Otitis media was seen in eight patients (3%) in our trial compared with <5% 
in the steroid trial in Malawi. A descriptive study from Europe showed that 25% of 
patients with proven bacterial meningitis had a concomitant diagnosis of otitis media 
. Localised infection predisposing to bacterial meningitis is unlikely to be less 
common in this setting than in Europe; the differences in reported levels of otitis 
media are doubtless due to less rigorous establishment of such a diagnosis.
CSF biochemistry was more likely to show classical findings associated with 
bacterial meningitis (low glucose and high protein) in patients with proven bacterial 
meningitis as compared to patients with probable bacterial meningitis. These 
findings, combined with the diagnostic challenges outlined above, suggest that a 
number of ‘probable bacterial meningitis’ cases may have been due to alternative 
organisms such as cryptococcus or TB.
History of reduced level of consciousness, reduced GCS on admission and history of 
confusion were all more likely in proven bacterial meningitis than probable 
meningitis. This may be a reflection on the more aggressive progression particularly 
of pneumococcal meningitis. Fever, reduced conscious level and neck stiffness were 
all more likely in proven than probable meningitis. The triad of all three were only 
presenting 15% and was more common in proven than probable meningitis.
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Pre-hospital treatment led to delays in presentation to hospital. Patients who had 
received antibiotic or anti-malarial therapy prior to randomisation not only had a 
significantly longer history than those who did not receive anthnicrobial therapy, but 
this directly affected diagnostic accuracy by reducing the chance of seeing organisms 
on CSF microscopy and of culturing an organism from CSF (but not blood). 
Therefore, pre-hospital treatment was most common in those with probable 
meningitis and this group had a worse outcome than those with proven bacterial 
meningitis. Twenty six percent received malaria treatment with Fansidar prior to 
admission suggesting over-diagnosis of malaria and misdiagnosis of early 
meningitis.
With the high prevalence of HIV infection, there is more cryptococcal infection 
and TBM in the population. In such a setting the differential for possible and 
probable bacterial meningitis is therefore much wider than in a lower HIV 
prevalent setting. In this study, the most relevant risk factor for invasive 
pneumococcal disease (IPD) was HIV infection. The incidence of IPD in North 
America, was shown to be 803 per 100,000 person years in HIV infected as 
compared to 35 per 100,000 person years in the HIV negative population 33. Other 
known risk factors for IPD include diabetes, chronic renal/pulmonary/cardiac/ liver 
disease, solid organ transplant or other forms of immunosuppression and extremes 
of age (<2 or >65 years). Since this study was completed, the 13-valent conjugate 
pneumococcal vaccine has been introduced into Malawi following results 
demonstrating efficacy of the 7-valent conjugate vaccine at reducing IPD 59. Sixty
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nine patients (26%) had a prior AIDS defining event (WHO Stage 3 or 4) and 
therefore likely had advanced immunosuppression. This figure contrasted with 
only 39 patients being on ART and nine on cotrimoxazole prophylaxis. This 
would suggest that the roll-out of ART although deemed effective on a national 
level, was not reaching all those in need of treatment at the time of the study
Laboratory investigations in our trial were limited to blood culture, full blood count, 
malaria film and CSF microscopy and culture. Few patients had biochemical tests 
apart from bedside capillary blood glucose measurement. Blood cultures were 
positive in 15% of all recruited patients. This is lower than the 32% figure reported 
from tire steroid trial in Malawi and much lower than developed countries where 
rates of blood culture positivity is over 50% 15,171.
It is unsurprising that S. pneumoniae was the most common organism isolated as this 
is the most common cause of bacterial meningitis in Malawi and is likely to reflect 
the population. Only one case of H. influenzae was seen (in Phase 1) and this may 
reflect the success of the immunisation programme.
7.2. The glycerol trial: GLAM Study
Mortality
The overall mortality was 55%. Outcome was slightly better for pneumococcal 
(53% mortality) than probable meningitis (55% mortality) which is comparable to 
results from the steroid trial14 where overall mortality was 51%.
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Like the steroid trial in Malawi, the majority of deaths occurred early in the course of 
admission. Those given glycerol did less well. Mortality for the glycerol arm was 
63.2% overall (vs 48.8% in the placebo arm). The reasons for this are not clear. An 
unlikely explanation is a positive effect in the placebo arm from sugar solution. This 
worse outcome in the glycerol arm was most marked in pneumococcal meningitis 
There was no difference in mortality in probable meningitis between the treatment 
arms. Given that most of those with pneumococcal disease were also infected with 
HIV may suggest that glycerol has some effect in those with impaired cellular 
immunity due to HIV which confers increased mortality.
These findings from die first adult study of glycerol are strikingly different from 
paediatric studies. Oral glycerol was found to reduce severe or profound hearing 
loss in children in a small study of infants and children in Finland 92, and the larger 
multi-centre paediatric study in Latin America 93 recommended glycerol to prevent 
neurological sequelae. No significant difference was found between glycerol and 
dexamethasone in improving hearing loss or neurological sequelae in a small 
randomised double blind study by Sankar et al 94 in children with acute bacterial 
meningitis. Our findings suggest glycerol is not beneficial and appears harmful in 
adults with bacterial meningitis.
There are differences in our study population; our patients were adults, 81% were 
HIV positive and glycerol was given for 4 days rather than 2 days.
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HIV serostatus was not reported in the paediatric studies. In particular, in the Latin 
American paediatric study (which did not test routinely for HIV) one must assume 
that in view of the lower prevalence of HIV within the population (<1%) [UNAIDS 
2010], the majority of their patients would have been HIV negative. In addition, 
many patients had delays to presentation (as is common in sub-Saharan Africa 
compared with other settings). Even with these population differences, it is 
challenging to explain why glycerol appeared to be harmful. Hyperglycaemia was 
rarely found and therefore is not an adequate explanation; there is the unlikely 
possibility that the sugar solution used for placebo was beneficial in some way. 
Given that hypoglycaemia was not detected prior to randomisation in any patient 
makes this postulation implausible.
The causes of meningitis are very different in adults in Malawi compared to Latin 
America. In the paediatric Latin American study, H influenzae b was the most 
common causative organism isolated with pneumococcus and meningococcus next 
most common 93.
The mean weight of a Malawian is 60 kg 190; therefore the dose of glycerol 
administered was in the region of 1.25 g/kg/day for 4 days. The Latin American 
paediatric study administered 1.5 g/kg/day but over 2 days 9\
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Sub-group analyses
HIV positive patients, females and also those who took longer time to presentation 
did less well with glycerol than with sugar solution. There is no obvious or 
identifiable explanation for these differences in outcome.
ONSD and CSF OP did not predict outcome. GCS <12 did not reach statistical 
significance in terms of being an outcome predictor. Reduced level of consciousness 
is usually an indicator of more severe disease and is therefore associated with worse 
outcome (see below) 191'193; however, in this setting, poor outcome may have been 
inextricably associated with so many other factors that this effect was not seen.
Seizures were more common in the glycerol arm than placebo arm and could relate 
to poor outcome. This may be a coincidental finding in a severely ill population or 
could be directly due to the glycerol. Such findings have not been reported in 
humans hi the literature. Changes in behaviour and seizures have been seen in mice 
within 30 min of oral glycerol 194. The underlying mechanism for this was not 
known but it was suggested that increased IL-1 j3 concentrations within the 
hippocampus associated with increased oxygen species might be the cause.
In tliis study, mortality was most marked from Days 2-4 during and just after the 
administration of study drug. The occurrence of fits on Days 1-3 was the strongest 
risk factor for mortality — glycerol did not appeal* to either improve or exacerbate the 
risk. However, if there were no fits on Days 1-3, giving glycerol appeal's to increase
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the risk of death relative to placebo (but not to the level of risk associated with fits). 
The aetiology is unclear and may be associated with rebound phenomenon but this is 
not supported by other measures of ICP (ONSD, CSF OP and GCS and fundoscopy). 
Rebound phenomena may occur in humans following osmotic therapy although 
evidence for this with glycerol therapy is conflicting 82,125’128,130’195. Reversal of the 
osmotic gradient between blood and CSF or brain interstitium is thought to occur as 
the drug is eliminated but die significance of this occurring in bacterial meningitis is 
unclear. This could possibly be related to rebound phenomenon although this theory 
was not supported by other measurement of possible raised CSF including CSF OP 
at Day 2, ONSD Day 2 and 10 or neurological examination.
There was no statistical difference in hearing loss between the two arms. There was 
a trend towards less hearing loss in survivors who received glycerol (p=0.026; 5.6% 
vs 21.3%). In the paediatric study in Latin America, there was no difference in 
severe healing loss between glycerol (12/136, 9%) and placebo aims (12/131, 9%).
There was a trend towards survivors who had received glycerol were less likely to 
have a disability (cranial nerve palsy, limb paresis, focal neurological deficit, debility 
GOS 1 or 2, blind, profound deafness) (p=0.013). In die paediatric study in Latin 
America severe disability between the four arms almost reached statistical 
significance (p=0.022) (dexamethasone + placebo 10/139, 7%; dexamediasone only 
8/134,5%; glycerol only 7/47, 5%; placebo arm 19/136,14%).
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In our study in adults, which was stopped early by the DSMB, glycerol was 
associated with significantly increased mortality within 40 days, and worse outcomes 
in all major secondary analyses except deafness and disability at Day 40. This trial 
therefore does not support the use of glycerol as adjunctive treatment for bacterial 
meningitis in adults in Malawi.
Adverse events
In the dose finding and tolerability study preceding the main trial, glycerol was well 
tolerated. There was no difference in gastrointestinal side effects between the three 
doses. Impaired glucose tolerance or elevation of glucose due to stress response was 
seen in 31% of patients. This compared starkly with the main trial were only one 
patient had an elevated blood glucose and this was transient, not requiring any 
intervention. Due to concerns with reliability of glucose monitoring in Phase 1, the 
digital glucometers were changed to more reliable methodology (Glucostix® test) in 
the main trial. The Glucostix® kits were sourced regularly during the trial and there 
was no question of their reliability.
Both sugar- solution (placebo) and glycerol might be expected to produce 
hyperglycaemia however there was no difference in hyperglycaemia between the 
two arms. There was no suggestion of difference in gastrointestinal side effects 
between tire two arms. There was no patient who presented with hypoglycaemia and 
no Type 2 diabetes was diagnosed during the study. One patient had capillary blood 
glucose over 11.1 mmol/L whilst receiving study drug.
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Two possible adverse events involving the death of two patients could also have 
been explained as a consequence of their underlying meningitis rather than any effect 
of study drug. One patient received glycerol and the other placebo.
7.3 ONSD and ICP
ONSD is a non-invasive bedside test which has proven effective at measuring ICP in 
a number of settings with evidence of reproducibility between different operators 154, 
156-158 effec^jve jn this setting it could be used to diagnose raised ICP which could 
potentially predict outcome. We aimed to examine if ONSD correlated with CSF 
OP and whether glycerol affected the ONSD or if ONSD predicted outcome.
In the main trial and Phase 1 there was no difference in ONSD between die treatment 
arms at randomisation, after 2 days therapy or follow-up at day 10. There was no 
correlation seen between ONSD and CSF OP.
Papilloedema at presentation was associated whh ONSD >5 mm (p=0.002). There 
was a trend towards GCS <12 at presentation being associated with ONSD >5 mm. 
ONSD did not predict outcome, was not associated whh CSF OP or other signs of 
raised ICP.
ONS diameter measurement was feasible in this setting of busy medical wards with 
severely ill patients. Although patients with papilloedema at presentation were likely
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to have increased ONSD, ONSD did not predict outcome and was not associated 
with other clinical signs of raised ICP. It did not add any benefit in terms of 
management or prediction of outcome and is therefore not a useful tool in this setting 
in bacterial meningitis.
7.4 Study limitations
There are potential limitations to this study. Although QECH is well supported and 
has better staffing levels than many hospitals in a similar setting, patient care on 
medical wards is not as good as drat in developed countries. In addition, access to 
intensive care or high dependency care for such severely ill patients was inadequate. 
In general, this is a typical southern African hospital and tire patient population 
characteristic of such a setting, therefore this trial is representative of a sub-Saharan 
African high HIV prevalence setting. The results may not be transferable to a low- 
HIV prevalent setting where glycerol might be effective. Although residual 
confounding is a theoretical possibility, the fact that glycerol increases mortality in 
bacterial meningitis is highly statistically significant, subgroup analysis did not 
identify any possible benefit, and adjusting for identified confounding factors simply 
strengthened the association between glycerol and death, makes residual 
confounding unlikely. The decision made by the DSMB to stop recruitment to the 
trial early because of a mortality difference between the two aims at interim analysis 
was supported by subsequent analysis which confirmed this adverse effect.
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7.5 Future studies
Intervention to reduce delays to admission could potentially improve outcome. This 
would include education, particularly around seeking medical attention earlier rather 
than community administration of antibiotics, empiric malaria treatment or 
traditional medicine.
7.6 Overall conclusions
Mortality from bacterial meningitis is high in this high HIV prevalent setting. 
Glycerol has been proposed as a cheap locally relevant adjuvant therapy however 
tliis study has shown glycerol to be harmful and its use cannot be recommended in 
adults in Malawi or other resource-poor regions where bacterial meningitis presents 
late and often occurs in those who are HIV infected. Other ways of reducing the 
considerable mortality associated with this disease need to be explored. The 
introduction of conjugate pneumococcal vaccination combined with the falling 
prevalence of HIV will hopefully go some way to reduce the incidence of IPD. 
Timely presentation to hospital, prompt resuscitation and antibiotic therapy are also 
essential for unproved outcome. Glycerol appears harmful as adjuvant therapy in 
adults with bacterial meningitis in this setting however the outcome of the paediatric 
study of glycerol adjuvant therapy in Malawi is awaited with great anticipation.
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1. Applicants:
Principal
Applicant
Applicant 2 Applicant 3 Applicant 4
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The principal applicant is normally the corresponding applicant. If correspondence
should be addressed to another applicant, please use an asterisk to indicate this in 
the table above. If there are more than four applicants, please attach details on a 
separate page.
2a) Institution/Authority (administering grant if approved):
Liverpool School of Tropical Medicine and Malawi College of Medicine
155
b) Address at which work is done:
Department of Medicine QECH, College of Medicine, P. Bag 360,
Blantyre, Malawi
3. Title of Investigation (not to exceed 116 characters including spaces)
Randomised trial and dose finding study of glycerol adjuvant therapy in 
adult bacterial meningitis in Malawi.
4. Summary information
a. Proposed start date b. Duration (in months) c. Total funding requested
1st April 2005 36 £ 90390
(Please choose a realistic starting date: no earlier than July if applying in the spring 
round or January if applying in the autumn round.)
5. Type of Grant sought:
Small project grant
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6. Research Summaries
a) Scientific Abstract (not to exceed 250 words)
Malawi has a high incidence of bacterial meningitis among adults. Currently, 
mortality exceeds 50%. More effective locally appropriate treatments are an 
urgent priority.
Glycerol has been shown to reduce mortality by approximately 50% in 
children with bacterial meningitis in South America. If similarly effective in 
adults, glycerol would represent a cheap, locally produced adjuvant therapy 
appropriate for use in this setting. It has been used as a food additive and for 
medicinal and cosmetic purposes for many years.
The proposed study is a proof of principle placebo controlled trial and dose­
finding study of glycerol adjuvant therapy in bacterial meningitis in Blantyre, 
Malawi. All patients will be treated with antibiotic therapy according to the 
national guidelines. In addition, patients will receive 25ml bd, 25ml qid or 
50ml qid 85% glycerol or water orally or via nasogastric tube. The primary 
endpoint will be mortality, with measures of morbidity as the secondary 
endpoint.
One hundred patients per treatment arm and 160 controls (460 patients in 
total) will be required to provide data on efficacy of glycerol adjuvant therapy 
at each dosage. At current incidence this is likely to be met in just over two 
and a half years from the start of the trial.
This study will provide the first information on the efficacy and optimum 
dosage of glycerol in meningitis in adults. The data will be used in the design 
of a subsequent larger multi-centre trial in four tropical research centres that 
will include patients with acute and chronic meningitis.
The current MRF funded trial of dexamethasone in bacterial meningitis in 
Blantyre will cease recruitment in December 2004. There will therefore be an 
immediately available and established infrastructure, recruitment 
mechanism, staffing structure and administrative procedure for a new 
adjuvant therapy trial.
b) Please state clearly the aims and objectives of your study.
1) To assess the safety and tolerability of glycerol adjuvant therapy in 
bacterial meningitis.
2) To assess the effectiveness of glycerol in reducing mortality in 
meningitis in the high HIV context of Malawi.
3) To provide an assessment of optimal dosing schedule of adjuvant 
glycerol
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c) What is your study design?
Open label placebo controlled randomised trial and dose finding study
d) Summary of research proposal for the layperson (not to exceed 250 words). 
Please include a brief outline of the clinical benefit / potential value of this study in 
relation to the prevention, diagnosis or treatment of these diseases and their 
complications. Grant holders are expected to refer to this when discussing outcomes 
of the project in their final report.
Despite the advent of new antibiotics, bacterial meningitis remains an 
important cause of death and disability, particularly in resource poor 
settings. We therefore urgently need additional therapies to improve the 
outcome.
Used in combination with antibiotics, glycerol, a sweet tasting liquid that is 
widely used as a food additive, has recently been shown to reduce death 
rates by about one half in children with bacterial meningitis in South 
America. If similar results were found amongst adults, glycerol would 
represent a very significant advance in the treatment of bacterial meningitis. 
As it is cheap and locally produced, it would be a particularly appropriate 
additional therapy for use in developing countries where meningitis is most 
common.
One of the effects of meningitis is that it causes swelling of the brain inside 
the skull. This is an important factor contributing to the high death rate. 
Glycerol acts by pulling fluid out of the tissues and therefore reduces such 
swelling. Theoretically, this should help reduce the death rate seen in 
meningitis.
In order to test its effectiveness, we plan to treat some of our meningitis 
patients with glycerol and antibiotic therapy, and others with antibiotic 
therapy alone. To establish the safest and most effective dose of glycerol, 
we will compare three different dosage schedules. In all cases we will 
monitor the patients closely for possible side effects throughout their stay in 
hospital.
If we demonstrate an advantage from the use of glycerol in our hospital in 
Malawi, we plan to do a larger study involving four tropical research centres 
to test the effectiveness of glycerol in several different types of meningitis 
and in differing populations.
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7a) Summary of support requested:
Project 
Year 1 
£
Project 
Year 2
£
Project 
Year 3
£
Project 
Year 4
£
Project
Year5
£
Total
£
Staff 19200 19200 19200 57600
Consumables 7400 7400 6100 20900
Travel and
Subsistence
460 460 380 1300
Exceptional items 3310 3340 3940 10590
Equipment
Grand Total 30370 30400 29620 90390
b) Breakdown of costs by financial year (1 April to 31 March);
Financial Financial Financial Financial Financial Total
Year 1 Year 2 Year 3 Year 4 Year 5 £
£ £ £ £ £
Stair 19200 19200 19200 57600
Consumables 7400 7400 6100 20900
Travel and
Subsistence
460 460 380 1300
Exceptional
items
3310 3340 3940 10590
Equipment
Grand Total 30370 30400 29620 90390
*5 years is the maximum duration for grants, but 5-year grants starting after April
of the current year will incur expenditure over 6 financial years.
8. Does this project involve the use of human participants or human tissue? 
YES
If yes, please attach copies of your submission to the relevant Ethics Committee(s) 
along with your letter of approval if available. The Foundation will consider 
applications before ethics committee approval is obtained, but expects a copy of the 
ethics approval letter within six months of notification of grant. If you answered yes 
to question 8 and are applying from outside the UK, please attach copies of 
documents that show compliance with your country’s research ethics regulations 
(along with translation into English, for documents in other languages).
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The College of Medicine Research and Ethics Committee (COMREC) 
consider applications only after the receipt of a processing fee. It is therefore 
normal local practice to obtain funding prior to submission to COMREC. 
Attached is a copy of the University of Malawi COMREC guidelines for 
research proposals and the revised operating procedures of January 2004.
9. Other research grants and grant applications
a) Is this application currently being submitted elsewhere? NO
If yes, to which organisation, and by what date is a decision expected?
b) Has this, or a similar application been submitted elsewhere over the past 
year? NO
If yes, to which organisation, and what was the result?
c) Do you hold, or are you currently applying for another research grant(s) on a 
similar or related topic? YES
If yes, please give details, and explain how this does not overlap with your current 
application to Meningitis Research Foundation.
We are currently recruiting patients to an MRF funded trial of 
dexamethasone adjuvant therapy in adult bacterial meningitis in Malawi. 
This trial will cease recruiting in December 2004. The proposed trial of 
glycerol adjuvant therapy will start in April 2005. The glycerol trial is 
complimentary to the steroid trial and forms an obvious continuation into 
the investigation of adjuvant therapies in bacterial meningitis. There will 
be no temporal or clinical overlap between the two trials although the 
glycerol trial will benefit from the existing equipment and from a well- 
established research mechanism and staffing structure currently 
employed in the steroid trial.
d) Is this application a resubmission of an application previously considered by 
the Foundation?
NO
If yes, please attach a covering letter briefly stating how this application differs from the 
original.
e) Have you previously held (a) grant(s) from Meningitis Research Foundation? 
YES
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If yes, please list project titles and start dates along with details of any resulting 
publications and other outcomes.
Title: Dexamethasone adjuvant therapy and intramuscular ceftriaxone in the 
management of bacterial meningitis in Malawi.
Start date: October 2001
Publications and presentations:
1) Bacterial meningitis in Sub-Saharan Africa - challenges to a better 
outcome.
M. Scarborough, Y. Njalale 
Tropical Doctor (In press)
2) Application of the Vietnam diagnostic scoring system for TB meningitis to 
patients in the Queen Elizabeth Central Hospital, Blantyre.
A.Checkley, Y.Njalale, M.Scarborough, E.E.Zijlstra
College of Medicine Research Dissemination Conference, Blantyre.
November 2003
3) Neurological Manifestations of HIV infection 
M Scarborough
National Aids Council of Malawi Training Programme 2003
9. Other research grants and grant applications (continued)
f) Please list other current grants you hold, including name of awarding body, title of 
project, amount awarded and dates of support
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12. Full official contact details of all applicants
10. Declaration:
Applicants:
I have read the Terms And Conditions of Grant Aid and agree to abide by them. If a grant 4s made, I
i. will take all reasonable actions to ensure that the Foundation's contribution to funding the 
research is suitably acknowledged in all publications arising from it, and ensure that copies of 
any such publications are forwarded to the Foundation.
ii. will comply with policies on intellectual property rights and commercial exploitation as set out in 
the Terms and Conditions
iii. will inform the Charity of any changes to details set out in the application
I shall actively be engaged with the project, and in day-to-day control of the project.
To be signed by: Signature Name in block capitals Date
Principal Applicant
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f'
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■ - .ii
Applicants
Applicant 4
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be responsible for administering any grant that may be awarded. Each should sign the following declaration:
I confirm that I have read this application and that, if granted, the work will be accommodated and 
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external audit.
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13. Proposed Investigation:
1 Title: Randomised trial and dose finding study of glycerol adjuvant therapy in
adult bacterial meningitis in Malawi.
2. Purpose:
1. To investigate the feasibility and tolerability of glycerol as an adjuvant therapy in 
adult bacterial meningitis.
2. To assess the efficacy of glycerol adjuvant therapy in reducing mortality from 
adult bacterial meningitis in Malawi.
3. To compare three dosage regimens for glycerol adjuvant therapy in adult 
bacterial meningitis
The study will provide the first information on the efficacy and optimum dosage of 
glycerol in meningitis in adults. The data will be used to help design, if appropriate, 
a subsequent larger multi-centre trial in four tropical research centres that will 
include patients with acute bacterial meningitis and chronic meningitis (e.g. TB 
and cryptococcai meningitis). It will inform investigators of the potential benefits, 
constraints, side effects and optimal dosing regime for glycerol adjuvant therapy.
The proposed setting of the current study will differ from other sites in that the 
local patient population in Malawi is predominantly HIV positive, presentation 
tends to be late and the vast majority of bacterial meningitis is pneumococcal.
The results of this study will therefore not necessarily represent patient 
populations elsewhere.
3. Background:
Bacterial Meningitis in Malawi.
Bacterial meningitis is a common and serious health problem in sub-Saharan Africa. 
Data from Malawi suggests that bacterial meningitis in adults is mainly 
pneumococcal and that the majority of patients are co-infected with HIV. Since the 
start of the HIV epidemic, the incidence of bacterial meningitis in Malawi has risen 
by over 800% and is now approximately 40 times the incidence seen in Europe. 
Currently, mortality from pneumococcal meningitis in this region exceeds 50% and 
up to 50% of survivors are left with neurological sequelae such as deafness, 
intellectual impairment or physical disability. More effective locally appropriate 
therapy in an urgent priority.
GLYCEROL
Glycerol has recently been shown to reduce mortality and morbidity by 
approximately 50% in children with bacterial meningitis in South America 
(personal communication H. Peltola). The mechanism of action of glycerol is 
thought to be through an osmotic reduction of intracranial pressure (ICP). Raised 
ICP is thought to be a significant contributory factor to mortality and morbidity from 
all forms of meningitis including bacterial meningitis. Early reduction of the ICP 
should theoretically reduce the incidence of adverse outcome. No trials of glycerol 
adjuvant therapy in bacterial meningitis have been reported in adults. If the
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findings from the paediatric population can be replicated in adults, glycerol would 
represent a very significant advance in the treatment of bacterial meningitis.
Glycerol is locally produced, cheap and widely available. It has been used as a 
food additive and for cosmetic purposes for many years and is widely used 
amongst sportsmen and sportswomen to improve performance and 
thermoregulation by hyperhydration prior to endurance events. Medicinally, it has 
been used as a laxative, in the treatment of acute glaucoma and in the diagnosis 
of Meniere’s disease. In the clinical setting, glycerol may be administered enterally 
or intravenously. It has been subject to several clinical trials in the treatment of 
ischaemic stroke. A meta-analysis of these stroke trials, all of which employed 
intravenous glycerol, suggested short-term advantage from glycerol therapy but no 
benefit in terms of long-term survival (1). There is one published trial of oral 
glycerol adjuvant therapy in bacterial meningitis in children (2) that demonstrated 
significant benefit in terms of neurological sequelae and deafness. No serious 
adverse events were reported.
Toxicity data for oral glycerol indicates that it is safe in the proposed dosages (3). 
Side effects are infrequent, mild and are most commonly gastrointestinal in nature. 
These include nausea, vomiting, bloating and diarrhoea. There are rare reports of 
neurological side effects such as headache, dizziness, confusion and amnesia (in 
elderly patients). There is one report of spontaneously reversible hemiparesis in a 
patient who accidentally ingested 500ml pure glycerol (4).
Antibiotic therapy in Malawi
Bacterial meningitis in Malawi is currently treated according to standard guidelines 
with parenteral penicillin and chloramphenicol for a minimum of 10 days. Data 
from the current steroid trial demonstrates that dual resistance to these agents 
occurs in less than one percent of cases attending QECH. It is therefore unlikely 
that there will be a change in the national prescribing policy within the timeframe of 
the proposed trial. If such a change were to be introduced, it would be unlikely to 
affect the interpretation of the results from the proposed trial unless mortality fell 
considerably in which case the power of the study would be reduced.
Dexamethasone adjuvant therapy
Dexamethasone is not currently used in the treatment of bacterial meningitis in 
Malawi and its use remains controversial. A recent trial in Europe demonstrated 
benefit from dexamethasone in adults in a predominantly HIV negative population 
(5). A trial in the paediatric population in Malawi showed no benefit (6). An 
ongoing trial of dexamethasone adjuvant therapy in adults in Malawi is due to 
complete enrolment by December 2004. If the results from the steroid trial show 
significant benefit of dexamethasone, the trial steering group will decide whether 
the proposed trial should seek to include an additional treatment arm of both 
glycerol and steroids. The rationale for this is that it may be considered unethical 
to withhold a potentially beneficial intervention outside the context of a rigorous
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clinical trial. There is no reported interaction between glycerol and steroids but this 
possibility cannot be excluded on the basis of data currently available.
Study design and rationale
The proposed study is an open label randomised clinical trial and dose finding 
study to be conducted in two phases. The first phase aims at identifying 
immediate logistic or tolerability problems associated with glycerol administration. 
The second phase will consist of an open label clinical trial to assess the effect of 
glycerol adjuvant therapy at three different doses on the clinical outcome of 
bacterial meningitis at one month. The dosages to be used for this trial will be 
25ml BD, 25ml QDS or 50ml QDS unless, in the opinion of the trial steering 
committee, results from phase one indicate that alternative dosages should be 
used. The higher dose of 50ml QDS is selected as it represents the accepted 
dosage used by sportsmen prior to endurance events and most closely replicates 
the 6ml/kg/day dosage used in the paediatric study.
If, as the paediatric studies suggest, mortality were reduced by up to 50%, the use 
of glycerol adjuvant would represent an important therapeutic advance in bacterial 
meningitis. Glycerol is easy to administer, cheap and widely available making it a 
potentially highly appropriate therapy for resource poor settings.
It is anticipated that the results from this study will precede a larger multi-centre trial 
in four tropical research centres aimed at investigating the use of glycerol in 
bacterial, tuberculous and cryptococcal meningitis.
4. Plan:
Phase one - April 2005 - May 2005
Feasibility study of 24 patients to assess tolerability of enterally administered 
glycerol adjuvant therapy at a dose of 25ml BD, 50ml BD or 50ml QDS during the 
first four days of antibiotic therapy.
Phase two - June 2005 - December 2006 
Open label placebo controlled trial of glycerol adjuvant therapy at a dose of 25ml 
BD, 25ml QDS or 50ml QDS or placebo (sterile water) during the first four days of 
antibiotic therapy.
5. Methods:
Study place
Adult medical wards, Queen Elizabeth Central Hospital (QECH), Blantyre, Malawi. 
Study population; entry and exclusion criteria.
All patients admitted to the adult medical wards at QECH with headache, fever and 
neck stiffness have a lumbar puncture. Any patient with CSF findings suggestive of 
bacterial meningitis (or in the case of unconscious patients, their guardian on their 
behalf) will be invited to participate. This will be defined as:
• Cloudy CSF in a patient requiring immediate treatment
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• or greater than 100 white cells/j.il in the CSF with predominant neutrophils,
• or gram-stain showing bacteria.
Exclusion criteria will be pregnant females, type II diabetics, patients with heart 
failure or patients whose CSF results indicate infection by cryptococcus or 
mycobacteria by direct staining or antigen detection procedures.
Treatment allocation.
Phase I - Twenty four patients will be recruited for assessment of glycerol 
tolerability. Eight patients each will receive glycerol at a dose of 25ml BD, 25ml 
QDS or 50ml QDS for four days.
Phase II - Patients will be randomised by computer generated permuted blocks to 
receive glycerol adjuvant therapy at a dose of 25ml BD, 25 mi QDS, 50ml QDS 
glycerol or 50ml water QDS for four days. If, in the opinion of the trial monitor and 
steering committee, phase I demonstrates significant patient intolerance to one (or 
more) of the dosage regimens, this will be modified prior to the start of recruitment 
to phase II. Recruitment for phase II will continue until 460 patients have been 
recruited or until the stopping rules have been achieved.
Administration of drugs.
In patients who are fully conscious, glycerol/placebo will be administered orally. In 
semi-conscious and unconscious patients, glycerol/placebo will be administered 
through a nasogastric tube (NGT). The NGT will be placed and secured by an 
experienced nurse. Its position will be checked using the two standard techniques 
of auscultation and litmus test of the aspirate prior to the administration of any 
medication via the NGT. Glycerol or placebo will be administered for the first four 
days of treatment.
Protocol changes and other therapy.
If, in the view of the attending physician there is a clear clinical need to withdraw the 
patient from the trial or adjust the dosage of glycerol, this will be taken as a 
secondary endpoint.
All other treatments, and treatment of complications such as fits will be as for any 
case of bacterial meningitis in this clinical setting.
Sample size and study period.
Phase I will take two months to complete.
For phase II, power calculations based on a 0.05 (3 0.8 with current mortality of 50% 
indicate that 100 patients per treatment arm and 160 controls will be required to 
detect an absolute risk reduction of 20%. At current incidence, it is likely that this 
will be within thirty two months of recruitment to phase II. Recruitment to may cease 
earlier than this if interim analysis performed at twelve, eighteen and twenty four 
months indicates that the stopping rules have been reached.
Estimates of patient recruitment rates are considered entirely realistic based upon 
the current recruitment rate into the steroid trial. An additional two months will allow 
for recruitment variation, contingencies and data analysis.
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Interim analyses and stopping rules
The trial monitor will be asked to review outcome data at twelve, eighteen and 
twenty four months of recruitment. In light of these analyses, the monitor will advise 
the Chairman of the steering committee if, in his view, the randomized comparisons 
in the trial have shown both
a) proof beyond reasonable doubt that for all, or for some, types of patient one 
particular treatment is clearly indicated or clearly contra-indicated in terms of a net 
difference in mortality
and
b) evidence that might reasonably be expected to influence the patient management 
of many clinicians who are already aware of the results of other studies.
The steering committee can then decide whether to modify intake to the study.
Appropriate criteria of proof beyond reasonable doubt cannot be specified precisely, 
but the criteria that have been provisionally agreed are that the trial will have uneven 
stopping rules to avoid stopping on a random high:
a) Recruitment to be halted if a treatment arm has evidence of harm exceeding 
conventional levels of chance alone (p<0.05)
b) Recruitment to be halted if clear evidence of benefit with significance level of 
p<approx.0.002 (3SD)
The trial monitor may decide to stop the trial in other circumstances if it is his view 
that continuing is not justified on ethical grounds. In exceptional circumstances, the 
independent monitor would, after taking further ethical advice, seek to extend the 
trial if there were clear ethical reasons so to do.
Budget and costings
The budget is estimated from expenditure incurred during the steroid trial.
Staff increments are not calculated into the budget, as the influence of exchange 
rate fluctuation would render these meaningless in terms of local salary. Clinical 
staff employed by the trial will, at the start, receive approximately 10% more than 
the equivalent grade working for the Ministry of Health. Adjustments to salaries will 
be made at least annually to take into account currency fluctuation and changes in 
local wage scales. Nursing staff are recruited preferentially from the retired 
population to ensure that Ministry of Health resources are not compromised. Fewer 
nurses will be required than were employed in the steroid trial, as new patients will 
now be assessed on the medical wards rather than in a geographically distinct 
admissions unit. There will therefore now only be two areas (male and female 
wards) in which meningitis patients will require cover by trial staff.
Laboratory and consumable costs are likely to be lower than those incurred during 
the steroid trial as the proposed study will employ antibiotic therapy as per the 
national guidelines (rather than ceftriaxone) and will only process a second CSF if 
clinically indicated.
The immediate availability of items purchased for use in the steroid trial will 
considerably reduce the cost of trial establishment and equipment.
It is requested that the Liverpool School of Tropical Medicine and the College of 
Medicine, Malawi jointly administer any new award arising from this application.
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This arrangement has proven a reliable, effective and secure fund management 
mechanism during the steroid trial.
Data collection 
Historical data 
Demographics
Presentation including duration of symptoms
Prior medication and consultation for current illness
Past medical history including AIDS defining conditions and neurological
deficits.
Drug history and social history
Physical examination
Glasgow coma score
Focal neurological deficits
Hearing assessment where possible
Ophthalmoscopy
Co-existing physical signs
Physical examination to be repeated daily
Formal neurological examination to be repeated at day 10 and at day 40
Investigations 
On admission:
Full blood count (FBC) and random blood sugar 
Urea and electrolytes (U&E), liver function tests (LFT’s)
Blood culture
CSF opening pressure on admission
CSF microscopy, culture, sensitivity and protein and glucose estimation 
CSF cryptococcal antigen testing
During treatment:
Daily random blood sugar
U&E and LFT’s on day 4 and as clinically indicated thereafter 
CSF opening pressure on day 4
CSF microscopy, culture and sensitivity on day 4 if clinically indicated
Patients capable of giving valid consent on completion of therapy will be pre­
counselled for HIV testing so that HIV positivity can be controlled for in the trial 
analysis. Those giving consent will be tested and be given post-test counselling 
with their HIV test result as per WHO PROTEST guidelines. Where a patient 
accepted testing but actively insisted they did not want to know the results their 
wishes will be respected. Stored, anonymised samples may be submitted for further 
microbiological and biochemical analysis relevant to the understanding of the 
pathophysiology and treatment of bacterial meningitis.
Neurological deficit of survivors at discharge and at one month will be assessed by 
audiometry and by Glasgow Outcome Score. A fixed transport fee for the patient
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and a guardian on attendance will facilitate one-month follow up appointments. 
Defaulters will be visited at home within two weeks of their missed appointments 
wherever possible.
Endpoints.
Phasei
Tolerability of glycerol adjuvant therapy and serious adverse events
Phase II
Primary endpoint
1) Death.
Secondary endpoints
1) Physician decision to alter treatment based on the occurrence of complications
2) Death or residual neurological deficit (Glasgow Outcome Score and hearing loss) 
at discharge, and one month after completing antibiotic therapy.
3) Time to death, time to discharge
Analysis
Phase I
Data monitoring and ethics committee to review all cases and provide 
informed decision as to dosages to be employed in phase II
Phase II
Essential data will be double entered onto a computer database. Analysis will be 
performed on an intention-to-treat basis. A further analysis will be performed after 
excluding those who do not have bacterial meningitis, according to the following 
pre-defined laboratory criteria:
• a patient entered only on the basis of a cloudy CSF where white cells are less 
than 10 cells/jjJ
• or the red cell: white cell ratio >500:1.
• or cryptococcus or mycobacterial species identified without another organism 
being isolated.
At endpoint, uncorrected odds ratios will be calculated, as well as odds ratios 
corrected for potential confounding factors by logistic regression. Baseline 
prognostic features will be compared between the different groups. Analysis will be 
performed with the STATA or SPSS statistical package.
Ethical considerations.
All patients will sign consent having had written and verbal explanations of the trial. 
Where patients are deemed to be incapable of giving valid informed consent next- 
of-kin or guardians will be asked to give consent on their behalf.
Patients will be offered pre- and post- test counselling for HIV tests in accordance 
with local guidelines (see previous sections for details). The justification for 
requesting HIV testing is that HIV infection, and AIDS (which for WHO case
170
definition requires an HIV test) is an important potential confounding factor which 
will need to be controlled for in the analysis of those who consent. It is helpful to 
know HIV status in critically ill patients, and therefore testing should benefit 
individuals who consent to testing when unexpected clinical complications arise.
The treatment being investigated is appropriate in the Malawian context and, if 
proved effective, could be deployed locally.
Possible constraints.
The major foreseeable constraint would be if the mortality from meningitis drops 
significantly due to unrelated advances in management. This would reduce the 
power of the study and possibly therefore extend the time frame.
6. Detailed justification for support:
Personnel
Nurses: To provide nursing cover for the trial participants at all times it is estimated 
that 6 nurses must be employed, after allowing for sick leave and other periods of 
absence. The adult medical wards cannot support this trial without maintaining the 
standing force of research nurses. The trial, as designed, is a net contributor to staff 
levels rather than any drain on resource.
Clinical officers: The clinical officers will coordinate patient recruitment and ensure 
optimal clinical care, data and sample collection and outpatient follow-up. Together 
with the PI, the clinical officers provide nightly and week-end cover for new recruits 
and medical emergencies. Experience from the steroid trial currently underway 
demonstrates that this is not sustainable with a core staff of less than three 
clinicians with prescribing rights, knowledge of the trial and experience in the 
management of acutely ill patients with bacterial meningitis.
Technical staff: Data entry, daily logistic and administrative aspects of the study 
require a committed full time research assistant. The laboratory work generated by 
the trial cannot be accommodated by the hospital laboratory service. The 
Laboratory technician employed will use the facilities at the Wellcome Trust 
laboratories, which are fully equipped to deal with the requirements of this trial. 
There is a significant workload generated by such a trial including the processing of 
CSF’s and blood cultures, separating and storing specimens and maintaining 
laboratory equipment used by the trial.
Messenger: The messenger will be required to facilitate patient recruitment, to 
transport patients to and from the wards, to deliver urgent specimens to the 
laboratory and to ensure the timely availability of results. He will be responsible for 
organising defaulter tracing and for maintaining ward stocks of consumables and 
equipment.
Equipment and consumables
No large equipment purchase will be necessary, as the ongoing steroid trial has
171
provided for these, items such as ward furniture, filing cabinets, audiometers, 
refrigerators (but not freezers), glucometers, sphygmomanometers and computer 
hardware will be available. A fully established follow-up clinic is currently 
operational and will continue to be available for the proposed trial.
The provision for ward and laboratory consumables will ensure a continuous and 
reliable supply of items necessary for the investigation and management of patients 
with bacterial meningitis. We have been fortunate in the past to receive intermittent 
donations of ward equipment which, although unpredictable, have helped 
considerably in reducing expenditure.
Transport
Patients: Provision must be made to cover patient transport for effective follow up. 
Patients who attend for their one-month follow up appointment will therefore receive 
a fixed fee to ensure maximal compliance. In the case of those who default from 
follow up appointments, a hospital car, borrowed car or hire car will be used to trace 
the patients to their homes. Such mechanisms have proven highly successful in 
ensuring completeness of follow-up data in the steroid trial.
Staff: Out-of-hours staff transport costs will be minimised by the use of an on-call 
room at the hospital. Costs associated with international travel will be avoided by 
ensured the deployment of a trial monitor and steering committee chairman resident 
within Malawi.
Exceptional items:
Sample handling, storage and transport are arranged through the Wellcome Trust 
laboratories. Insufficient samples will be generated by this trial to justify the 
purchase of a -80 freezer or a dry shipper.
The use of telephones is essential for on-call commitments and for defaulter tracing 
activities. Small two-way radio sets have been used most effectively in the steroid 
trial in order to communicate information between colleagues within the hospital. 
The sets currently in use are unlikely to provide a reliable service for another three 
years.
Dissemination costs include the teaching materials, travel and subsistence for three 
local meningitis workshops each year. This is necessary to ensure that the findings 
of the trial are fed back to the clinicians who are mainly responsible for the delivery 
of care to patients with meningitis. Although we acknowledge that The Foundation 
will not normally consider fees or travel associated with conference attendances, the 
trial falls outside the jurisdiction of any organisation capable of meeting such costs. 
In order to fulfil the scientific and ethical obligation of appropriate dissemination of 
results, we request that consideration be given to this item should the need arise. 
The College of Medicine in Malawi raises a 10% levy on all research conducted 
locally. The funds are used to cover incidental costs incurred by the College that 
are othen/vise not recoverable. This levy has been the subject of recent debate and 
is currently being audited. Ethical approval for all research activities is dependent 
upon provision for this payment.
Refs:
1. Glycerol for acute stroke (Cochrane Review)
172
Righetti E, Celani MG, Cantisani T, Sterzi R, Boysen G, Ricci S 
The Cochrane Library, Issue 3, 2004
2. Oral glycerol and intravenous dexamethasone in preventing neurologic and 
audiologic sequelae of childhood bacterial meningitis. The Finnish Study Group 
Kilpi T, Peltola H, Jauhiainen T, Kallio.M.J 
Pediatr. Infect. Dis. J., 14 (4); 270-278, 1995
3. Joint FAO/WHO Expert Committee on Food Additives, Geneva.
WHO Technical Report Series No. 599, 1976
4 Reversible Neurologic manifestation after glycerol: a short report.
Singh R, Lehl SS, Sachdev A, Sood A, Malhotra HS 
Neurology India 49(3); 320-321,2001
5 Dexamethasone in adults with bacterial meningitis 
de Gans,J.; van de,Beek D et al.
NEJM 347 (20); 1549-1556, 2112
6. Dexamethasone treatment in childhood bacterial meningitis in Malawi.
Molyneux E, Walsh A, Forsyth H, Tembo M, Mwenechanya J, Kayira K, Bwanaisa 
L, Njobvu A, Rogerson S, Malenga G.
Lancet 360 (9328); 211-21, 2002
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14. Details of support requested broken down by project year (summarised in 
Section 7)
Details of Grade Start Incre- Start Londo Other Superan Total
posts by Point mental Salary n and costs
name date weight Nat Ins Yr 1
Research staff
1 Principal 
Investigator
2 Clinical
N/A N/A N/A N/A N/A N/A N/A
Officer 1 CO 1.4.06 2200 N/A N/A N/A 2200
3 Clinical 
Officer 2 CO 1.4.06 2200 N/A N/A N/A 2200
Technical
staff 1.4.06 2200 N/A N/A N/A 2200
1 Laboratory 
technician
(MLSO)
2 Research 
assistant
1.4.06 900 N/A N/A N/A 900
Other staff
1 Nurses (6) H 1.4.06 10800 N/A N/A N/A 10800
2 Messenger 1.4.06 900 N/A N/A N/A 900
Annual Costs Effort on Year 1 Year 2 Year 3 Year 4 YearS Total
of above posts project per 
cent months
Research staff % months
1 Principal 
Investigator
2 Clinical
40 24 N/A N/A N/A
Officer 1
3 Clinical 100 24 2200 2200 2200
Officer 2
100 24 2200 2200 2200
Technical
staff
% months
1 Laboratory 
technician
100 24 2200 2200 2200
(MLSO) 100 24 900 900 900
2 Research
assistant
Other staff % months
1 Nurses (6) 100 24 10800 10800 10800
2 Messenger 100 24 900 900 900
Grand Total: 19200 19200 19200 57600
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14. Continued
Consumables Year 1 Year 2 Year 3 Year 4 Year 5 Total
please specify £ £ £ £ £ £
Animals - purchase
1) Intended source of 
supply
2) Species and 
microbiological
quality required
3) Number required
4) Purchase price per 
animal
Animals - 
maintenance
Subtotal annual costs 
£
Consumables etc. Year 1 Year 2 Year 3 Year 4 YearS Total
(continued)
Please specify
£ £ £ £ £ £
Laboratory costs 
(haematology, 
microbiology and 
biochemistry)
3900 3900 3350 11150
Ward consumables 2600 2600 2200 7400
(Syringes, needles, 
gloves, dressings etc)
700 700 350 1750
Glycerol
Sundries 
(Bank charges, 
customs clearance, 
phones, etc)
200 200 200 600
Total Annual Costs 7400 7400 6100 20900
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14. Continued
Travel and 
subsistence, 
destination 
and purpose
Number
of
journeys/
days
Mode of 
transport
Fare/
milage
Subsistence Fees Total £
Within the 
UK
N/A
Overseas
Patient 
follow up
240
journeys
Public
transport
2.50 per 
/patient 600
Defaulter
tracing
140
journeys
Hospital
vehicle
5.00 per 
patient
700
Total Annual
Costs £
Year 1
460
Year 2
460
Year 3
380
Year 4 Year 5
1300
The Foundation will not normally meet costs associated with travel to conferences. 
See Guidance.
Exceptional
Items
Total
Sample storage, handling and transport
Phones and two way radios for on-call commitments
Dissemination costs including meningitis workshops and conference fees.
10% administrative levy payable to the College of Medicine
900
270
1200
8220
Total Annual Year 1 Year 2 Year 3 Year 4
Costs
3310 3340 3940
Year 5
10590
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14. Continued
Equipment
Description of items and 
country of manufacture
Expiry 
date of 
quotation
Likely
Delivery
Date
Basic
Price £
Import
Duty
Total
£
1 Refrigerators A
2 Ward furniture and storage
3 Filing cabinets
4 Glucometers
5 Sphymomanoteters
6 Audiometers
7
>
Items in
place from 
steroid trial
Annual cost of above items Year 1 Year 2 Year 3 Year 4 Year5
1
2
3
4
5
6
7
Total Annual Costs
Medical / scientific equipment purchased with charitable funds, when donated to 
designated non-profit making (hospital or research) institutions to be used for 
medical research is zero rated for VAT. VAT should therefore be excluded when 
applying for equipment costs from the UK and Republic of Ireland.
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15. Curriculum Vitae of applicant (please complete a copy of this page for each 
applicant and for any named staff for whom salary support is requested in section 14)
Name: Matthew Scarborough
Age and Date of birth: 41; 25.12.1962
Degree etc. (subject, class, university, and date):
BSc Anatomy. 1st Class. Queen’s University, Belfast. 1988
MB, BCh, BAO. Distinction. Queen’s University, Belfast. 1990
MRCR. Royal College of Physicians, London. 1998
Diploma in Tropical Medicine and Hygiene. University of Liverpool 1998
Posts held (with dates):
Lecturer in Medicine, University of Malawi. November 2001 - December 2004 
Specialist Registrar in Internal Medicine, Oxford Deanery. October 1999 - 
September 2001
Specialist Registrar in Infectious Diseases, London. March 1998 - September 1999
Do you have assured salary support for the period of the grant?
Yes
Do you have links (eg. consultancies, equity holdings) to companies or other organisations 
that are relevant in any way to the current proposal? No
If yes, please give details.
Recent Publications; also papers in press:
Bacterial meningitis in sub-Saharan Africa; challenges to a better outcome 
M Scarborough, Y Njalale 
Tropical Doctor (In press)
Clinical Features and Outcome of Cryptococcal Meningitis in Zambia 
Postgraduate Medical Journal. 2001 Dec;77(914):769-73.
P Mwaba, J Pobee, M Scarborough, S Portsmouth, A Zumla
Varicella Zoster Virus associated neurological disease in HIV-Infected patients 
Int J STD & AIDS 2001; 12: 79 - 83 
M Brown, M Scarborough, N Brink, H Manji, R Miller
Lymphocytic Interstitial Pneumonitis in an HIV infected adult: response to 
antiretroviral therapy.
Int J STD & AIDS 2000; 11: 119-122 
M Scarborough, S Lishman, P Shaw, A Fakoya, R F Miller
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15. Curriculum Vitae of applicant (please complete a copy of this page for each 
applicant and for any named staff for whom salary support is requested in section 14)
Name: Yasin Njalale
Age and Date of birth: 24; 18.7.1980
Degree etc. (subject, class, university, and date):
Diploma in Clinical Medicine, Malamulo College of Health Sciences, Malawi 2001
Posts held (with dates):
Intern Clinical Officer, QECH. April 2002 - March 2003
Research Clinical Officer, College of Medicine, Malawi. April 2002 - present
Honorary Registrar, Department of Medicine, QECH. March 2004 - present
Do you have assured salary support for the period of the grant? 
Salary applied for in current proposal
Do you have links (eg. consultancies, equity holdings) to companies or other organisations 
that are relevant in any way to the current proposal? No
If yes, please give details.
Recent Publications; also papers in press:
Bacterial meningitis in Sub-Saharan Africa - challenges to a better outcome.
M. Scarborough, Y. Njalale 
Tropical Doctor (In press)
Application of the Vietnam diagnostic scoring system for TB meningitis to patients in 
the Queen Elizabeth Central Hospital, Blantyre.
A.Checkley, Y.Nialale. M.Scarborough, E.E.Zijlstra
College of Medicine Research Dissemination Conference, Blantyre. November 
2003
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15. Curriculum Vitae of applicant (please complete a copy of this page for each
applicant and for any named staff for whom salary support is requested in section 14)
Name: Eduard Evert Ziilstra
Age and date of birth: 50 years; 19 April 1954
Degree etc. (subject, class, university, and date):
• Medical licensure (“artsexamen”), Medical Faculty Rotterdam, 27 July 1979
• Registered as internist, University Hospital Rotterdam, 1 April 1986
• MSc Clin Trop Med, London School of Hygiene and Tropical Medicine, 19 October 
1988
• DTM&H, London School of Hygiene and Tropical Medicine, 14 July 1988
• PhD, University of Amsterdam, 2 February 1995
• MRCP (UK), 14 July 1989; FRCP (UK), 1 May 2002
• MRCPath, 27 June 2002
Posts held (with dates):
• Academic Specialist:, University Hospital Rotterdam, March 1986 - September 
1987, and January 1989 - July 1989.
• Programme Coordinator:Kala-azar programme in the Sudan, Medecins sans 
Frontieres - Holland, July 1989 - October 1991.
• University Lecturer/ Academic Specialist, Department of Infectious Diseases, 
Tropical Medicine and AIDS, Academic Medical Centre, University of Amsterdam, 
November 1991 - March 1995.
• Assistant Professor, Institute of Endemic Diseases, University of Khartoum, 
Sudan, April 1995 to August 1998.
• Associate Professor of Medicine, College of Medicine, University of Malawi, 
August 1998 - October 2003. Head of the Department of Medicine from August 
1999.
• Professor of Medicine, College of Medicine, University of Malawi, 31 October 
2003.
Do you have assured salary support for the period of the grant?
Yes
If neither of the above is true, please explain the circumstances below.
Do you have links (eg. consultancies, equity holdings) to companies or other organisations 
that are relevant in any way to the current proposal? No
If yes, please give details.
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Recent Publications; also papers in press:
James J, Hofland HWC, Borgstein ES, Kumiponjera D, Komolafe OO, Zijlstra EE. 
The prevalence of HIV infection among burn patients in a burns unit in Malawi and 
its influence on outcome.
Burns 2003; 29: 55-60.
Zijlstra EE, Musa AM, Khalil EAG, El Hassan IM, El-Hassan AM.
Post-kala-azar dermal leishmaniasis (Review).
Lancet Infectious Diseases 2003; 3: 87-98.
Lewis D, Joaki G, Peters R, Schijffelen M, Walsh A, Kublin J, Kumwenda J, 
Kampondeni S, Molyneux M, Zijlstra E.
Mycobacteraemia in adults admitted to hospital in Blantyre, Malawi.
International Journal for Tuberculosis and Lung Disease 2002; 6: 1067-74.
Peters RPH, Zijlstra EE, Schijffelen MJ, Walsh AL, Joaki G, Kumwenda JJ, Kublin 
JG, Molyneux ME, Lewis DK.
The importance of bloodstream infections as cause of fever in a population with high 
HIV prevalence in Blantyre, Malawi - identification of clinical predictors and 
implications for management: a prospective study.
Tropical Medicine & International Health, 2004; 9: 928-934.
15. Curriculum Vitae of applicant (please complete a copy of tills page for each 
applicant and for any named staff for whom salary support is requested in section 14)
Name: Katherine Mary Brzechwa Ajdukiewicz
Age and Date of birth: 31,23 August 1973
Degree etc. (subject, class, university, and date):
MBChB Dundee 1997, MRCP (UK) 2000
Posts held (with dates):
August 2002 - present Specialist Registrar Infectious Disease/Medicine, 
Newcastle upon Tyne
August 2001- July 2002 Specialist Registrar (LAT) ID/Medicine, Dundee
August 2000 - July 2001 SHO Infectious disease/Microbiology, Newcastle upon
Tyne
August 1998 - July 2000 SHO Medicine, Gateshead
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Do you have assured salary support for the period of the grant?
YES Salary applied for in current proposal □
If neither of the above is true, please explain the circumstances below.
Do you have links (eg. consultancies, equity holdings) to companies or other organisations 
that are relevant in any way to the current proposal? NO
If yes, please give details.
Recent Publications; also papers in press:
Cost-minimization analysis and audit of antibiotic management of bone and joint 
infections with ambulatory teicoplanin, in-patient care or outpatient oral linezolid 
therapy.
D Nathwani, G Barlow, K Ajdukiewicz, K Gray, J Morrison, B Cleft, A France, P 
Davey
Journal of Antimicrobial Chemotherapy 51; 391-396: 2003
An African HIV cohort in a provincial infectious diseases unit 
H Hadi, J Smith, K Ajdukiewicz, M Schmid, E Ong, M Snow 
Federation of Infection Societies 2003
Differences in adult and paediatric meningococcal sero-group and mortality in 
Northern England
M Schmid, K Ajdukiewicz, B Fultton, T Flood, D Price, H Thaker, M Snow, E Ong, V 
Holiyoak
Federation of Infection Societies 2002
Outcome of meningococcal disease in adults and children within Northern NHS 
region 1998-2000
Federation of Infection Societies 2001
16. Experiments involving animals
Applicants must have regard to animal welfare and advances in the refinement, 
replacement and reduction of animal use. Meningitis Research Foundation will 
not support research involving live animals unless there is no alternative, and it 
is essential to the outcome of the research. If the proposed research project
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involves research on live animals, their use must be minimised and optimised. 
The number of animals requested must be fully justified. Meningitis Research 
Foundation emphasises the importance of refining procedures to minimise any 
pain or distress caused.
Please refer to the Foundation’s policy on the use of live animals before answering 
these questions:
16.1 Do the experiments you propose involve the use of protected animals in 
regulated procedures under the Animals (Scientific Procedures) Act 1986? (For 
the information of non-UK applicants, this includes all vertebrates as well as 
octopus.) NO
If yes, which species and how many animals?
Are any of the procedures of substantial severity? Yes D No D
16.2 Has a project licence, under the terms of the Animals (Scientific 
Procedures) Act 1986, been granted which authorises the proposed 
experiments? Yes D No D
If yes, please state the name and address of the licensee. Home Office reference and 
date of issue and attach a copy of the front page of the project licence.
If not, has it been applied for? Yes □ No □
Does each individual cariying out work on animals have a personal licence?
Yes □ No □
If you are applying from outside the UK, please explain what efforts have been made 
to comply with local procedures regulating the use of animals in scientific 
experiments.
16.3 Have all those involved in the care and use of animals before, during and after 
the experiments, received appropriate training in animal care and in the procedures 
involved? Has this training included attendance at the relevant courses?
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16.4 Does your institution have an Ethics (or Animal Care and Use) Committee for 
animal experiments? If so, have the proposed experiments received its approval?
If not, what steps have been taken to gain its approval?
If no such committee exists, what alternative measures have you taken?
16.5 Will the animals be conscious for all or part of the experiments?
If so, explain why this is necessary, what, if any, discomfort they are likely to 
experience and how it is ameliorated.
16.6 If the animals are to be anaesthetized, will they be allowed to regain 
consciousness? Unless the animals are to be the subject of survival studies, 
explain why this is being allowed.
16.7 Have the appropriate power calculations been performed to determine 
the number of animals required? If so, please give the calculations.
16.8 Does the proposed experimentation on live animals duplicate any other 
research which has already taken place, or which is known to be currently 
taking place in any research establishment?
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16.9 Will you be engaging any other establishment to carry out experiments on 
live animals as part of this research project? If so, please provide full details.
17. Scientific Integrity
The Foundation expects the highest standards of integrity to be adhered to by 
researchers whom it funds. Institutions in the UK and Republic of Ireland are 
required to have hi place their own published standards of good research practice and 
formal written procedures for the investigation of allegations of scientific 
misconduct. These must comply with the Association of Medical Research 
Charities’ Guidelines on Good Research Practice ( 
http://www.amrc.org.uk/aboutus/Good Research Practice.PDF).
Please attach a copy of your Institution’s policy on good research practice/scientific 
integrity. If you are applying from outside the UK and Republic of Ireland, please 
outline your institution’s procedure on a separate sheet or attach a copy of the 
relevant document from your institution (in English).
18. Dissemination
The Foundation has a responsibility to ensure that all useful knowledge acquired 
from research it funds is disseminated to the public and to others able to utilise or 
benefit from it. Annual and final reports are required which specifically indicate the 
relevance of research progress and outcomes to meningitis and associated infections. 
Grantholders are expected to seek publication of findings in peer reviewed journals 
as soon as possible, even where results prove negative. The Foundation must be 
notified in advance of publication, and acknowledged in all publications and 
presentations arising from research it funds.
Please outline proposed arrangements for dissemination.
The results of the ongoing or completed parts of the trial will be presented at 
the College of Medicine Research Dissemination Conference in Blantyre, 
Malawi in November 2005, 2006 and following completion of the trial. We 
are currently organising three regional Meningitis workshops annually in 
Malawi to discuss research findings and medical updates in meningitis in 
each of the county’s three main regional hospitals. In addition, the findings 
will be published in the Malawi Medical Journal and more widely in the
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international medical press and at international conferences where 
appropriate.
19. Monitoring and Evaluation
The Foundation’s Trustees have a responsibility to ensure that work of the highest 
quality is produced. The Foundation therefore requires that die Research Institution 
ensures that all funded work is adequately supervised at all times, monitored and 
evaluated. The results of the research must be subject to proper evaluation before 
they are published.
Please indicate what arrangements are in place for monitoring and evaluation.
The College of Medicine Research and Ethics Committee requires quarterly reports 
and an annual presentation on all ongoing research activities within its remit. This is 
attended by academics, clinicians, lay representatives and medical ethicists 
appointed by the College to ensure that research is of a high quality and that it 
conforms to the Universities research code of conduct.
An experienced trialist and senior scientist in Malawi will serve as trial monitor and 
will be asked to visit the trial and review the data every three months. The trial 
monitor will review the standard operating procedures prior to recruitment and have 
open access to all patient data throughout the recruitment period. Any possible or 
probable adverse events will be recorded and reported to a senior physician 
unconnected with the trial who will decide whether the trial monitor should be asked 
to review the case immediately.
The steering committee will provide overall supervision of the trial, provide advice to 
the investigators, host institution and the DMEC on matters relating to the conduct of 
the trial, notify the investigators of emerging evidence from other trials which may be 
relevant, and ensure adherence to the study protocol and MRC guidelines for 
clinical trials. It will oversee the progress of the trial and serve to protect the 
interests of the trial participants and sponsors.
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The analysis plan and the evaluation of final results will be reviewed by the trial 
steering committee in order to ensure that the results truly represent the findings 
from the study.
Trial Monitor: Professor Anthony Harries, Foundation Professor of Medicine, 
University of Malawi
Steering Committee Chairman: Dr. David Lalloo, Clinical Director, Liverpool School 
of Tropical Medicine
20. Collaboration on a research project
Any individuals named as collaborators (NOT as applicants) in this research
application should complete a copy of this form.
Name of principal applicant:
Principal applicant’s department and institution:
Name of collaborator:
Full address of collaborator, including department and institution:
Title of research grant application:
Extent and nature of collaboration:
I confirm that I am willing to collaborate as stated above on this research 
project:
Signed:
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Appendix 2. Research Grant additional funding application 2006
Costings
7a) Summary of support requested:
Project
Year 1 
£
Project
Year 2 
£
Project
Year 3 
£
Projec 
t Year
4
£
Project 
Year 5 
£
Total
£
Staff 23800 25750 28000
Consumables 21400 21400 21400
Travel and
Subsistence
460 460 460
Exceptional items 9120 900 2400
Equipment
Grand Total 54780 48510 52260 155550
b) Breakdown of costs by financial year (1 April to 31 March):
Financial 
Year 1 
£
Financia
1 Year 2 
£
Financia
1 Year 3 
£
Financ
ial
Year 4 
£
Financia
1 Year 5 
£
Financia
1 Year 
6*
£
Total
£
Staff 23800 25750 28000 77550
Consumables 21400 21400 21400 64200
Travel and
Subsistence
460 460 460 1380
Exceptional items 9120 900 2400 12420
Equipment
Grand Total 54780 48510 52260 155550
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14. Details of support requested broken down by project year (summarised in 
Section 7)
I Details of Gra Start Incre- Start London Other Superan Total
posts by de Point mental Salary weight and costs
name date Nat Ins Yr 1
Research staff
Principal Investigator N/A N/A N/A N/A N/A N/A
Clinical Officer 1 
Clinical Officer 2 CO 1.3.7 2700 N/A N/A N/A
CO 1.3.7 2700 N/A N/A N/A
Technical staff
Laboratory 
technician (MLSO)
1.3.7 3000 N/A N/A N/A
Research assistant 1.3.7 1200 N/A N/A N/A
Other staff
Nurses (5) H 1.3.7 10500 N/A N/A N/A
Principal nurse 
Messenger
I 1.3.7 2500 N/A N/A N/A
1.3.7 1200 N/A N/A N/A
Annual Costs of Effort on Year 1 Year 2 Year 3 Year 4 Year5 Total
above posts project per
Cent months
Research staff % months
Principal Investigator 40 36 N/A N/A N/A
Clinical Officer 
Clinical Officer 100 36 2700 3000 3300
100 36 2700 3000 3300
Technical staff % months
Laboratory 
technician (MLSO) 100 36 3000 3300 3600
Research assistant
100 36 1200 1350 1400
Other staff % months
Nurses (5) 100 36 10500 11100 12000
Principal nurse
2 Messenger 100 36
2500 2700 3000
100 36 1200 1300 1400
Grand Total: 23800 25750 28000 77550
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14. Continued
Consumables 
please specify
Year 1 
£
Year 2 
£
Year 3 
£
Year 4 
£
Year 5 
£
Total
£
Animals - purchase
1) Intended source of 
supply
2) Species and
microbiological 
quality required
3) Number required
4) Purchase price per 
animal
5) Animals - maintenance
Subtotal annual costs £
Consumables etc.
(continued)
Please specify
Year 1 
£
Year 2 
£
Year 3 
£
Year 4 
£
Year 5 
£
Total
£
Laboratory costs 
(haematology, 
microbiology and
biochemistry)
4000 4000 4000
Ward consumables 
(Syringes, needles, gloves, 
dressings etc)
5700 5700 5700
BM Stix 3000 3000 3000
Ceftriaxone 7700 7700 7700
Glycerol 700 700 700
Sundries
(Bank charges, customs 
clearance, phones, etc)
300 300 300
Total Annual Costs 21400 21400 21400 64200
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14. Continued
Travel and 
subsistence, 
destination 
and purpose
Number
of
journeys/
days
Mode of 
Transport
Fare/
mileage
Subsistence Fees Total £
Within the UK N/A
Overseas
Patient follow 
up
240 journeys Public
transport
2.50 per 
/patient
600
Defaulter
tracing
140 journeys Hospital/Pl 
’s vehicle
5.00 per 
patient
700
Total Annual 
Costs £
Year 1
460
Year 2
460
Year 3
460
Year 4 Year 5 1380
The Foundation will not normally meet costs associated with travel to conferences. 
See Guidance.
Exceptional Items Total
Sample storage, handling and transport 2500
Phones and two way radios for on-call commitments 500
Dissemination costs including meningitis workshops and conference fees. 1200
10% administrative levy payable to the College of Medicine 8220
Total Annual Costs Year 1 Year 2 Year 3 Year 4 Year 5 12420
9120 900 2400
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14. Continued
Equipment
Description of items and 
country of manufacture
Expiry 
date of 
quotation
Likely
Delivery
Date
Basic 
Price £
Import
Duty
Total
£
1 Refrigerators ^
2 Ward furniture and storage
3 Filing cabinets
4 Sphymomanoteters
5 Audiometers j
> Items inplace from 
steroid trial
On loan from 
UK
physician
Annual cost of above items Year 1 Year 2 Year 3 Year 4 Year5
1
2
3
4
5
6
7
Total Annual Costs
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Appendix 3. Proforma
PHASE TWO 
ISRCTN70121840
TRIAL NO:
QECH Glycerol Trial ISriCTN7012t840 Phase 2: Version 6
-i -
1*’Name................................ 2^ Name............................................... Front sheet
Admission date:
Sex: Male / Female Admission time:
Age (exclude if <l6yrs) DOB: I I
acmar*
acntirre
Into each of the boxes below insert a number: YES=1; NO=0: DON’T KN0W=9 
Into each of the circles (O) place a tick when indicated 
Write an explanation/description on lines.
Inclusion criteria
CSF critena at recruitment (one or more of the following): 
Cloudy / hazy CSF in a patent nequinng immediate treatment doucy
>100 white cells/pl of CSF. >50% neutrophils wo: ICC
Gram-stain showing bacteria in CSF <yys
AN D C!iQi£aL£rit§naj 1 or more of the following)
»«adacre 
neck|»in
roe
photobu 
con‘ 
fts 
rash 
f»v»r
Exclusion criteria
Pregnancy ..LMP:___________ / postmenopausal / no sexual contact /
pregnancy test done t other________________ . ..................
Age <16yrs........................................................................................
BM>20mmoL‘L..................................................................................
Type 2 Diabetes...............................................................................
Heart failure......................................................................................
In order to recruit 
tne answer must be 
"NO' to all exclusion 
crrtera.
neaoacne.............
Neck pain/stiffness 
I consciousness ...
Photophobia..........
Confusion..............
Fits.........................
Rash.....................
Fever.....................
Is the patent suitable for enrolment^..........................
(at least 1 clinica and 1 CSF critera; no exclusion critena)
Consent obtained........................................................
Randomization Date: / / 
Randomization Time:
(i.e. point at which trial number allocated)
□
□
randdate
ra^dbme
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PHASE TWO 
ISRCTN70121840
TRIAL NO:
QECH Glycerol Trial ISRCTN70121840 Phase 2: Version 6
•)
I^Name.............................. 2na Nome
Admission samples: Dote: / I Time:
CSF 1 O 4ml CSF for Microbiology (WT)
Whole blood: O 4ml si Rain tube for U&Es. LFTs (QECH)
(20ml minimum) O 2ml m EDTA for FBC (QECH or WT if QECH unable to do)
O MPs (QECH)
O 1ml EDTA for HIV test (Jimmy, Tiyaniane.l 
O 8ml Blood culture (WT)
O 4ml in EDTA for storage* (WT)
O Random blood glucose using BM sticks 
O Other.............................
Who has taken blood admission samples? (wnte your name here) ___
Por
Ov*f th* weekend' on 
bo»cays: place tios d tor 
HIV l**t m tn* fndge or 
4A pack bay. Samples 
can be taken to Jimmy 
on the oext efork ng day.
‘Label admission sample like this ‘GLAM XXX A’ where ‘X’ is the trial number of the patient
Outcome
Completed 10 days IV antibiotics ........Date / / ..................................
Number of doses given Ceftriaxone............. ..........
Cefotaxime ............ .............
Benzyipenicillm . ...... ............
Chloramphenicol..... ...........
Other_________________
If <10days. reason for stopping cryptococcal / T8M / died / other 
Absconded ................... Date / / ........................................... .
Discharge......................  Date / /
Died ................................. Date / /
Glycerol'piacebo discontinued . .. Date / I 
Reason: cryptococcal / IBM / other 
Total number of doses glycerol/placebo given __
1 1 eompi*-.*
P0S4C4
3os*cm
»*40*n
flottchc*
ttopjfei
□ absc
□ pitch
□ P*d
□ piyetJop
nurregly
Record complete..........  Date / /
If incomplete, details 1)_________
2)__________
3)_________
O (Tick when rectified)
O
O
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PHASE TWO 
ISRCTN70121840
I^Nnme...............
Contact details
Residential address.
Residential location:
Residential Tel:
TRIAL NO:______
QECH Glycerol Trial ISRCTN70121040 Phase 2. Version 6
- 3 -
............. 2ra Name.................................................Contact details sheet
(Please record precise details and directions below or overleaf)
Personal contact 1
Name:
Relation:
Address:
Tel:
Location:
Personal contact 2
Name;
Relation:
Address:
Tel:
Location:
Continue over the page if necessary
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PHASE TVVO TRIAL NO:
ISRCTN7012184Q QECH Glycerol Trial ISRCTM7D121040 Phase 2: Version 6
-4-
I’1 Nome................................. 2r0NftniD................................................. Date: / /
Timo:
Source of history: Patient I Spouse / Parent / Sibling! Friend / Other____________
P/C nnrl duration
Headache hours / days..................................................................
_
Neck stiffness hours/davs ...............................................................
—
Confusion hours/days.....................................................................
Fever hours / days.......................................................................
Photophobia hours / davs...............................................................
^consciousness hours / davs...........................
Fits hours / days..............................................................................
Rash hours/days..........................................
Ear ache or pain davs.................................
Night sweats davs.................
—
Couqh davs.......................... ................
SOB days............................................
Chest pain days...........................................................
Abdo pain davs...........................................
Diarrhoea days...........................................
Vomiting davs.........................................................
Frequency day's..............................................
Dvsuria davs.................................... ....... ... . .
Other
Other
Other
HPC
Date of onset:
Duration of iiln
/ / Time of onset:
ass: days: hre
Symptoms / Events..
I'ed3::he
r.ftit
CC-Mn
fovr 
phij a 
fftcllor. 
ftshp;
eardi'is
r.l«\ts
r.c-.Kh
soS>
r,p.i n
P.p^in
diarr
vnmt
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QECH Glycerol Trial ISRCTNT0121S40 Pltase 2: Version 6
-5-
PHASE TWO 
ISRCTN70121840
TRIAL NO:
1s1Nnme................................. 2r,a Nome................................................ Dote: /
Drug, history Time:
Hove antibiotics been taken during this illness before admission?................................ p"~j
Which ones?________________________
For how long in days?_______________________
Start date? ______________ _
Were antimalarials taken for or during this illness?........... .............................................| |
SP / Quinine f other
Start date?_________________________
Have any other medications been taken in the past month?..........................................| ^""|
W'hich ones?________________________
When?
ARV start date / /
Was any treatment or advice obtained from a traditional healer for this illness? . .......□
Details_________________________________
Coexisting conditions
Acute diarrhoea 
Known epilepsy 
TB....................
prsahsr
abjwlvch
abidarn
jMSs-sin’.*
premsl?
msstypi
arr^-vs
midiype
PtSdrthsn
srtstarl
tral:l
*r,i! "if::
a:Li*6t!
spil
1b
Ear pain or ache......
Ear discharge
HIV positive,........
Pregnancy" ............
Type 2 diabetes* . .
Head failure* ..........
Other____________
Has the nntient had
Deafness L / R.........
Gaze palsy/squint-.,.
Paralysis...................
Mental disorders......
Other _______
Date / / 
Date / / 
Date / / 
Date / /
esrs
eanliscb
tw
pra-g
lypfiSdm
.............................. ...... ccf
*if yes, do not administer glycerol
deaf.'r
psralys
martial
ot^ar
Ptmctlonlnq ability before this illness
4=Fully iirdependsnt with no disability....................
3-Disabletl but independent, able to work..............
2=Disablecl: dependent on others for daily support. 
■^Minimally responsive............................................
fucciion
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PHASE TWO 
ISRCTN70121WQ
TRIAL NO:
QECH Glycerol Trial ISRCTN70121EI40 Phase 2. Version 6
-<$-
I^Nome............................... 2r{J Nnme............................................. Dnte; / /
Time;
Past Medical History (PMH)
Meningitis (admitted)................................ Date/s:
Shingles ..........................................   Oaie/s:_
TB...........................................  Date/s:.
Pneumonia (admitted).................. Oate/s:_
Ofal Candida...............................................................
Oesophageal candidiasis....................................
Chronic diarrhoea 1/t 2........................................
Weight loss.............................................................
ngi.s
lb
pneum
candors
ntlQSS
Kaposi's sarcoma..__
Chronic fevers>1/12... 
Penpheral neuropathy.
kspmti
chrtemp
pn
Social History
Married (now) ............................. .............. ..............
Divorce or separated (ever)......................................
Widowed (ever)........... .............................................
Currently employed?.................................................
Any children?.............................. . ......................
No. of children alive 
No. of children died
literate / Illiterate Education level reached:,
Lives: Urban / Rural
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QECH Glycerol Tnal ISRCTN70121840 Pha«ve 2 Veraior 6
-7-
PHASE TWO 
ISRCTN70121840
TRIAL NO:
I^Name ..................... 2nd Name ,
O/E: Is the patient fully onentated in Time
Place
Person
Eve opening 
04=Spontaneous 
03=To speech 
O2=lo pam 
01=Norve
Verbal
05=Onentated speech 
04=Confused speech 
O3=lnapprop. no conversation 
02=lncomprehensible 
Ot=None
Wt____________ kg (estimated / measured
Dote: / /
Time:
Y / N tun*
Y / N pue*
Y / N P#rv>n
Motor/ pa n response
O6=0beys commands 
05=localises 
04=Withdr3v,s 
03=Ftexes to pain 
02=Extends to pam 
01=No response
GCS.tptal
______ aal
/15
Oxygen saturation (Sp02)________%
Neck stiffness ............................................................
Photophobia ....... ................ ...........  ..........................
Kemig’s +ve.......................................................................
Lymphadenopathy ...............................................
If present. Cervical / Axillary / Inguinal 
Oral thrush.........................................................................
KS.............................................................................
Fungal skin disease .......... ...................................
Shingles scars ............................................................
Oral hairy leukoplakia.................................................
Wasting ............................................................................
w*C
neotstr
pfcbiac*
mod**
thrash
k«
fU'NJJI
¥IVSCjr
ohl
Heart sounds: Any abnormality
If abnormal, explain
□
Chest: Crackles____________
Effusion_____________
Bronchial breathing__
Rhonchi____________
Any other abnormality
Abdomen:
Tendemess________________
Hepatomegaly_____________
Splenomegaly__________ cm
Ascites....................... ...............
Any other abnormality...........
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PHASE TWO 
ISRCTN70121W0
TRIAL NO:
QECH Glycerol Trial lSRCrN70l2iB40 Phase 2: Version 6
• 8-
1"Nome.................................... 2"° Name ................................................. Date: / /
Time:
Neurological system:
PERLA OYes ONo-details___________ p«rt»
Vision RIGHT 
O normal 
O counting fingers 
C hand movement 
O not able to see fight 
O unable to assess
Vision LEFT Fundus RIGHT
O normal O normal
O counting fingers Opapilloedema
O hand movement Ounable to assess
O not able to see lightOother_________
O unable to assess
Fundus LEFT »*ionr'i
Onormal •unojvii
Opapilloedema 
Ounable to assess 
Oother________
Optic nerve sheath diameter 1 RIGHT / LEFT________mm opt^ei
Eye movements
Any abnormality ....................................................................................................................... | | ♦y«-Kv*
If abnormal, indicate which RIGHT III / IV / VI
LEFT III / IV / VI
Other cranial nerves - any abnormality of:
CNV-corneal ........................... ... ............................. ........... ................... .1 I cxv
If abnormal, indicate RIGHT / LEFT
CN VII ............................................ .......................... □ CNV I
If abnormal, indicate: RIGHT / LEFT
Gag reflex .. (If unable to ass*s* wnte 0 - don t knew) ................................................................. I___ Gag
CN XII .....................................................................................................................................M cnxji
If abnormal, indicate: RIGHT / LEFT
Any other alMvxmality ..................... ...............................................n fUNfCN
Hearing assessment RIGHT_________db LEFT_________db
[Circle minanum sound heard]
RIGHT
LEFT
Finger rub / Whisper / Speech / Shout / Totally deaf/Untile to assess 
Finger mb / Whisper / Speech / Shout / Totally deaf/Unable to assess
ngteS
wftdb
neamgr I
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PHASE TWO 
ISRCTN70121840
TRIAL NO:
QECH Glycerol Trial I3RCTN70121840 Phase 2: Version 6
-9-
18,Name................................. 2r‘tl Name................................................ Date: / /
Time:
Neurological system cont’d:
Anns
RIGHT LEFT
Tone l / Normal / t i ! Normal i t
Power D/1/2/3/4/5/ 
unable to assess
0/1/2/3/4/5/ 
unable to assess
Reflexes l (Norma! /1 4- / Normal / T
Legs
RIGHT LEFT
Tone 4- / Normal / T 4- / Normal / T
Power 0 / 1 / 2 / 3 / 4 / 5 / 
unable to assess
d/1/2/3/4/5/ 
unable to assess
Reflexes 4- / Normal / ^ 4- / Normal / t
Planters 4- / t / equivocal 4- / f /equivocal
Summary of neurological findings: Normal / Abnormal
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PHASE TWO 
ISRCTN70121840
TRIAL NO:
QECH Glycerol Trial ISRCTN70121840 Phase 2: Version 6
1*' Name 
Investigations:
“ IV ■
2"° Name
FBC Date: / / Biocbem Dote: 1 1
Hb q/dl Urea mo'dl Total prot g/dL
MCV fl Creatinrie mo/dl Albumin o/dl.
MCHC g/dl Sodium mEo/1 Tot Bill mg/dL
wcc 10*/l Potassium mEo/l Direct Bil mg;dl
PIT tO5/! Chloride mEq/l Aik phos U/L
RBS mmol/1 AST/SGOT U/L
MPs ALT/SGPT U/L
Negatrve /+■/++ / +++ / ++++ mps GGT U/L
HIV test
Positive (known on admission) / Positive (tested by us) / Negative / Not done 
Post-test counselling Signature __________________ date / /
Pregnancy test
Positive / Negative / Not done 
Sputum AFB (if indicated)
Sputum 1 Positive / Negative / Not done Jbioa
Sputum 2 Positive / Negative / Not done 
Sputum 3 Positive / Negative I Not done
CXR
Not done / Date of CXR f /
Any abnormality?...............................................................................................................
If abnormal explain________________________________
Blood culture result (Lab No............... ) tKpvwr
Pneumococcus..............................................................................................................................O
Meningococcus.....................................................................  O
H influenzae,..................................................................................................................................O
Group A Strep / Strep pyogenes O
Cryptococcus................................................................................................................................O
Other................................ O
No growth........................................................................................................ O
Sensitivities
Penicillin........................................................................................................................................ O
Chloramphenicol...........................................................................................................................O
Tetracycline....................................................................................................................... .....
Co-tnmoxazole O
Gentamicin ........................................................................................................................ O
Erythromycin ........................................................................................................................ O
Cefaclor ...................................................................................................  o
Ceftriaxone.................................................................. o
CtoxaaHin......................................................................................................................................O
Other......................... O
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TRIAL NO:__________
QECH Glycerol Trial l5RCTN7ai2t840 Please 2 Veralon 6 
-11-
.............. 2"° Name .................................................. . Investigations sheet B
CSF 1 (Lob No................) Date of LP: / /
Opening urenufe cm x>i
CSF appearance: Clear / Turbid or hazy / Bloodstained
WCC: ______________min'3 Protein: +/+♦/♦>+/+♦»► aeci / poy*tt
% Polys_________ % Glucose: Neg/Trace/* / ♦♦ / w 9^1
RBC _____________ mm'*
Gm stain: No organisms / Gm+ diplococci / Gm dipkxrocci / Gm rods
India Ink: Positive / Negative ndui
CRAG (CSF): Positive / Negative / Not done eragi
CSF culture demti
Pneumococcus .......        o
Menngococcus ...... o
H influenzae....................................................................................................     o
Group A Strep / Strep pyogenes .................................................... o
Cryptococcus ......................................................... O
Other................................    o
No growth ..................... . O
Sensitivities
Penicillin............................................      o
Chloramphenicol ................................................................................. o
Tetracycline ................................................................................................................................... O
Co-tnmoxazoJe ..............................................................................................................................O
Gentamicin ...............  O
Erythrontyon .............     O
Cefaclor ...................    O
Ceftriaxone....................................................................................................................................... O
Ckwacilm .......................................................................................................................................O
Other       o
PHASE TWO 
ISRCTN70121&40
I^Name
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PHASE ONE 
ISRCTN70121840
TRIAL NO:
QECH Glycerol Trial lsecTN7012i840 Phase 2: Version 6
-12-
1'1 Name................................... 2,,a Name.................................................. Investigations sheet C
For most patients, there will be a second LP by consent after 2 complete days of treatment. 
Take samples in the morning to reach the lab by 10:30 (Mon-Fri), 11.30 (Sat & Sun).
Place a yellow sticker on the form, label CSF and EDTA blood ‘GLAM XXX B’ where X is the 
patient trial number, place these into a plastic specimen bag and take to the WT lab.
Second lumbar puncture O Consent obtained
O Not done__________________________________
Clinical indication for LP________________________
DAY 2 SAMPLES: Date: / / Second LP/bloods:
CSF 2: O 4ml for Microbiology (WT) rime taken:___________  *21™
Whole blood: O 4ml EDTA Wood (WT) Time frozen:___________
O Blood in plain tube for U&Es. LFTs (QECH)
RIGHT/LEFT optrve2
CSF 2 fLab No...................)
Opening pressure________cm op:
CSF appearance: Clear / Turbid or hazy / Bloodstained
WCC: _____________ mm*3 Protein: +/++/+++/++++ wccs/poyw
%Polys________ % Glucose: Neg/Trace/+ / ++/ +++ prot:: »uc:
RBC:  mm'3
Gm stain: No organisms / Gm+ dipbcocci / Gm- diplococci / Gm- rods / not done grrsum:
India Ink: Positive / Negative mdia:
CRAG (CSF): Positive / Negative / Not done crag:
CSF culture
Pneumococcus...............................................................................................................................................O csfcuit:
Meningococcus.......................................................................................................................... O
H influenzae................................................................................................................................ O
Group A Strep / Strep, pyogenes......................................................................................... O
Cryptococcus.............................................................................................................................O
Other............................... O
No growth................................................................  O
Sensitivities
Penicillin.......................................................................................................................................O
Chloramphenicol...............................  O
Tetracycline.................................................................................................................................O
Co-tnmoxazole............................................................................................................................O
Gentamicin ......................................................................................................................O
Erythromycin ......................................................................................................................O
Cefaclor ...................................................................................................................................O
Ceftriaxone..................................................................................................................................O
Cloxacillm.....................................................................................................................................O
Other........................  O
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I^Nomo.............. .................. 2na Name................................................. Investigations slieet D
Date sample taken: l I
Urea mq/dl Total prot ci/dl Mren2
Creatinine mq/dl Albumin q/dl
Sodium mEa/l Tot Bili ma/dL iotbi'i2
Potassium mEq/l Direct Bil ma/dL
Chloride mEa/l Aik ohos U/L
AST/SGOT U/L 3512
RBS mmol/I ALT/SGPT U/L sit?
GGT U/L
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r1 Name................................. 2ra Name.,......... ................................. . Day 10 Sheet
Date I 1
Day 10 neurology summary
Deafness L / R......................... Date i l
Gaze palsy/squint..................... Date / /
Paralysis.........................................Date / /
Mental disorders....................... Date / !
Other______________________________
Desfl.'rio 
Sc|iiin-.1Q 
ParalylO 
Menial 10 
ol'isrtO
Functioning ability Day 10
4=Fully independent with no disability....................
3=Disabled but independent, able to work..............
2=Disabled: dependent on others for daily support. 
1=lVlinimaIly responsive............................................
fjnc'n 1D
Day 10 examination
Is the patient ftilly orientated in: Time......................     Y / N nmeio
Place...........................................................  Y / N piacsio
Person.............................................................. Y I N pereonio
PERLA OYes ONo — details pedalO
Vision RIGHT
Onormal
Ocounting fingers 
Ohand movement 
Onot able to see light 
Ounable to assess
Vision LEFT 
O normal 
O counting fingers
Fundus RIGHT
Onormal
Opapilloedema
O hand movement Ounable to assess 
O not able to see lightOother________
O unable to assess
Fundus LEFT 
Onormal 
Opapiiloedema 
Ounable to assess 
Oother________
Optic nerve sheath diameter 3 RIGHT / LEFT mm
visrIO 
vislIQ 
funa'ji D 
lunaVIO
optnveS
Eye movements
Any abnormality.........................................................................
If abnormal, indicate which: RIGHT lit / IV / VI
LEFT ill / IV / VI
Other cranial nerves - any abnormality of:
ON V -corneal .....................................................................
If abnormal, indicate: RIGHT / LEFT
CN VI! .................................................................................
If abnormal, indicate: RIGHT / LEFT
Gag reflex..................................................................................
CN XII .................................................................................
If abnormal, indicate: RIGHT / LEFT 
Any other abnormality....................................... .......................
□
□
□
□
□
eye,-Tic.'10
CNV1G
CNVI10
gag 10 
CnxiilO
OEiiCNIO
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1*Name................................. 2n<,Nanie................................................ Day 10 Sheet
Date / /
Hearing assessment RIGHT________ db LEFT________ db
[Circle minimum sound heard]
RIGHT Finger rub / Whisper / Speech / Shout / Totally deaf / unable to assess 
LEFT Finger rub / Whisper / Speech / Shout / Totally deaf / unable to assess
Amis
RIGHT LEFT
Tone i / Normal / T i 1 Normal / T
Power 0/1/2/3/4/5/ 
unable to assess
0/1/2/3/4/5/
unable to assess
Reflexes i / Normal / T 1 / Normal / T
Legs
RIGHT LEFT
Tone i / Norma! / T i I Normal 1
Power OM/2/3/4/5/ 
unable to assess
OM/2/3/4/5/ 
unable to assess
Reflexes i / Normal / T 1 / Normal /
Plantars 1 / T / equivocal i / T / equivocal
Summary of neurological findings: Normal / Abnormal reurolC
Ensure Oyisome is 
completed on Page 2
ORemains for further treatment (PTO for further details)
Does this patient need post-test counselling, cotrimoxazole prophylaxis and ARVs?
207
PHASE TWO 
ISRCTN70121840
TRIAL NO:
QECH Glycerol Trial ISSCTN70121840 Please 2 Version 6
-16-
I^Name..................................... 2"° Name......................................... Day 1-10 inpatient sheet
Day 1 (Day recruited to GLAM)
Date / /
Ward round notes
O CXR if signs of aspiration CXR findings 
Day 2
Date / /
Ward round notes
O CXR if signs of aspiration CXR findings,
GGS....................................
Confusion .......................
Fits m the past 24 hours
Diarrhoea........................
Nausea ..........................
Vomiting.............................
Dizziness.......................
Anuna ...............................
Jaundice...........................
Chest dear......................
GCS...................................
Confusion ......................
Fits m the past 24 hours
Diarrhoea . . .................
Nausea ..........................
Vomiting.............................
Dizziness . ......................
Anuna ...............................
Jaundice..........................
Chest dear........ .............
Day 3
Date / /
Ward round notes
O CXR if signs of aspiration CXR findings
GCS...................................
Confusion ......................
Fits m the past 24 hours..
Darrhoea ......................
Nausea..............................
Vomiting............................
Dizziness...........................
Anuna ...............................
Jaundice...........................
Chest clear ..................
Total number of glycerol doses given:
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1" Name.................................. 2M Name................. .................... Day 1-10 inpatient sheet
Day 4
Date / /
Ward round notes GCS.....................................
Confusion ....................
Fits in the past 24 hours
Diarrhoea......................
Nausea ...........................
Vomiting ........................ ’
Dizziness.........................
Anuna .............  ......... .
Jaundice........................
Chest dear...................
O CXR if signs of aspiration CXR findings__________________________________ L
Day 5
Date / /
Ward round notes GCS................................
Confusion ... .
Fits m the past 24 hours
Diarrhoea....................
Nausea ....................
Vomiting .....................
Dizziness .............. .
Anuria.......................... .
Jaundice............ ..........
Chest dear...................
O CXR if signs of asp ration CXR findings_________________________________
Day 6
Date: / /
Ward round notes
O CXR if signs of aspraCon. CXR findings
GCS................................
Confusion .....................
Fits in the past 24 hours
Diarrhoea......................
Nausea ....................
Vomiting .................
Dizziness ......................
Anuria
Jaundice.........................
Chest dear....................
Total number of glycerol doses given:
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I” Name......................... ..... 2na Name..........................
Day..............
Date: / /
Ward round notes: GCS................................
Confusion ....................
Fits in the past 24 hours..
Diarrhoea.....................
Nausea...........................
Vomiting .......................
Dizziness........................
Anuria
Jaundice ... 
Chest clear
O CXR if signs of aspiration. CXR findings________________________________
Day................
Date / /
Ward round notes: GCS.................................
Confusion.....................
Fits in the past 24 hours.
Darrhoea.....................
Nausea..........................
Vomiting.......................... I
Dizziness........................
Anuria.............................
Jaundice.........................
Chest clear....................
O CXR if signs of aspiration. CXR findings_________________________________
Day.......................
Date: / /
Ward round notes: GCS.................................
Confusion.....................
Fits in the past 24 hours..
Diarrhoea.....................
Nausea ..........................
Vomiting.........................
Dizziness........................
Anuria..............................
Jaundice.........................
Chest dear....................
O CXR if signs of aspiration. CXR findings_________________________________
Total number of glycerol doses given:__
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1*'Name........................... ....... 2l>a Name..............................
Day...........
Date / /
Ward round notes: GCS...................................
Confusion.......................
Fits in the past 24 hours..
Diarrhoea.......................
Nausea.................  .........
Vomiting.
Dizziness
Anuria.......
Jaundice ... 
Chest clear
O CXR if signs of aspiration. CXR findings__________________________________
Day......................
Date / /
Ward round notes: GCS..................................
Confusion.......................
Fits in the past 24 hours.
Diarrhoea.......................
Nausea............................
Vomiting...........................
Dizziness..........................
Anuria................................
Jaundice...........................
Chest clear.....................
O CXR if signs of aspiration. CXR findings___________________________________
Total number of glycerol doses given:
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1,'Name
Post cloy 10 injjatlent Sheet
2nd Name.,...,.................................... .
(Please use blank sheets to continue if needed. Date each entry)
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I^Name................................... 2^ Name.................................................... Day 40 Sheet
Date of follow up: / / 3at*4S
Number of days after recruitment:____ aay
Follow up visit at:
O Hospital (planned clinic FU) pianneo
O Hospital (remains an inpatient) phosp
O Home following tracing traced
O Not followed up: O 1. Patient died. Date of death: / / rx*,
O 2. Lost to follow up
O 3. Withdrew consent
O 4. Other___________________________
Day 40 neurology summary
DeafnessL/R........................... Date / /
Gaze palsy/squint....................... Date / /
Paralysis.......................................... Date / /
Mental disorders........................ Date I /
Other________________________________
Functioning ability Day 40
4=Fully independent with no disability.......
3=Disabled but independent, able to work 
2=Disabled: dependent on others for daily support 
l=Minimally responsive..............................................
Day 40 examination
Is the patient fully onentated in: Time.................................................................. Y / N
Race................................................................ Y / N ptacMo
Person.................................................................Y / N persoMD
PERLA OYes ONo - details___________ oeruac
Vision RIGHT Vision LEFT Fundus RIGHT Fundus LEFT »*r40
Onormal O normal Onormal Onormal w*kc
Ocounting fingers O counting fingers Opapilloedema Opapil(oedema
Ohand movement O hand movement Ounable to assess Ounable to assess fc»no40
Onot able to see light O not able to see lightCother________ Oother________
Ounable to assess O unable to assess
Optic nerve sheath diameter 4 RIGHT / LEFT____  mm opt-ve*
KrcT>40
Deafl.'r40
Squim40
Paraly4C
MentaMC
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1B!Name.............................. . 2r,:iName.............. ................................. Day40 Sheet
Date / /
Eye movements
Any abnormality................................................................................................................. j | fcye.'iicv'tO
If abnomial, indicate which: RIGHT 111 / IV / VI
LEFT III / IV / Vi
Other cranial nerves - any abnormality of:
CN V -corneal ...............................................
If abnormal, indicate: RIGHT / LEFT
CN VII .................... .......................................
If abnormal, indicate: RIGHT / LEFT
Gag reflex.............................................................
CN XII ............................................................
If abnormal, indicate: RIGHT I LEFT 
Any other abnormality___________________ ..
□
□
CNV40
CNVI4D
gag40
Cn>:ii40
OtnaCMO
Hearing assessment RIGHT________ db LEFT________ db
[Circle minimum sound heard]
RIGHT Finger rub / Whisper ! Speech / Shout / Totally deaf / unable to assess 
LEFT Finger rub / Whisper / Speech / Shout ! Totally deaf / unable to assess
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1*Name................................ ?na Name............................................... Day 40 Sheet
Date / /
Arms
RIGHT LEFT
Tone ! / Normal / T i 1 Normal / T
Power 0/1/2/3/4/S/ 
unable to assess
0/W2/3/4/5/ 
unaWe to assess
Reflexes i / Norma! / T i / Normal / T
Legs
RIGHT LEFT
Tone i / Normal / t i / Normal / T
Power 0/1/2/3/4/5/ 
unable to assess
OM/2/3/4/5/ 
unable to assess
Reflexes i 1 Normal / t i / Normal / T
Planters i / T / equivocal 1 / * / equivocal
Summary of neurological findings Normal / Abnormal n*uro«c
Is this patient on cotrimoxazole prophylaxis and booked for/started ARVs?
Transport fee: Paid: MK
Received by _ 
Witnessed by
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Appendix 4. Patient information sheet Chichewa
PATIENT INFORMATION SHEET
THIS SHEET CAN BE GIVEN TO THE 
PATIENT/GUARDIAN TO READ AND 
KEEP
GLYCEROL ADJUVANT THERAPY IN 
ADULT MENINGITIS IN MALAWI
Kuchokera mukuyeza kwathu ndiponso kutengedwa madzi a pa msaiia zikusonyeza 
kuti Inu / m’bale wanu akudwala matenda oumitsa khosi. Tikufuna kuti tione ngati 
mankhwala atsopano wotchedwa Glycerol atha kuchepetsa imfa ndiponso zilema 
zina za pathupi zobwera ndi nthendayi. Kuti izi zitlieke tikupempha kuti inu / mbale 
wanu alowe mukafukufukuyu pogwiritsa nthito “glycerol” ndi madzi a sugar'. 
Makhwalawa adzakhala okumwa, koma ngati inuyo kapena mbale wanuyo 
akulephera kumwa ndiye kuti tidzayika ka tube kakang’ono ka plastic kudzela 
mphimo mpaka kufikira m’mimba, kuti mankhwalawa aperekedwe.
Panopa palibe umboni woti Glycerol ndi wa phindu kwa odwala matendawa kapena 
kuti gulu la wodwala ena angathandizike kuposera enawo.
Odwala onse adzalandira mankhwala (antibiotics) a nthendayi monga mwa nthawi 
zonse muno m’ Malawi.
Pofuna kudziwa mulingo wa Glycerol mu madzi a pa msana ndiponso kuwona ngati 
mankhwalawa angathe kuchepetsa ululu (pressure) mu mutu, tidzakupemphani kuti 
tidzatenge madzi a pa msana a chiwiri patapita masiku awiri (maola makliumi anayi 
ndi mphambu zisanu ndi zitatu) mukulandira mankhwala.
Tidzakliala tikuyesa zoyesa zina ndi zina pofnfuza matendawa, mu madzi a pa nsana 
ndi magazi, zokhuzana ndi nPmene mukupezera, choyambisa matenda, komanso 
mankhwala ake. Zitha kukhala kwenikweni zofima kudziwa mtundu wa tizilombo 
tomwe tayambitsa, komanso kuti thupi likuchita bwanji polimbana ndi tizilomboto 
ndiponso mulingo wa mankhwala (antibiotic) mu madzi a munsana. Tidzafimanso 
tiyeze inu / m’bale wanu ngati ali ndi kachilombo koyambitsa matenda a Edzi, ndi 
cholinga chakuti ife madokotala tikuthandizeni ndi chithandizo choyenera. Odwala
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a mukafakufukuyu, omwe apezeka kuti ali ndi kachilombo koyambitsa Edzi 
adzakhala ndi mwayi oyamba kulandira mankhwala aja a ARV akayamba kupeza 
bwino.
Wodwala onse ali ndi ufulu wofuna kulowa miikafukufuku kapena kukana popanda 
kusokoneza chisamaliro chawo pachipatala. Ngati wodwala sangathe kuvomereza 
yekha m’bale wake kapena womuyang’anira angathe kutero m’malo mwake.
Inu / m’bale wanu, ndipo wodwala wina aliyense ndi womasuka kusiya kupanga 
nawo kafukufuku ntliawi yina yili yonse, ndipo izi sizikhuzana ndi ufulu wanu 
wolandila thandizo molingana ndi ndondomeko zovomelezeka za za chipatala.
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Appendix 5. Patient Information sheet English
PATIENT INFORMATION SHEET
Glycerol adjuvant therapy in adult bacterial meningitis in Malawi.
The results from the examination and /or the brain fluid test (lumbar puncture) 
suggest that you / your relative have been diagnosed with bacterial meningitis.
We wish to see if a new treatment called glycerol reduces the mortality and 
disability. In order to do this we are asking if you / your relative would like to 
participate in a trial comparing glycerol with an inactive agent (sugar water). Half of 
the patients enrolled will receive glycerol and half will receive sugar water. This 
will be swallowed, but if you / your relative is unable to swallow then we will place 
a small plastic tube (naso-gastric tube) via the nose and into the stomach so that the 
glycerol or sugar water can be given. We currently have no evidence that glycerol is 
of benefit in meningitis or if either group of patients will be at a disadvantage 
compared to the other.
In order to treat the meningitis effectively, we will be using antibiotic (ceftriaxone) 
which is effective medication used for meningitis treatment in Malawi.
In order to measure the glycerol level in the brain fluid and to see if the glycerol 
reduces the pressure around the brain, we would also like to ask you if we could 
perform a second lumbar puncture after 48 hours of treatment.
We will want to see you / your relative one month (40 days) after starting treatment 
to follow you / them up. We will assist with transport costs.
Samples of blood and of brain fluid will also be subject to a range of other tests 
relevant to you / your relative’s progress and to the cause, effect and treatment of 
meningitis in general. This may include looking more closely at the type of infection 
which has caused the meningitis, how the body has responded to the infection and 
what antibiotic levels are in the brain fluid. We will also test you / your relative’s 
blood for HIV because this will help us when treating you / your relative. Anyone in 
the trial who tests positive for HIV will be eligible for free HIV treatment (ARVs) 
when they are better.
All patients are free to choose whether they wish to take part in the trial without 
jeopardy to their care in hospital.
Where patients are unable to give their consent, guardians or relatives will be invited 
to act on their behalf. You / your relative, and any patients entering the trial are free
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to withdraw at any time without affecting your right to hospital treatment according 
to the standard clinical guidelines.
Sept 2006
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Appendix 6. Consent form Chichewa
Patienfs Name
KUVOMELEZA KULOWA MUKAFUKUFUKU
Ine___________________wodwala* / woyang’anira wodwala*_________________
ndawerenga ndipo ndamvetsetsa zonse zalembedwa pamwambazi choncho 
ndavomereza kulowa mu kafukufliku wa mankliwala wotchedwa Glycerol ndi 
mankliwala ena pochiza matenda owumitsa kliosi.
Ine, wodwala^/woyang’anira wodwala* ndavomereza mwauflilu wanga kutengedwa 
kacliiwiri madzl a pa msana ngati mbali ya kafiikuflikuyu. Ndondomeko ndiponso 
zovuta zina andilongosolera momveka bwino ndipo ndikudziwa kuti zotsatira za 
zoyesazi zidzakhala zoyenera mukaftikufuku yekhayu.
Ine odwala/kapena woyang’anira wodwala, ndikuvomereza kuti ndiyikidwe kapena 
ayikidwe ka chubu (Naso-gastric tube) ngati kudya ndi kumeza kuli kovuta.
Ine odwala/kapena woyang’anira wodwala ndikuvomera kuti magazi amene 
ndatengedwa akayezemo zina ndi zina monga mlingo wa glycerol ndiponso 
kachilombo koyambitsa matenda a EdzL
Ine ndikudzindikira kuti mugwirizanowu ungathe kuthetsedwa nthawi ina yili yonse 
popanda kuphwanya ufulu wanga wopitiliza kulandira mankliwala.
Tsiku:
Woyang’anira wodwala: ______
Dzina ___________________
(* futani moyenera)
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Appendix 7. Consent form English
Patient’s Name
GLAM Trial - Glycerol adjuvant therapy in adult bacterial meningitis in Malawi.
Consent to enter the clinical trial
I,__________________the patient* / legal guardian of* _________________ ,
have read and understood the above statement and agree to the enrolment in the 
clinical trial of glycerol with antibiotics in the treatment of bacterial meningitis.
I, the patient / legal guardian, consent fully and freely to a second lumbar puncture as 
part of the above clinical trial. The procedure and its possible side effects have been 
satisfactorily explained and I am aware that the information obtained from this test 
will be of relevance only to the clinical trial outlined above.
I, the patient / legal guardian, consent to placement of a naso-gastric tube if 
swallowing is not possible.
I, the patient / legal guardian, consent to blood samples being taken for various tests 
including measuring glycerol levels and HIV testing.
I understand that this consent may be withdrawn at any time without affecting my 
right to continuing treatment.
Date:
Verbal consent witnessed by legal guardian:_____________________
Name:_______________________
(*Delete as appropriate)
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Appendix 8. Serious adverse event proforma
Study Number
GLAM Serious Adverse Event (SAE) Report Form 
STUDY
(initials)completed by
presentation
SUSAR onset
SYMPTOMS AND SIGNS
Description of adverse (signs symptoms, time course and treatment if any)
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Relevant diagnostic tests/laboratory data
Check all appropriate:
_ Patient died date: | | | /| | | /| | |
_ Life threatening illness Fatal
_ Required hospitalisation (..........Days)
Resulted in prolongation of 
_ hospitalisation
Resulted into pennanent 
__ disability/incapability
_ Other SUSAR (specify. .)
ACTION TAKEN 
_ No action
_ Other treatment given (specify) Supportive care given, see above
_ Study drugs discontinued N/A
Other action (specify) CT brain scan was performed. Unfortunately results are
_ not available.
OUTCOME
_ Completely recovered (on II)
_ Condition improving
_ Condition unchanged
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_ Condition deteriorating
_ Death (attach autopsy findings if done) Autopsy not available in Malawi
CONCLUSION BY INVESTIGATOR
Diagnosis (if made).
Adverse event occurred Yes ____ No
Event defined as: (tick one)
Adverse Event (AE)
Adverse Reaction (AR)
Serious Adverse Event/Serious Adverse Reaction (SAE/SAR)
Unexpected Adverse Reaction (UAR)
Suspected Unexpected Serious Adverse Reaction/Event (SUSAR/SUSAE)
Intensit
y
Causalit
y
l - Mild, 2 = Moderate 3 = Severe 
1 = Not Related, 2 — Remote, 3 = Possible 4 = Probable
Reporting (tick if reported to the following bodies)
DMC F
Ethics
committee MW _
Ethics
committee LP _
Information Source
Signature, Date / /
227
Appendix 9. Nurse/Clinical Officer contract
UNIVERSITY OF MALAWI 
COLLEGE OF MEDICINE
Principal
Prof. R.L. Broadhead, MBBS, FRCP, FRCPCH, DCH
Our Ref.: 
Your Ref.:
College of Medicin 
Private Bag 36 
Chichii 
Blantvre 
MALAW 
Telephone: 67724 
67729 
Fax: 67470 
Telex: 4374
MEDICINE DEPARTMENT
The GLAM Trial (glycerol in adult meningitis)
Official title: “Randomised controlled trial of glycerol adjuvant therapy in adult 
bacterial meningitis in Malawi”.
Job description and terms and conditions of: Clinical Research Nurse
Job description
1) To provide daily nursing care to all patients enrolled into the GLAM study and to 
any other patient assigned to the care of trial nurses by medical consultants, lecturers 
or trial clinical officer.
2) To ensure strict adherence to the trial protocol for administration of medications, 
completion of data collection and collection of laboratory results.
3) To carry out duties at the request of the investigators, trial clinical officers, medical 
consultants and lecturers.
4) To keep other members of the trial staff informed of progress of each patient at all 
times with organised and agreed meeting times including with any shift change.
5) To attend trial meetings on a monthly basis or as requested by the investigators 
regardless of off-duty or leave arrangements. Special dispensation may be granted 
by prior arrangement with the investigators.
6) To initially provide nursing care during the day and at weekends according to a pre­
defined timetable, taking into account annual leave and public holidays.
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Once the full team of nursing staff (6 nurses) are employed, this will comprise 
nursing cover at night using a rolling rota.
Appointment
Employees are hired with the understanding of the special nature of the GLAM study with 
the commitment to uphold the highest standards in thoroughly performing their tasks, as 
assigned by the Principal Investigator, and in protesting confidential information.
All project employees will, on the first appointment, be engaged on probation. The 
probationary period will be for 2 months. During this period, in the event of unsatisfactoiy 
performance, the probationary appointment may be extended or terminated at the discretion 
of the Principal Investigator. After the probationary period, a notice period of one month 
will be served if a staff member wishes to resign.
All staff must be registered with the relevant professional body e.g. Malawi Council of 
Nurses, before practicing at QECH.
Salary and wages
The commencing salary shall be based on the level and seniority of the position and the 
profession, as well as the qualifications necessary to carry out the functions of the project. 
The basic salary includes leave and overtime grants, which will therefore not be separately 
paid.
Tax liability will be calculated according to standard levies by the College of Medicine 
finance office.
All issues related to salaries will be dealt with by the College of Medicine unless trial staff 
are otherwise advised — this includes any application for an advance payment from a salary.
Hours
The workday is from 7.30AM to 5.00PM, Monday through Friday and at weekends (with 2 
days off per week), with 40 minutes lunch break and two 20-minute tea breaks. Breaks can 
be rearranged at the discretion of the Principal Investigator, if necessary, based on the 
workload.
[Once the full team of musing staff (6 nurses) are employed, this will comprise 
nursing cover at night using a rolling rota. This will include a stretch of seven nights 
on duty.]
Pay Day
The GLAM Study pay day shall be the 25th of each month (as per COM current practice) 
unless the 25lh falls on a Saturday, Sunday or Malawi Public Holiday, in which case pay day 
shall be the last working day preceding the 25th.
Death of an Employee
In the event of the death of a project employee, the deceased employee’s next-of-kin will 
receive the following on behalf of the deceased:
One month’s salary in addition to the remaining month’s salary.
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If possible, GLAM Study will provide transport for employees to attend the funeral.
Name of next of kin: __________________________ ____
Workman’s Compensation
In the event of an employee being injured while on duty in laboratories, clinic, office or
authorized field activities, the GLAM Study shall comply with and be guided by the Laws of
Malawi and act in accordance with the provisions of the law regarding compensation.
Termination of contract
A. A permanent employee wishing to resign his appointment shall give one months notice in 
wilting to the project of his intention to resign or pay the GLAM Study three months 
salary in lieu of notice. Likewise, the GLAM study may discharge a permanent 
employee giving him one month’s notice or paying him three months salary in lieu of 
notice. Any part of holiday period may be included in the period of due notice.
B. Serious misconduct will result in immediate dismissal of the employee. An employee is 
guilty of serious misconduct if he/she:
a. Is under the influence of intoxicating liquor or habit forming drugs during normal 
working hours of attendance or during such other hours as he may be required to 
be on duty
b. Commits any of the following acts of misconduct:
i. Breach of communication of privileged information.
ii. Extortion, bribeiy and corruption.
iii. Theft, theft by false pretences and receiving stolen property knowing it to 
have been stolen.
iv. Fraud, forgery, uttering a forged instrument knowing it to have been 
forged.
C. Two warning letters that will contain all relevant information will precede dismissal for 
less serious neglect of duties or “less serious misconduct”. Warning letters will be 
presented by the Principal Investigator and discussed with the employee. The employee 
has the right to respond to warning letters and any letters will be placed in the personal 
file.
A project employee is guilty of less serious misconduct if he/she:
a) Absents himself from his post during normal working hours of attendance, without 
permission from his immediate boss or without valid excuse
b) Performs his duties negligently.
c) Fails to perform any duties assigned to him/her or to obey any instructions given to 
him by persons having authority to give such instructions and
d) Displays insubordination by word or by conduct.
Leave
Annual Paid Leave
All GLAM Study employees are eligible for annual paid leave and leave must be taken at a 
time approved by the Principal Investigator, based on the project activities. To be considered 
for approval, leave must be requested at least one month prior to the start of the requested
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leave time. Annual leave will be calculated as 2 days earned per month. Annual leave will 
only be given after it is earned.
Staff members must ensure that a trial colleague covers any allocated shifts in their absence. 
Sick leave
In the event of sickness, all reasonable effort should be made to arrange cover for the shifts 
affected. Where, due to unforeseen circumstances there is a significant staff shortage, staff 
members may be expected to work additional shifts until such time as the crisis can be 
resolved.
Compassionate Leave
In the case of emergencies or urgent private affairs, an employee can apply for 
compassionate leave.
The granting of paid compassionate leave of up to 10 working days per year is at the 
discretion of the Principal Investigator and each case will be considered on its own merit. 
When such leave is granted, the reason will be recorded and kept on file. When requests are 
received after the 10 days have been exhausted or when no prior permission has been 
obtained, days of compassionate leave will be deducted from the employee’s annual leave.
Disability/Extended illness
Employees are eligible for 30 days paid leave for disability or extended illness, provided the 
leave is medically certified and approved by the Principal Investigator. Employees taking 
such leave for 30-60 days will receive half-pay and employees taking such leave for more 
than 60 days will receive no pay.
Maternity
A female employee of the project shall be granted paid maternity leave up to 90 consecutive 
days for the purpose of confinement before or after delivery as the case may be, after she has 
worked for a minimum of 6 months for the project,. However, no maternity leave shall be 
granted unless three years have elapsed from the date of birth of the last surviving child.
Project vehicles
Employees are not provided with project vehicles for transport and from their houses or for 
personal use.
Grievances
All grievances should be addressed to the Principal Investigator.
Amendments
The GLAM Trial shall, from time to time, delete, substitute or add to these terms and 
conditions of seivice and shall notify the staff.
The Principal Investigator of the GLAM Trial is:
Dr Katherine Ajdukiewicz or Dr Katharine Cartwright (on behalf of KA)
Department of Medicine
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The GLAM Trial (glycerol in adult meningitis)
Official title: “Randomised controlled trial of glycerol adjuvant therapy in adult bacterial 
meningitis in Malawi”.
A research study of the Department of Medicine of the College of Medicine
College of Medicine 
Private Bag 360 
BLANTYRE 3
EMPLOYMENT AGREEMENT
Agreement made on this day...............................................................................
Between the GLAM Study of the Department of Medicine of the College of 
Medicine and:
(Hereinafter) called the “employee” whereby it is agreed as follows:
1. The employee is appointed to the position of Clinical Research Nurse. 
The total salary before deductions is MK 57,200 per month.
2. The salary includes housing allowance.
3. Duty allowance of K500 per night worked will be paid each month.
4. No pension will be paid at the end of the contract.
5. A performance-related bonus may be paid on completion of the project.
6. The AGREEMENT is for the duration of twelve months or until the 
project is completed.
7. The AGREEMENT is subject to the offer of appointment and the 
Conditions of Service of the GLAM Trial, which are constructed as and 
understood to be part of the AGREEMENT.
8. By signing this contract, the employee is confirming that he/she has 
resigned from the Ministry of Health and as such, is no longer receiving a 
Ministry of Health salary.
This contract replaces all previously signed contracts.
Date:_____________
As witness our hands the day and year above written
(On behalf of the project)
(Employee)
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(Witness)
Date probation period ends:____________________ Signed:
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Appendix 10. Trial Steering Group
Trial Steering Group Members:
Dr N French (Chairman), Director Karonga Prevention Study, Chilumba and College 
of Medicine, Blantyre, Malawi
Professor M Molyneux, Director Malawi-Liverpool-Wellcome Trust Programme.
Dr M Scarborough, Nuffield Department of Medicine, John Radcliffe Hospital, 
Oxford
Dr D Lalloo, Liverpool School of Tropical Medicine, Liverpool 
Observers:
Dr K Ajdukiewicz, Principal Investigator and Lecturer in Medicine, Blantyre, 
Malawi
Dr J Kumwenda, DSMB chairman
The TSG provided overall supervision of the study, and in particular-, provided 
independent advice through the chairman of the group to the Investigator, the MRF 
and the Host institutions. The group incorporated individuals with relevant 
complementary experience and skills to advise on the running of a randomised 
controlled trial of glycerol adjunctive therapy in adult bacterial meningitis in Africa.
Terms of reference:
1. To review and approve the study protocol, recruitment and follow-up procedures 
prior to the commencement of the study. This ensured participants were managed
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in the study in a way consistent with the advice of the independent ethical review 
boards and prevailing international standards.
2. To monitor the progress of the study which ensured recruitment targets were 
achieved and efforts to maxunise recruitment undertaken.
3. To identify and invite a Data and Safety Monitoring Board (DSMB) to convene.
4. To consider and act upon advice provided by the DSMB. The DSMB was invited 
to carry out an interim analysis after 100 deaths. Stopping rules for use in the 
case of serious adverse events were agreed and established before the study 
began. The TSG had responsibility for stopping the study in discussion with the 
Investigator and on the recommendation of the DSMB.
5. To provide advice and guidance to the investigator if significant changes in 
knowledge or clinical practice took place during the course of the study which 
will alter the trial equipoise, performance of the clinical trial or modify the 
likelihood of achieving a result.
6. To provide an annual, structured report to the MRF -this took the form endorsing 
a report submitted by the principal investigator.
7. To ensure as far as possible, the investigator was conducting the trial in an honest, 
ethical and credible way and did not inappropriately manipulate or falsify the data 
or results
8. To advise the MRF on the need for a study extension in the event of a meaningful 
result being unlikely at the end of the currently planned study timescale.
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Appendix 11. Data Safety Monitoring Board
Data and Safety Monitoring Board:
Professor E Molyneux, College of Medicine, Blantyre, Malawi
Professor R Auty, Consultant in Pharmaceutical Medicine, Salient Consulting Ltd,
UK.
Dr J Kumwenda, College of Medicine, Blantyre, Malawi,
Role of the DSMB:
1. To review safety data and unblinded data during the study and report any safety 
or ethical issues, which may lead to premature cessation of the trial.
2. To report to the TSG the results of unblinded analyses relevant to safety and 
ethics.
3. To undertake an unblinded interim analysis after 100 deaths and report to the 
TSG.
4. To review the integrity of data collection and handling by study team members.
5. To inspect labelling of glycerol and placebo and randomisation procedures to 
ensure it is done in a manner that maintains blinding and is safe and ethically 
sound.
6. To perform appropriate analyses in the event of sub-optimal recruitment or end 
point ascertainment and assess the consequences for achieving a valid and
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meaningful result.
7. If, in the view of the TSG, an extension to the study would produce a definitive 
result, to recommend to the MRF for the study to continue.
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Appendix 12. Ethics approval: COMREC
GLAM Trial
Department of Medicine 
College of Medicine 
P/Bag 360. Chichiri 
Blantyre BT3 
Malawi
ISRCTN70121840
fr-.ai Stffennt) G'Oi.p
Or Noil French (Chairman)
Direcwr Karonga Prevention SluSy Cnilumoa and College orMedic.ne Malawi
Professor Malcolm Molyncux
Director Malawi-Lvorpooi-Wollcome Trust Programme
Or Matt Scartaorough
NuffioW Dooartmont of Medicine John Radcl *fe Mosoital Oxford
Data and Safety Mon ;;r r; 5;» ■
Or Johnstone Kumwenda, 
College of Meaione Blantyre 
Professor Eliiaboth Molyneux 
College of Meaione Blantyre 
Professor Richard Auty 
Pharmacologist UK
Or David Lalloc
Liverpool School Jl Trooical Medicine Liverpool 
rsoposcasis.
Or Katherine AjOuklowicz Pnnc pa Investigator Blantyre. Malawi 
Or Johnstone Kumwenda .DSMB Chairman)
fnal statisticnn Professor Christopher Whitty London School of Trooical Medicine London
Prof E Borgstem
Chairman
COMREC
3'3 January 2007
Dear Professor Borgstem
RE: P.04/05/363 - Randomised trial of glycerol adjuvant therapy in adult bacterial meningitis in 
Malawi by Dr K Ajdukiewicz
Thank you for your letter dated 20''' December 2006 regarding storage of samples for bacterial PCR 
Quantitative PCR to measure bacterial load within blood or CSF is only earned out at dedicated 
specialist centres within the UK These are specific Health Protection Agency (Public Health) 
laboratories which produce quality controlled results
It would be extremely difficult to carry out the tests here due to the lack of local expertise and 
equipment The results may not be accepted as appropriately verified I understand that one of the 
paediatric studies within QECH also transoorted samples back to the UK for similar tests due to the
• same reasons This paediatnc study has shown that there is a correlation between bacterial load and outcome oarticularly in the context of HIV1
I hope that COMREC agree that the only way we will be able to adequately measure bacterial load ana 
thus determine if this is the cause of high mortality in our adult patients is to transport samples to a 
specialist laboratory in the UK for testing
Yours sincerely
Dr K Ajdukiewicz 
Principal Investigator
Carrol ED et al High pneumococcal DNA loads are associated with mortality in Malawian children 
with invasive pneumococcal disease Pediatr Infect Dis J 2007. in press
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UNIVERSITY OF MALAWI
Principal
Prof. R.L, Broadhoaci, MBBS. FRCP, FRCPCH, OCN
OiirRcl., C0HRECI16 
YourRof.: P.04/0S/363
Collage of Medicine 
Private Bag 360 
Cfilchlrl 
Blantyro 3 
Malawi 
Telephone: S77 245 
677 291 
Faa: 674 700 
TolO*: 43744
10;h January, 2007
Dr Katherin Ajdukiewicz 
Medicine Department 
P/Bag 360 
Blantyre 3
Dear Dr K. Ajdukiewicz,
RE: P.04/05/363- Randomised trial of qlvceroi adjuvant therapy In adult bacterial meningitis
in Malawi
Thank you for your tetter of response dated 3ra January, 2007. Thank you for your explanation and 
the justification. You may go ahead with your plans as requested.
Yours sincerely.
Prof E. Borgstein 
CHIARMAN - COMREC
EB/tck
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UNIVERSITY OF MALAWI
Principal
Prof.
R.l. Brcafihcad. MBBS. F^CP. FRCPCH. OCH
College of Modicino 
Private Bag 360 
Chichirl 
Blantyre 3
Our Ref.: MC/COMRECM6
nn jiarei ^ . ___
Telephone: 01 671 911/01 674 3. 
Fax: 01 674 700/01 674 740 
Telex: 43744
S'" February 2007
Dr Katbienre Ajdu*iewic: 
Paediatrics DeoartTrent 
P/Bag 360 
Chichin
Blantvre 3
Dear Dr A|Cuk;ewicz.
d m,n4nF3 - Rando^i^d trial of nWcernl admvant therapy in adult bacterial meninqitis_in
Malawi (GLAM)
Tl»s renewal is sutiect to coninued adherence Id the Collese ol Medkiine requrrements for all
COMREC aporoved research studies 
Yours sincerely.
Prof E. Borgstein
CHAIRMAN-COMREC
Appendix 13. Ethics approval: LSTM
LIVERPOOL 
SCHOOL OF 
TROPICAL
MEDICINE W tn# OnMwvty o* UW'POcO
2'’ F<teuary 2006
Di Katherine MB A)duk»e-»x/ 
& Dr I) Lalioo
•‘wntycwr A*.
i/vefooo U SO* 
Tftrphor* 0»51 
tm CIS! W33/0
»<RB ' WrtV. W « i.lAln
Drat Di Ajdukte^ic/
I he research protocol Randonusnl cenlruUed trial of (hcrrol ail)uvanl lhrra|>\ in adult bartrrlal mrnin|>itU In 
Malani rr-tubrnmed on 4 January 2006 Reterence No 05.64A was ciNMuJered hy die Resratch Fthics C omnullrr 
on 12 January 2006
Thank you lor your tetters sent vu e-mail on 6 February 2006 and 16 February 2006 with the information 
requested by the committee The protocol now has formal ethical approval from the 1 STM Research F.thics 
Comminee
Conditions of Approsal
• The approsal is for a fixed period of three yean or for the duration of die pant, renewable annually 
thereafter
• The committee may suspend or wtthdiaw ethical approval wheir it is felt appropiiatc
• in accordance with Invnudotul Committee- on Harnuimsalnin of Good C'llmcal Ptact >ce (ICH CRT I 
Guidelines, ammal update must be provided to (he conmuttee Faihue to do so amid resull in suvt>cnsi«i of 
the study wsthoul further notice
• A copy of the final report should he sent n> ihe committee
• Any serums adverse events must be reported to the commuter
Any proposed amendments to die protocols must he notified to the IN IM Research l.ihics l omimttrc lot approsal 
before implementation (Full application is not necessary at this stajtei
The Research Support Office (RSO) maintains a Database Of 1 .oca) Research romnunees in the countries whrtv 
collabnrative wnrli is bcmjt earned out. Could ytiu, Iherefote, feed hack to me |su Slutda Mnlry in the RSO) as 
much information as possible on the local C'omnattrcsiRevicw Hodies dut will review (uc tiave reviewed) this 
protocol The following details would he much appreciated
• Name
• Address
• Contact numbers or individuals (tel / fax / e-mad)
• A copy of the appropriate fotm or sonic details on the submission mechanism (me ludmg charges)
• Any details you are able to obtain on
a) number on the committer
b) hnw many lay teprcsentatives sit on the committee ’
Yours sincerely
Dr T O’Deinpsey
Acting-Chair, Research Fthicsf ommitlee
■MSI *****
ICMW
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Glycerol adjuvant therapy in adults with bacterial @
meningitis in a high HIV seroprevalence setting in Malawi: 
a double-blind, randomised controlled trial
Kathrrinr M BAjdiAwwiit Katharirvrf Cartwright. Matth#w Scarborough, Jam«BMwambrnr. Patricl Goodion, MakolmE Mo/yncu*.
EduardBZifitra, NoilFrench Christopher; M Whitty. DavidGtnFoo
Summary
Background Soutliem Africa has a high incidence of bacterial meningitis in adults, often associated with HIV co­
infection. Mortality exceeds 50%, even with appropriate antibiotic tlierapv. and is not iniproved with corticosteroids 
Glycerol adjuvant tlierapv reduces long-term morbiditv in bacterial meningitis in children, and its nse is being 
promoted. We aimed to assess the effectiveness of ghcerol as an adjuvant tlierapv for adults with bacterial meningitis 
in Africa.
Methods The sntdy was done in two phases. First, in an open-label dose-finding study, 45 adult patients w ith 
symptoms, signs, and cerebrospinal fluid findings consistent w ith bacterial meningitis received either 50 mL. 75 rnL, 
or 100 ml of glvceml four times a day for 4 davs. We titen did a randomised, dotilile-blind, placebo-controlled trial of 
oral ghcerol in adults with bacterial meningitis. Patients with clinical and cerebrospinal fluid hnditigs suggestive of 
bacterial meningitis were randomly assigned in blocks of 12 by use of a random number list produced bv an 
independent statistician to receive either ghcerol or an equivalent volume of sugar solution Ghcerol and placebo 
were indistinguishable by colour or taste. Tile primarv outcome was mortality at 40 days, with secondary outcomes 
including disability and mortality restricted to pneumococcal disease. All patients were analysed for the primary 
outcome excluding those who were lost to follow-up. This trial is registered at controlled-trials.rom. number 
ISRCTN70121840.
Findings 75 mL ghcerol four times a dav was the higliest tolerated dose, and w as used for the main study. 265 patients 
were assigned treatment: 137 ghcerol and 128 placebo. Tile trial was stopped earfv on die adv ice of tlie data and safety 
monitoring board after a planned interim analysis. Bv day 40, 61 (49%) of 125 patients in the placebo group and 
86 (63%) of 136 in the ghcerol group had died (adjusted odds ratio 2-4. 95% Cl l-3-4'2, p=0 003). There was no 
benefit from ghcerol for death and disability bv dav 40, and ghcerol did not improve death and disability bv dav 40 or 
death at day 40 in patients w ith prov en bacterial disease or pneumococ cal disease. Two serious adverse ev ents occtirted 
dial w ere possibh due to the study drug.
Interpretation Oral ghcerol tlierapv cannot be recommended as an adjuvant therapy in aduhs w ith bacterial meningitis 
in resource-poor settings with a high HIV prevalence.
Funding Meningitis Research Foundation
Introduction
Meningitis is a common cause of adult in-patient death 
in Malawi. The incidence of bacterial meningitis has 
risen substantially in Malawi, as it has in other southern 
African countries, since the start of the HIV epidemic.1 
Even with effective antibiotics in-patient case fatality 
exceeds 50%. and up to half of survivors are left with 
neurological sequelae and disability.11 Measures to reduce 
mortality are urgently needed.1
Corticosteroids, which can be an effective adjunctive 
treatment in settings with a low prevalence of HIV.* are 
not effective where most meningitis is HIV-related, 
including Malawi.11* Raised intracranial pressure impairs 
cerebral blood How, and might be a significant 
contributory factor to mortality and morbidity from all 
forms of meningitis: therefore, early reduction of 
intracranial pressure might improve outcome. Glycerol.
an orally administered hyperosmolar liquid widely used 
as a food additive, has been suggested as a promising 
adjuvant treatment. In children with bacterial meningitis, 
glycerol reduces neurological sequelae but not case 
fatality when given either alone or in combination with 
dexamethasone.'1 although there is some controversy 
surrounding the design of a Latin American study that 
found a benefit for glycerol.* Glycerol has previously been 
used in stroke, head injury, and glaucoma to reduce 
increased tissue pressure.*"11 A meta-analysis of 
intravenous glycerol in ischaemic stroke suggested that 
glycerol conferred a short-term advantage, but no benefit 
in terms of long-term survival.1*
No trials of glycerol adjuvant therapy- in bacterial 
meningitis have been reported in adults. If the paediatric 
findings were replicated in adults, glycerol would 
represent a significant advance in the treatment of
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bacterial meningitis particularly in resource-poor 
settings with a high prevalence of HIV. such as southern 
Africa, where the burden of disease is high and adjuvant 
steroid therapy has no clinical advantage.
Glycerol has been used as a food additive and for 
cosmetic purposes for many years. Toxicity data for oral 
glycerol indicate that it is safe. Side-effects are infrequent, 
usually mild, and are mostly gastrointestinal in origin.** 
There are rare reports of neurological side-effects, such 
as headache, dizziness, confusion, and amnesia (in 
elderly patients).21” and one report of spontaneously 
reversible hemrparesis in a patient who ingested 500 mL 
of pure glycerol as a single dose." Glycerol is stable in hot 
climates, widely available, and inexpensive, and would 
therefore be ideal for use in resource-poor settings.
Queen Elizabeth Central Hospital (QECH) is a large 
hospital in Blantyre. Malawi, and serves a catchment 
population in excess of 1 million people. According to 
UNAIDS. HIV prevalence in adults in Malawi aged 
15-49 years in 2006 was 12%.” Admissions to QECH 
exceed 10000 per year, and 70% of admitted patients are 
infected with HIV.” Meningitis is one of the commonest 
causes of admission, with Streptococcus pneumoniae the 
most common form of bacterial meningitis.' Mortality 
from bacterial meningitis exceeds 50%. and adjunctive 
steroid therapy in adults does not reduce mortality, so it 
is not routinely used.1
We designed a randomised, double-blind, controlled 
trial to test whether glycerol is an effective and safe 
adjuvant treatment for adults with bacterial meningitis 
in a setting with high HIV seroprevalence and high 
mortality from meningitis.
Methods
Patients
The trial started on Sept 10. 2006. and recruitment was 
halted on Aug 23, 2008. There were no facilities for the 
invasive monitoring of patients at the time of the trial.
Adult patients admitted to the QECH with signs and 
symptoms of meningitis were screened by clinicians on 
the wards. All patients had a lumbar puncture and 
received intravenous ceftriaxone- Patients were then 
referred to the trial staff for assessment of eligibility. 
Trial inclusion criteria were clinical suspicion of 
meningitis (headache, neck pain or stiffness, reduced 
level of consciousness, photophobia, confusion, fits, 
rash, or fever) plus cerebrospinal fluid evidence of 
bacterial meningitis (>100 white cells per pL with 
predominant neutrophils or Gram-stain showing 
bacteria), or cloudy cerebrospinal fluid if microscopy 
was delayed (eg. at night). Exclusion criteria were age 
less than 16 years, cryptococcal meningitis (India ink 
stain or cryptococcal antigen positive on cerebrospinal 
fluid), less than 100 white cells per pL or lymphocytic 
meningitis, pregnancy, heart failure, and known type-2 
diabetes. A capillary whole blood glucose (BM glucose) 
greater than 12 mmol/L was added as a criterion for
exclusion for phase 2 of the study on the advice of the 
data and safety monitoring board.
Ethics approval was granted by the College of Medicine 
Research Committee, Malawi, and the Liverpool School 
of Tropical Medicine. UK. Written informed consent was 
obtained from all stud)' participants.
Randomisation and masking
A randomisation number list in blocks of 12 was produced 
by an independent statistician using Stata version 9.0. 
Numbers and allocation were placed into sealed 
envelopes. Envelopes were opened sequentially by an 
independent person not involved in the clinical care or 
assessment of trial participants, who labelled pre­
prepared containers of glycerol and placebo with a unique 
study number. Study drug packs were then placed in 
consecutive order within a secure room. If a patient 
fulfilled the study inclusion criteria, verbal and written 
informed consent was obtained from the patient or. if the 
patient was unconscious or confused, from the patient s 
legal guardian. Those unable to read gave witnessed 
consent. Allocation of the next available study number 
constituted entering the trial, and analysis was based on 
study allocation irrespective of subsequent treatment. All 
envelopes were accounted for. Allocation was masked 
from clinicians and patients. Treatment with glycerol or 
placebo was given by trial staff. After the addition of 
Orange SOBO (a locally produced orange squash) into 
glycerol and placebo, both liquids were a pale orange 
colour and were more palatable and indistinguishable in 
appearance and taste, as assessed by medical and clerical 
staff within the Department of Medicine. QECH
Procedures
The study w'as done in two pluses. The first was an open- 
label study to assess the ease of giving glycerol and the 
tolerability of a range of doses by patients to find the 
highest tolerated dose for use in the second phase—the 
double-blind, randomised controlled trial.
45 adult patients with symptoms, signs, and 
cerebrospinal fluid findings consistent writh bacterial 
meningitis infection who fulfilled inclusion criteria were 
recniited. After consent was obtained. 15 pabents each 
received 50 mL. 75 mL. or 100 mL of glycerol four times a 
day for 4 days. Paediatric studies used 6 mL/kg per day:* 
this corresponded to 300-360 mL glycerol daily for the 
average Malawian weighing 50-60 kg. Glycerol was 
diluted with water at a rarto of 5:4 so that the consistency 
was indistinguishable from that of 50% sugar solution 
(the proposed placebo for phase 2). Pabents therefore 
received diluted glycerol 90 mL 135 mL or 180 mL four 
times a day. Clinical details of all cases, including possible 
or probable adverse events due to glycerol, were 
recorded.
Tlie second phase of the study was the main trial, in 
which pabents were randomly assigned to receive the 
highest tolerated dose of glycerol or equivalent volume of
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placebo. All patients with probable meningitis were treated 
with intravenous ceftriaxone twice a day for at least 10 days. 
or until treatment was changed according to the results of 
culture and sensitivity testing. If cryptococcal infection 
was diagnosed after recruitment to the study, patients 
were treated with oral fluconazole (in accordance with 
national guidelines), and the study drug was discontinued. 
Those not enrolled in the study received standard care in 
accordance with national guidelines.
Glycerol or placebo was given orally or via nasogastric 
tube immediately after enrolment at a dose of 1J5 mL 
(75 mg glycerol mixed with water or 1J5 mL 50% sugar 
solution) four times a day for 4 days (16 doses). This was 
tire highest tolerated dose in the dose-finding study. The 
dose was repeated after antiemetics if vomiting occurred 
within 30 min of administration. A nasogastric tube was 
routinely inserted in those with a score on the Glasgow 
coma scale (GCS) of less than 8. or in any patient unable 
to swallow for any other reason. Position of the tube was 
checked daily by auscultating over the epigastrium while 
injecting air through the nasogastric tube and by 
ensuring that tube aspirate was acidic (turned blue 
litmus paper pink).
After 48 h or at least eight doses of glycerol therapy, a 
second lumbar puncture was done. After 10 days of 
antibiotic therapva full neurological examination including 
hearing assessment was done. Hearing tests were done 
with a Kamplex Diagnostic Audiometer AD12. All patients 
were treated in hospital for at least 10 days, with daily 
clinical assessment Patients alive at discharge were asked 
to return at day 40 for follow-up assessment: those who did 
not attend were traced at home. At day 40, patients had a 
full neurological examination including hearing 
assessment using audiometry, and the Glasgcsv outcome 
scale was used as a measure of neurological disability.
The primary endpxaint was death by day 40. Secondary 
endpoints were death or disability (Glasgow outcome 
score—disabled and partially or completely dependent) 
by day 40:r death by day 10: hearing loss in those not dead 
or disabled by day 40: time to death; cerebrospinal fluid 
opening pressure 2 days after treatment: and serious 
adverse events (SAEs). A-priori subgroup analyses 
included patients with proven or probable bacterial 
meningitis alone and proven pneumococcal meningitis.
Adverse events and SAEs were recorded. SAEs were 
classified as definitely, ptossibly, or probably related to 
study drug, as defined by the International Conference 
on Harmonisation Guidelines.
All patients were tested for HIV. Consent with appropriate 
counselling was sought at recruitment to the study, or 
retrospaectively after recovery for those initially unconscious 
or confused. Patients' guardians were aware that HIV 
testing would be done, but they were not informed of 
results. Relatives and guardians were encouraged to attend 
for voluntary HIV testing, regardless of patients' results. 
Pahents were counselled about their results before 
discharge from hospital. Those found to be HIV p>ositive
were started on cotrimoxazole prophylaxis and referred to 
the antiretroviral therajiy clinic.
Cerebrospinal fluid and blood for culture were analysed 
by Are Malawi-Liverpool-Wellcome Trust (MLW) 
laboratory. Cerebrospinal fluid was processed by use of 
standard laboratory techniques for cell count, differential 
white-cell count (when >20 cells pier pLpresent) and Cram 
stain. Cerebrospinal fluid was cultured on sheep blood 
and chocolate agar for 48 h and subcultured for
137 wceWedglyawcJ 128 receWfd ptocebo
125 at <i*y 4013& assessed M day 40
380 met entry criteria
3716 patients underwent lumbar puncture
assigned pbcebo or gWovol
371 bad cryptococcal meningitis 
799 bad lymphocytic or norvdiagnost* 
cerebrospinal Hurd 
2166 bad normal cerebrospinal fluid
63 dkd before reovitment
13 were pregnant 
3 were under 16 yean old
2 had cryptococcal menmgitis
3 were outpatients
13 were withdrawn for other reasons 
3 bad laboratory data missing 
6 patents not traceable m the bosprtal 
1 unnamed sample 
1 GLAM patient readmitted
Tahiti: Results of the dose-finding study
Gastiolntesttnal skJe-elfcas' 
Number with random capflatv 
Wood glucose >12 2 mmoi/LT 
Number with proven bactet lai 
meWngitb
n (%) 'Nausea, vomiting. <4airhoea. World Health organisation definition for diabetes1
50 ml glycerol four 
tbntsaday (n»15)
4(27%)
75 ml glycerol four 100 mL glycerol four
times a day (n-IS) times a day (n-15)
7(47%)
Figure 1. Trial profile
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Placebo Glycerol
Numb* refruired 128 137
HW SCfopottk** 104/124(84*-) 111/134(83%)
Prior AIDS dcAnm; linen rtati« modified WHO 3 o< 4 13/128(26%) 36/137(26%)
MedUn ilQfo *)c 32(27-38) 32(27-40)
Female 67/128(52%) 72/137(53%)
Initul CJmqcw (onut uJe < 12 48/128(375*.) 39/137(293%)
Initial Glasgow coma scale < 8 14/128 (11%) 9/137(6 6%)
Msxlun (IQ*) tvi ebfospirvtl fluid white ceV count (white 
criKpeffiL)
400 (200-1040) 395 <200-1120)
Proven b*-refMi roeningms 54/128 (42%) 64/137(47%)
Pnetwnor cxcA rttvAv 52/128 (41%) 46/137(34%)
MedUn (IQfh octet*(n^rvil fluid opening pressure (omCSF) 28(18-34) 215(125-34)
Mts o* history of firs m list 2 weeis 51/128(40%) 49/137(36%)
Phot ait tbiotk use 59/128 (46%) 53(137(39%)
On Antfcetrovttafc 16/128 (13%) 23/137(17%)
Median (IQft) duration of symptoms (days) 6(3-8) 5(3-7)
Data are n(%)wiieuothenMie stated 'HtVaatut not known m three pJtientsw4*> received placebo and four 
patents who fecetved^ycefoi
ToM« 2: Baseline charac tertstk s In the main trial
identification as appropriate. Blood was cultured with the 
BacT alert system. Organisms were identified by use of 
conventional culture-based microbiological techniques. 
Cerebrospinal fluid cryptococcal antigen agglutination 
tests (Pastorex Crypto Plus Biorad. Mames-la-Coquette. 
France) were done by the MLW laboratory on a subset of 
patients. Blood for malaria film, full blood count, and 
biochemistry was analysed by the QECH laboratory. HIV 
serological testing was done in duplicate for every patient 
by use of Uni-Cold Recombigen HIV rapid test (Trinity- 
Biotech, Wicklow. Ireland) and Determine HIV-1/2 
(Abbott. USA). BM glucose was measured with Glncostix 
(Bayer Diagnostics. Basingstoke. UK) at least twice a day- 
while the patient was taking study drug.
Statistical analysis
The sample size required to detect a reduction in 
mortality from 5f>% (previous mortality in observational 
studies) to 40%. with a=0 05 and p=0-9. was 216 patients 
per group (calculated using Stata 8.0). Data were double 
entered into Microsoft Access and verified before being 
analysed with Stata 8.0. The analytical plan was finalised 
before unmasking.
All patients were analysed for the primary outcome 
excluding those who were lost to follow-up. A per-protocol 
analysis (restricted to those not withdrawn from glycerol 
or placebo for reasons other than death) w-as also planned 
for the mortality-defined end-points. Logistic regression 
was used to construct a model to estimate the primary 
and secondary outcomes (with the exception of hearing 
loss and cerebrospinal fluid opening pressure at 2 days), 
and odds ratios (ORs) calculated unadiusted and adjusted 
for the following prespecified potential confounding 
factors: HIV serostatus. antiretroviral use. prior
AlDS-defining illness (modified WHO grades J or 4 ).“ 
age. sex. prior antibiotic use. score on the CCS on 
admission, fits before admission, duration of symptoms, 
pretreatment with antibiotics, and organism isolated 
from cerebrospinal fluid or blood. The secondary analysis 
of time to death was analysed with Cox's proportional 
hazard ratios, unstratified and stratified by the same 
potential confounding factors. Statistical significance for 
the primary outcome was defined as p less than 0-0S.
An unblinded interim analysis by the data safety- 
monitoring board had been prespecified after 100 deaths. 
Indicative criteria for stopping included recruitment to 
be halted if a treatment group showed evidence of harm 
exceeding conventional levels of chance alone (p<0-01). 
and recruitment to be halted if there was clear evidence 
of benefit with a significance level of p less than 0 001.
The trial is registered with controlled-trials.com. 
number ISRCTN70121840.
Role of the funding source
The sponsor had no role in study design, data collection, 
data analysis, data interpretation, or writing of the report. 
The corresponding author had full access to all the data 
in the study and had final responsibility- for the decision 
to submit for publication.
Results
The dose-finding study ran from March, 2006. to 
|uly. 2006. 4S patients were randomly assigned to receive 
one of three doses of glycerol (table 1). About 50% of 
patients in each group experienced nausea, vomiting, or 
diarrhoea. Vomiting did not occur in any- pa bent receiving 
glycerol via nasogastric tube. No clear relahon existed 
between the dose of glycerol and frequency of side- 
effects. 14 (31%) pabents had transiently' increased blood 
glucose concenbations greater than 12 2 inmol/L after 
taking study drug. Peak hyperglycaemia ranged from 
12-2-20.4 mmol/L One patient had a single reading of 
40 mmol/L at recruitment, but died before receiving 
study drug. No patients needed treatment with insulin. 
Five pabents had hyperglycaemia (12-2-20-4 mmol/L) 
after glycerol had been disconbnued. suggesbng type 2 
diabetes or a stress response was the cause. Pabents had 
difficulty swallowing the largest volume given. Eight of 
15 pabents in the 50 inL group, seven of 15 in the 75 mL 
group, and ten of 15 in the 100 mLgrotip died in hospital. 
On the basis of tolerability, the 75 mL dose was used for 
the subsequent trial.
The trial started on Sept 10, 2006, and recruitment was 
halted on Aug 23. 2008. 3716 patients were screened. 
380 met the inclusion criteria, and 265 were randomly 
assigned to placebo or glycerol (figure 1). Baseline 
characteristics of the two groups were similar (table 2). 
Follow-up of survivors to day 40 was 98% and 99% in the 
placebo and glycerol groups, respectively.
The study was stopped following the planned interim 
analysis after 100 deaths, with 7 months of the trial sbll to
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Placebo Glycerol Oddi ratio 
mscip)
Arointed odds ratio 
(•5%cipr
Died before day 40 61/125 (49%> 86/136(63%) 1-8 (11-3 0) p-002 2 4(13-42 p-0 003)
Wed oi disability before day 40f 75/124(60%) 93(135(69%) 14 (087-2 4) P-0 2 17(097-31P-O07)
Wed by day 10 53/126 (42%) 80(136(59%) 24) (12-3 2) p»0007 27(15-48. p-OOOl)
Pei-piotocol analysis death to day 40 57(106(54%) 77/118 (65%) 16(09-28) p-008 2 2(1 2-41>p-0 01
Wed by day 40 resumed to proven bacterial disease 21/53 (40%) 43/63(68%) 3-3 (15-70) p-0002 55(1-9-154. p-OOOU)
Wed by day 40 restricted to pneumococcal disease 20(51(39%) 31/45(69%) 3-4(15-8 0)p»O 004 82(2 4-285.p-0-0006)
Data irrn(%) unless othcfwrse stated ‘ Prcspedfied factory HfV statin, age. organism in blood cm cerebrospinal flud antiretroviralbeatmmt pre-treatment antibiotics fits 
pfior to admission Glasgow coma score, duration of sympterre stx, prior AIDS-defining merits. ttt> day 40 data for two patients
TaWeJ: Prltnary and secondary outcome data
run and 61% of the predetermined recruitment 
completed. The data safety monitoring hoard advised 
stopping recmitment on the grounds of futility. Patients 
already recruited to the trial were followed up until 
completion of follow-up or the primary endpoint was 
reached.
40 days after enrolment, the proportion of patients 
who died was significantly larger in the glycerol group 
than in the placebo group: this was the same for death 
and disability. Overall. 61 (49%) of 125 patients in the 
placebo group and 86 (6 J%) of lib in the glycerol group 
died by day 40 (odds ratio [OR] 1-8. 95% Cl 1-1-1-0; 
p=0-02). The OR adjusted for prespecified potential 
confounding factors was 2-4 (95%C1 1- 3—4-2. p=0-003). 
Glycerol did not improve death and disability by day 40. 
or death at day 40 in proven bacterial disease or 
pneumococcal disease (table 3). Among survivors tested 
by audiometry. 14 of 41 patients in the placebo group and 
four of 31 patients in the glycerol group were deaf at 
day 40 (p=0-02). Time to death is shown in figure 2. The 
unadjusted hazard ratio (HR) for death was 1-7 (95% Cl
1 - 2-2• 4). and the adjusted HR was2 • 0 (95%Cl 1 • 4-2-9). 
with glycerol seeming to be detrimental.
138 (52%) of265 patients had a second lumbar puncture. 
The median opening pressure of cerebrospinal fluid
2 days after randomisation was 15 cm CSF (IQR 9-21) in 
the placebo group, and 11-5 cm CSF (IQR 6-19) in the 
glycerol group (Willcoxon rank sum difference p=0-08). 
Median BM glucose on day 2 in both groups was 6 mmol/L 
(range 4-11 mmol/L).
There were two deaths thought possibly to be due to 
study drug in view of the rapid and unexpected 
deterioration in the patients' clinical condition. A 
70-year-old HIV-positive woman was admitted with 
1 week's history of headache, fever, and confusion, and 
on admission had a GCS score of 13. She was assigned 
glycerol Her level of consciousness improved, but on 
day 2 she developed seizures refractory to anticonvulsant 
therapy and she became hypertensive (170/90 mmHg 
fromabaselineofl20/80mmHg).Saimone(IatyphimiihMm 
was cultured from cerebrospinal fluid. A second lumbar 
puncture was not done, and the study drug was 
discontinued on day 3. She died on day 12. The second
Flgm 2; Kaplan-Metef survival MtimatM for glytrrol vs control
case was a 35-year-old HIV-positive woman with a 1-day 
history of illness and a GCS score of 12 on admission. 
She was assigned placebo. She improved rapidly to 
GCS score of 15 by day 2. SireptKoaus pneumoniaf was 
cultured from blood and cerebrospinal fluid. Discharge 
was planned on day 10 when she developed generalised 
weakness and vomiting without fever. She maintained a 
normal blood pressure and good urine output. On day 11 
her level of consciousness fell (GCS 6). although no focal 
neurological deficit was identified. She died on day 13. 
The most likely diagnosis for both patients was, on 
clinical criteria, a major cerebrovascular event secondary 
to meningitis. However, a brain scan was not possible in 
either case in this setting.
Glycerol was well tolerated compared with placebo. 
79 (65%) of 121 patients who were conscious and able to 
communicate had gastrointestinal adverse events 
(nausea, vomiting, diarrhoea) in the placebo group, 
compared with 85 (66%) of 129 patients who were 
conscious and able to communicate in the glycerol group. 
Seizure during the initial 10 days after randomisation 
occurred in 37 (31%) of 121 patients in the placebo group 
and 64 (50%) of 129 in the glycerol group (p=0-002);
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almost half of thesf occurred while talcing study drug. 
72 (27%) of 265 patients had a seizure within the first 
2 days of admission: 25 (19%) of 128 in the placebo group 
and 47/137 ( 34%) in the glycerol group (p=0-006. post- 
hoc analysis). No other symptoms or signs dirtered 
between the two groups after randomisation. A total of 
135 (51%) patients presented with a CCS score of less 
than 14, 23 of whom had a GCS score of less than 8 (14 in 
the placebo group, and nine in the glycerol group).
Discussion
In our study in adults, which was stopped early by the 
data safety monitoring board due to futility, glycerol was 
associated with significantly higher mortality within 
40 days than was placebo. Glycerol was also associated 
with worse outcomes in all major secondary analyses, 
except deafness, at day 40. This trial therefore does not 
support the use of glycerol as adjunctive treatment for 
bacterial meningitis in adults in Malawi.
These findings from the fitst adult study of glycerol are 
markedly different from those of studies in children 
(panel). In a small study of infants and children in 
Finland, oral glycerol reduced severe or profound 
hearing loss.’ A larger multicentre paediatiic study in 
Latin America* suggested that glycerol prevented 
neurological sequelae, although several methodological 
concerns were subsequently raised about this study.* A 
small, randomised, double-blind study in India by 
.Sankar and colleagues’* companng dexamethasone and 
oral glycerol adjuvant therapies in children with acute 
bacterial meningitis did not find any significant 
difference in hearing loss and neurological sequelae 
between the groups.” Animal models of pneumococcal 
meningitis have not shown a beneficial effect from 
glycerol.” Our findings suggest glycerol confers no 
benefit and might be harmful. However, there are major
Panel: Research in context 
Systematic review
We searched PubMcd using the terms "glyceror. 'adjuvant 
therapy', and ‘bacterial meningitis' There are no randomised 
controlled trials using glycerol adjuvant therapy In meningitis 
In adults There Is one trial m children in Latin America where 
adjuvant dexamethasone or glycerol with placebo was 
administered Glycerol did not Improve mortality or deafness, 
but did reduce severe n curologtcal sequelae Hearing loss was 
reduced In a small study in children in Finland, but no 
advantage was seen from glycerol in another small paediatric 
study in India
Interpretation
Our trial is in adults^ most of whom were HIV positive, and 
showed evidence of increased mortality with glycerol It 
therefore makes it unlikely that glycerol is beneficial m adults 
or In those who are HIV positive, but docs not exclude the 
possibility of benefit in children
differences in our study population and those of other 
studies: our patients were adults. 84% were HIV positive 
and glycerol was given for 4 days rather than 2 days. HIV 
serostatus was not reported in the paediatric studies, 
although it is highly likely that most participants were 
HIV negative. Additionally, access to health care is often 
delayed in sub-Saharan Africa compared with other 
settings: most of our patients had symptoms for 5 days 
or more, compared with over 85% presenting within 
48 h of the onset of symptoms in previous studies. 
Despite these population differences, why glycerol 
seemed harmful is hard to explain. Hyperglycaemia— 
which adversely affects outcome compared with 
nonnoglycaemia after stroke, acute myocardial infarct, 
pneumonia, and in those acutely ill on intensive 
care”"0—is not a plausible explanation, because it was 
rarely detected in either of the treatment groups in our 
study. One possibility is that the sugar solution used as 
placebo for blinding was beneficial, but this seems 
unlikely; there was no evidence of hypoglycaemia in any 
patient before giving the study drug.
That a higher proportion of patients had convulsions in 
the glycerol group than in the placebo group is concerning, 
and might relate to the poor outcome. This could be a 
coincidental finding associated with the severely ill 
population in this study, or could be directly related to an 
effect of glycerol. This has not been previously documented 
in humans. A study in mice found that oral glycerol could 
produce changes in behaviour and seizures within 
30 min.* The exact cause of these effects was not dear, 
but an increase in oxygen species might be the cause, and 
the effects were associated with increased interleukin Ift 
concentrations in the hippocampus. In human studies, 
rebound phenomena can occur with osmotherapy, 
particularly mannitol.’* but evidence for its occurrence 
with glycerol therapy is mixed. Some smdies do not show 
a rebound increase in intracranial pressure with either 
oral or intravenous glycerol (compared with mannitol) . “’•* 
others show substantial rises in intracranial pressure with 
continuous intravenous and intermittent oral 
administration."'*1 Rebound increase of intracranial 
pressure might be attributable to a reversal of the 
concentration gradient of the osmotic agent between 
blood and cerebrospinal fluid (or brain interstitial fluid) 
as the drug is eliminated." Although this increase in 
pressure is not generally thought to be dinically 
significant, its relevance is unclear in the context of 
bacterial meningitis. Reliable dinical interpretation of the 
changes in cerebrospinal fluid opening pressures is 
difficult, in part because of early mortality
There are potential limitations to this study. Although 
this hospital is better staffed and supported than many in 
a similar setting, general medical care is suboptimal 
compared with that offered in developed countries. 
Additionally, there was limited intensive or high 
dependency care available for such critically ill patients 
with severe sepsis. Overall, this is a typical southern
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African hospital, and the population of patients and trial 
setting is likely to be representative of other sub-Saharan 
African settings with a high prevalence of HIV. The 
results do not exclude the possibility that glycerol might 
be effective in a setting with low HIV prevalence in which 
patients present earlier and where HIV infection is less 
common. Residual confounding is a possibility, but the 
finding is highly statistically significant, no subgroup 
analysis suggested benefit, and adjusting for identified 
confounding factors only strengthened the association, 
making residual confounding unlikely. The mortality 
difference seen at interim analysis by the data safety 
monitoring board strengthened with follow-up of 
enrolled patients, and the adverse effect persisted after 
adjusting for confounding, thus supporting the decision 
to stop early.
In adults in Malawi or other resource-poor regions 
where bacterial meningitis presents late and commonly 
occurs in people who are infected with HIV. glycerol 
cannot be recommended as adjunctive therapy. Other 
ways of reducing the substantial mortality associated 
with this disease need to be explored. Glycerol might be 
harmful as adjunctive therapy in adults with bacterial 
meningitis in sub-Saharan African settings with a high 
prevalence of HIV.
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